SARM1 inhibitor compound, pharmaceutical composition containing SARM1 inhibitor compound, and preparation method and application of SARM1 inhibitor compound

CN118946553APending Publication Date: 2024-11-12SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032148.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-08
Filing Date
2023-04-07
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing SARM1 inhibitors are not active enough to effectively treat and prevent neurological diseases related to axonal degeneration, and there are pharmacokinetic and safety issues.

Method used

The oxo group on the 2,3-dihydroisothiazole of the compound in WO2019236890A1 was replaced with a thio group to develop a new compound with improved SARM1 inhibitory activity and optimized physical and chemical properties, pharmacokinetic properties and safety sex.

Benefits of technology

It has obtained higher SARM1 inhibitory activity than existing compounds, improved the solubility, physical and chemical stability, pharmacokinetic properties and safety of the drug, provided a wider therapeutic window, reduced side effects, and is suitable for treatment and prevention of neurodegenerative diseases associated with axonal degeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946553A_ABST
    Figure CN118946553A_ABST
Patent Text Reader

Abstract

The present disclosure provides SARM1 inhibitor compounds of formula (I), pharmaceutical compositions comprising the same, and methods of making and uses thereof. The compounds are useful for inhibiting SARM1 and / or treating and / or preventing axial degeneration as well as diseases, disorders or conditions characterized by axial degeneration. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

SARM1 inhibitor compound, pharmaceutical composition containing the same, and preparation method and use thereof

[0001] This application claims priority to Chinese patent application CN2022103687829, filed on April 8, 2022. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field

[0002] The present disclosure provides SARM1 inhibitor compounds of Formula I, pharmaceutical compositions comprising the same, and methods for preparing and using the same. The compounds can be used to inhibit SARM1 and / or treat and / or prevent axonal degeneration and diseases, disorders, or conditions characterized by axonal degeneration. Background Art

[0003] Axonal degeneration is a hallmark of a variety of neurological conditions, including peripheral neuropathy, traumatic brain injury, and neurodegenerative diseases (Gerdts et al., SARM1 activation triggers axon degeneration locally via NAD(+) destruction., Science, 348 2016, pp. 453-457, hereby incorporated by reference in its entirety). Neurodegenerative diseases and injuries are devastating for both patients and caregivers. Currently, the costs associated with these diseases exceed hundreds of billions of dollars annually in the United States alone. Because the incidence of many of these diseases and conditions increases with age, their incidence is rapidly increasing as the population structure changes.

[0004] WO2019236890A1 and WO2020247701A2 filed by Disarm Therapeutic, Inc. respectively disclose SARM1 inhibitor compounds having the following structures for inhibiting SARMI and / or treating and / or preventing axonal degeneration:

[0005] WO2020081923A1 and WO2020132045A1 filed by Disarm Therapeutic, Inc. respectively relate to the combined use of such SARM1 inhibitor compounds with other agents.

[0006] Basheer et al. (Ahmad Basheer, Zvi Rappoport, Journal of Organic Chemistry (2008), 73(4), 1386-1396) discussed the chemical reaction of thioenols derived from cyanomonothiocarbonylmalonamide and cyanodithiocarbonylmalonamide and disclosed a compound having the following structure, but did not disclose any pharmacological activity of the compound:

[0007] WO2004011461A1 relates to isothiazole derivatives useful as anticancer agents, which have TrkA receptor, KDR tyrosine kinase, receptor tyrosine kinase, VEGF-2 and TrkB inhibitory activities. This international patent application discloses intermediate 14 having the following structure for synthesizing its subject compound, but does not disclose any pharmacological activity thereof:

[0008] Lippa et al. (Blaise Lippa, Joel Morris, Matthew Corbett, Bioorganic & Medicinal Chemistry Letters, 16 (2006), 3444-3448) disclosed intermediate 13 for the synthesis of isothiazole inhibitors of TrkA kinase, but did not disclose any pharmacological activity thereof:

[0009] There is still a need to develop new, especially more active SARM1 inhibitors to meet clinical needs.

[0010] Summary of the Invention

[0011] The present inventors surprisingly discovered that when the oxo group (=O) on the 2,3-dihydroisothiazole of the compounds disclosed in WO2019236890A1 (e.g., positive controls 1 and 2 determined in the biological examples below) is replaced with a thio group (=S), a new compound having significantly improved SARM1 inhibitory activity than the corresponding compound is obtained. The compounds disclosed herein also have a variety of excellent properties, such as good physicochemical properties (e.g., solubility, physical and / or chemical stability), good pharmacokinetic properties (e.g., excellent drug exposure and excellent oral absorption effect), and good safety (lower toxicity and / or fewer side effects, and a wider therapeutic window).

[0012] Thus, in some embodiments, the present disclosure provides novel compounds having improved SARM1 inhibitory activity compared to the prior art for use in treating and / or preventing neurodegeneration (e.g., for reducing axonal degeneration), said compounds being compounds of Formula I:

[0013] or

[0014] in:

[0015] R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a , a 3- to 7-membered saturated or partially unsaturated carbocyclic group, a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the carbocyclyl, heterocyclyl, aryl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace;

[0016] R 2 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 2a 、-S(O)2R 2a and -CO2R 2a ,

[0017] R 3 Yes - (CH2) n Cy, and n is 0, 1 or 2;

[0018] or

[0019] R 2 and R 3 Together with the nitrogen atom to which they are attached, they form a saturated or partially unsaturated 4- to 7-membered ring fused to Cy, or a saturated or partially unsaturated 4- to 7-membered ring substituted by Cy;

[0020] Cy is selected from 3 to 7 membered saturated or partially unsaturated carbocyclic groups, 8 to 10 membered saturated or partially unsaturated bicyclic heterocyclic groups having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10aryl, 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8 to 10 membered bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the carbocyclyl, heterocyclyl, aryl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace;

[0021] R 4 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 4a 、-S(O)2R 4a 、-CO2R 4a , a 3- to 7-membered saturated or partially unsaturated carbocyclic group, a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are each separated by 0, 1, 2, 3, or 4 R x replace; and

[0022] Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 aliphatic, -SH, -S- optionally substituted C 1-6 Aliphatic, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b 、-N(R 3a )SO2R 3b 、-N(R 3a )C(O)R 3b , optionally substituted C 1-6 aliphatic, optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted 8- to 10-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0023] R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a are each independently hydrogen, optionally substituted C 1-6aliphatic, optionally substituted phenyl, or an optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclic ring; or

[0024] R 1a and R 1b , and / or R 3a and R 3b Together with the nitrogen atom to which they are attached, they form a 3- to 6-membered saturated or partially unsaturated heterocyclic ring;

[0025] Provided that the compound is not

[0026] In some embodiments, the compound of Formula I has a structure as shown in one of Formulas Ia, Iai, Ia-ii, Ia-iii, Ia-iv, Iav, Ia-vi, Ia-vii, Ia-viii, Ia-ix, Iax, Ia-xi, Ia-xii, Ia-xiii and Ia-xiv as described below.

[0027] In some embodiments, one or more compounds of Formula I are provided and / or utilized in solid form (eg, crystalline or amorphous form).

[0028] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the compound, or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound, or prodrug thereof; and optionally one or more pharmaceutically acceptable carriers.

[0029] In some embodiments, the present disclosure provides compounds and / or pharmaceutical compositions that are useful in medicine, particularly for treating neurodegeneration (eg, for reducing axonal degeneration).

[0030] In some embodiments, provided SARM1 inhibitors reduce or inhibit SARM1 binding to NAD+. In some embodiments, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., the catalytic cleft of SARM1).

[0031] In some embodiments, provided compounds and / or pharmaceutical compositions inhibit the activity of SARM1.

[0032] Alternatively or additionally, in some embodiments, provided compounds alleviate one or more attributes of neurodegeneration.

[0033] In some embodiments, the present disclosure provides methods of treating a neurodegenerative disease, disorder, or condition associated with axonal degeneration.

[0034] In some embodiments, the compounds and / or pharmaceutical compositions described herein may be used, for example, in the practice of medicine.

[0035] In some embodiments, the compounds and / or pharmaceutical compositions described herein are useful, for example, in treating, preventing, or ameliorating axonal degeneration (eg, one or more characteristics or properties thereof).

[0036] In some embodiments, the compounds and / or pharmaceutical compositions described herein can be used, for example, to inhibit axonal degeneration, including axonal degeneration caused by reduction or depletion of NAD+.

[0037] In some embodiments, the compounds and / or compositions described herein are useful, for example, to prevent axonal degeneration distal to axonal injury.

[0038] In some embodiments, the compounds and / or pharmaceutical compositions described herein are useful, for example, in treating one or more neurodegenerative diseases, disorders, or conditions selected from a neuropathy or an axonopathy.

[0039] In some embodiments, the compounds and / or pharmaceutical compositions described herein are useful, for example, in treating a neuropathy or axonopathy associated with axonal degeneration.

[0040] In some embodiments, the neuropathy associated with axonal degeneration is a hereditary or congenital neuropathy or axonopathy.

[0041] In some embodiments, the neuropathy associated with axonal degeneration is caused by de novo or somatic mutations.

[0042] In some embodiments, the neuropathy associated with axonal degeneration is selected from the list contained herein.

[0043] In some embodiments, the neuropathy or axonopathy is associated with axonal degeneration, including but not limited to Parkinson's disease, non-Parkinson's disease, Alzheimer's disease, herpes infection, diabetes, amyotrophic lateral sclerosis (ALS), demyelinating disease, ischemia or stroke, chemical injury, thermal injury, and AIDS.

[0044] In some embodiments, the subject to whom a compound or pharmaceutical composition described herein is administered can be or include a subject suffering from or susceptible to a neurodegenerative disease, disorder, or condition.

[0045] In some embodiments, the neurodegenerative disease, disorder, or condition can be or comprise traumatic neuronal injury.

[0046] In some embodiments, the traumatic neuronal injury is blunt force trauma, closed head injury, open head injury, exposure to concussive and / or blast forces, penetrating injury within or to the brain cavity or body innervation areas.

[0047] In some embodiments, the traumatic neuronal injury is a force that causes axonal deformation, stretching, compression, or shearing.

[0048] In some embodiments, provided methods comprise administering a compound described herein (eg, a compound of Formula I) to a patient in need thereof.

[0049] In some such embodiments, the patient is at risk for a disease, disorder, or condition characterized by axonal degeneration.

[0050] In some embodiments, the patient has a disease, disorder, or condition characterized by axonal degeneration.

[0051] In some embodiments, the patient has been diagnosed with a disease, disorder, or condition characterized by axonal degeneration.

[0052] In some embodiments, provided methods comprise administering a pharmaceutical composition described herein to a patient population in need thereof.

[0053] In some embodiments, the population is of individuals from those groups who participated in activities where the likelihood of traumatic neuronal injury was high.

[0054] In some embodiments, the population is from such athletes who participate in contact sports or other high-risk activities.

[0055] In some embodiments, the patient is at risk for developing a neurodegenerative disorder.

[0056] In some embodiments, the patient is an elderly person.

[0057] In some embodiments, the patient is known to have a genetic risk factor for neurodegeneration.

[0058] In some embodiments, the present disclosure provides compounds useful as, for example, analytical tools, probes in biological assays, or therapeutic agents according to the present disclosure. The compounds provided herein can also be used to study the function of SARM1 in biological and pathological phenomena and to comparatively evaluate new SARM1 activity inhibitors in vitro or in vivo.

[0059] In some embodiments, the compounds and / or pharmaceutical compositions described herein can be used as a method of, for example, inhibiting the degeneration of neurons derived from an individual.

[0060] In some embodiments, the compounds and / or pharmaceutical compositions described herein can be used to inhibit the degeneration of neurons or a portion thereof cultured in vitro.

[0061] In some embodiments, the compounds and / or pharmaceutical compositions described herein can be used as stabilizers to promote neuronal survival in vitro.

[0062] BRIEF DESCRIPTION OF THE DRAWINGS

[0063] FIG1 shows the structure of the SARM1 protein.

[0064] definition

[0065] Aliphatic: The term "aliphatic" refers to a straight (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation, and that has a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, straight or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl, and hybrids thereof.

[0066] Cycloaliphatic: The term "cycloaliphatic" refers to a monocyclic or bicyclic hydrocarbon (also referred to herein as "carbocycle" or "cycloaliphatic") that is fully saturated or contains one or more unsaturated units but is not aromatic and has a single point of attachment to the rest of the molecule. In some embodiments, "cycloaliphatic" (or "carbocycle") refers to a C3-C8 monocyclic hydrocarbon or a C7-C8 monocyclic hydrocarbon. 10 A bicyclic hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has a single point of attachment to the rest of the molecule.

[0067] Alkyl: The term "alkyl," used alone or as part of a larger group or moiety, refers to a saturated, optionally substituted, straight or branched chain hydrocarbon group having 1-12, 1-10, 1-8, 1-6, 1-4, 1-3, or 1-2 carbon atoms.

[0068] Cycloalkyl: The term "cycloalkyl" used alone or as part of a larger group or moiety refers to an optionally substituted saturated monocyclic or bicyclic hydrocarbon ring system having 3 to 10 ring carbon atoms. In some embodiments, "cycloalkyl" is a monocyclic C3-C8 cycloalkyl. In some embodiments, "cycloalkyl" is a bicyclic C7-C8 10 Cycloalkyl. Exemplary monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0069] Alkylene: The term "alkylene" refers to a divalent alkyl group. In some embodiments, an "alkylene" is a divalent straight or branched chain alkyl group. In some embodiments, an "alkylene chain" is a polymethylene group, i.e., -(CH2) n -, wherein n is a positive integer, For example, 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. An optionally substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are optionally replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups, and also include those described in this specification. It should be understood that two substituents of an alkylene group can form a ring system together. In certain embodiments, two substituents can form a 3 to 7 membered ring together. The substituents can be on the same or different atoms.

[0070] Alkenyl: The term "alkenyl," used alone or as part of a larger group or moiety, refers to an optionally substituted straight or branched chain hydrocarbon radical having at least one double bond and having 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms. The term "cycloalkenyl" refers to an optionally substituted non-aromatic monocyclic or polycyclic ring system containing at least one carbon-carbon double bond and having from about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentyl, cyclohexenyl, and cycloheptenyl.

[0071] Alkenyl: The term "alkenyl," used alone or as part of a larger group or moiety, refers to an optionally substituted straight or branched chain hydrocarbon group having at least one double bond and having 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms.

[0072] Cycloalkenyl: The term "cycloalkenyl," used alone or as part of a larger group or moiety, refers to an optionally substituted non-aromatic monocyclic or polycyclic hydrocarbon ring system containing at least one carbon-carbon double bond and having 3 to 10 carbon atoms. Exemplary monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, and cycloheptenyl.

[0073] Alkynyl: The term "alkynyl," used alone or as part of a larger group or moiety, refers to an optionally substituted straight or branched chain hydrocarbon group having at least one triple bond and having 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms.

[0074] Aryl: The term "aryl" (or "aromatic ring") refers to an all-carbon monocyclic or fused polycyclic aromatic group having a conjugated π electron system. As used herein, the term "C6- 12 "Aryl (aromatic ring)" means an aromatic group (aromatic ring) containing 6 to 12 carbon atoms, preferably C6- 10 Aryl (aromatic ring), preferably phenyl or naphthyl. Aryl is optionally substituted by one or more (such as 1 to 3) identical or different substituents (such as halogen, OH, CN, NO2, C1-C6 alkyl, etc.).

[0075] Aryl: The term "aryl" used alone or as part of a larger group or moiety refers to an all-carbon monocyclic or fused polycyclic ring system having a conjugated pi electron system. The term "aryl" is used interchangeably with the term "aryl ring" or "aromatic ring." In some embodiments, "aryl" refers to an aromatic group (C6-12) containing 6 to 12 ring carbon atoms. 12 In some embodiments, "aryl" refers to an aromatic group containing 6 to 10 ring carbon atoms (C6- 10 Aryl). Aryl includes but is not limited to phenyl, naphthyl, anthracenyl, etc. Aryl can be optionally substituted.

[0076] Heteroaryl: The term "heteroaryl," used alone or as part of a larger group or moiety (e.g., "heteroaralkyl" or "heteroaralkoxy"), refers to a group having 5 to 10 ring atoms, preferably 5, 6, 8, 9, or 10 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having 1 to 5 (e.g., 1-4, 1-3, or 1-2) heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of a basic nitrogen. Heteroaryl groups may be optionally substituted. Heteroaryl includes but is not limited to thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl and pteridinyl.Term " heteroaryl " as used herein also includes the group that heteroaromatic ring (such as 5 or 6 yuan heteroaryl ring) is fused with one or more aryl rings (such as phenyl ring), wherein linking group or attachment point are on heteroaromatic ring.In the embodiment of some such heteroaryl, heteroatoms are all in described heteroaromatic ring (such as 5 or 6 yuan heteroaryl ring), and are not shared atoms. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenanthrazinyl, phenathiazinyl, phenoxazinyl. Heteroaryl can be monocyclic or bicyclic. The term "heteroaryl" can be used interchangeably with the term "heteroaryl ring", "heteroaryl group" or "heteroaromatic", any of which includes optionally substituted rings. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, wherein the alkyl and heteroaryl moieties are independently and optionally substituted.

[0077] Heterocycle: As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and include stable 3- to 8-membered (e.g., 4-, 5-, 6-, or 7-membered) monocyclic or 7-10-membered (e.g., 8-, 9-, or 10-membered) bicyclic heterocyclic moieties that are saturated or partially unsaturated and have, in addition to carbon atoms, one or more, such as 1 to 4 (e.g., 1-3, 1-2, or 2-3) heteroatoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of a basic nitrogen. The term "nitrogen," when used in reference to a ring atom of a heterocycle, includes substituted nitrogen. For example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur and nitrogen, nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR +(as in N- substituted pyrrolidinyl). In some embodiments, term " heterocycle " is 5 or 6 yuan saturated or partially unsaturated monocyclic heterocyclic radical with 1,2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur. In some embodiments, term " heterocycle " is 8 to 10 yuan saturated or partially unsaturated bicyclic heterocyclic radical with 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. Heterocycle can be connected to its side group at any heteroatom or carbon atom, so as to produce a stable structure, and any ring atom can be optionally substituted. The example of this type of saturated or partially unsaturated heterocyclic radical includes but is not limited to tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolane, diazepinyl (diazepinyl), oxazepinyl (oxazepinyl), thiazepinyl (thiazepinyl), morpholinyl and thiamorpholinyl. Also included within the scope of the term "heterocycle" are bicyclic ring systems of a benzene ring fused to a non-aromatic heterocycle, and bicyclic ring systems of a heteroaryl group as defined above fused to a non-aromatic heterocycle or cycloaliphatic, wherein any of the bicyclic ring systems as a whole is non-aromatic, and wherein the attachment group or point of attachment is on the benzene ring or the heteroaryl ring. In some such embodiments, such bicyclic heterocyclyl groups are 8 to 10-membered (particularly 9 or 10-membered) bicyclic heterocyclyl groups having 1-3 (e.g., 1, 2, or 3) heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some such embodiments, such bicyclic heterocyclyl groups are fused ring systems of a benzene ring to a 5- or 6-membered saturated or partially unsaturated heterocyclyl group, wherein all heteroatoms are in the 5- or 6-membered saturated or partially unsaturated heterocyclyl ring and are not shared atoms. Examples of such bicyclic heterocyclyls include, but are not limited to, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, indolinyl, 2,3-dihydrobenzoindazolyl, 2,3-dihydrobenzimidazolyl, chromanyl, dihydrobenzothiopyran, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. The heterocyclyl group may also include a tricyclic or polycyclic system. Preferred are monocyclic, bicyclic, or tricyclic heterocyclyls, more preferably monocyclic or bicyclic heterocyclyls, as defined above. The term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, wherein the alkyl and heterocyclyl moieties are independently optionally substituted.

[0078] "Substituted" or "optionally substituted": As described herein, the compounds of the present invention may contain "optionally substituted" groups or moieties. In general, the term "optionally substituted" means that one or more hydrogen atoms of the designated group or moiety may or may not be replaced with a suitable substituent. "Substituted" applies to one or more hydrogen atoms explicitly or implicitly present in the structure (e.g., At least and At least ). Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at each position. The substituent combinations contemplated by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable" as used herein refers to a compound that does not substantially change when subjected to conditions that allow its production, detection, and in certain embodiments, its recovery, purification, and use for one or more purposes disclosed herein.

[0079] Suitable monovalent substituents on a substitutable carbon or nitrogen atom of an "optionally substituted" group are independently halogen; -(CH2) 0-4 R ○ ; -(CH2) 0-4 OR ○ ;-O(CH2) 0-4 R ○ ;-O-(CH2) 0-4 C(O)OR ○ ; -(CH2) 0-4 CH(OR ○ )2;-(CH2) 0-4 SR ○ ; -(CH2) 0-4 Ph, which can be R ○ Substitution; -(CH2) 0-4 O(CH2) 0-1 Ph, which can be R ○ Substituted; -CH=CHPh, which can be R ○ Substitution; -(CH2) 0-4 O(CH2) 0-1 -pyridyl, which may be R ○ Substitution; -NO2; -CN; -N3; ​​-(CH2) 0-4 N(R ○ )2;-(CH2) 0-4 N(R ○ )C(O)R ○ ;-N(R ○ )C(S)R ○ ; -(CH2) 0-4 N(R ○ )C(O)NR ○ 2;-N(R ○ )C(S)NR ○ 2; -(CH2) 0-4 N(R ○ )C(O)OR ○ ;-N(R○ )N(R ○ )C(O)R ○ ;-N(R ○ )N(R ○ )C(O)NR ○ 2;-N(R ○ )N(R ○ )C(O)OR ○ ;-(CH2) 0-4 C(O)R ○ ;-C(S)R ○ ;-(CH2) 0-4 C(O)OR ○ ;-(CH2) 0-4 C(O)SR ○ ;-(CH2) 0-4 C(O)OSiR ○ 3;-(CH2) 0-4 OC(O)R ○ ;-OC(O)(CH2) 0-4 SR ○ ;-(CH2) 0-4 SC(O)R ○ ;-(CH2) 0- 4C(O)NR ○ 2;-C(S)NR ○ 2;-C(S)SR ○ ;-SC(S)SR ○ ;-(CH2) 0-4 OC(O)NR ○ 2;-C(O)N(OR ○ )R ○ ;-C(O)C(O)R ○ ;-C(O)CH2C(O)R ○ ;-C(NOR ○ )R ○ ;-(CH2) 0-4 SSR ○ ;-(CH2) 0-4 S(O)2R ○ ;-(CH2) 0- 4S(O)2OR ○ ;-(CH2) 0-4 OS(O)2R ○ ;-S(O)2NR ○ 2;-(CH2) 0-4 S(O)R ○ ;-N(R ○ )S(O)2NR ○ 2;-N(R ○)S(O)2R ○ ;-N(OR ○ )R ○ ;-C(NH)NR ○ 2;-P(O)2R ○ ;-P(O)R ○ 2;-OP(O)R ○ 2;-OP(O)(OR ○ )2;-SiR ○ 3;-(C 1-4 linear or branched alkylene)ON(R ○ )2; or -(C 1-4 linear or branched alkylene) C(O)ON(R ○ )2, where each R ○ may be substituted as defined below and are independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0- 1Ph, -CH2-(5- to 6-membered heteroaryl ring), a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8- to 10-membered bicyclic aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the above definitions, two independent occurrences of R ○ Together with their middle atoms, they form a 3- to 12-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic or bridged ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which may be substituted as defined below. In some embodiments, suitable monovalent substituents on the substitutable carbon or nitrogen atom of the "optionally substituted" group are selected from halogen, -NO2, -CN, OH, SH, C 1-6 Alkyl, -OC 1-6 Alkyl, -C(O)OC 1-6 Alkyl, -NH2, -NH(C 1-6 alkyl) and -N(C 1-6 Alkyl)2.

[0080] In R ○ (or two independent occurrences of R ○ Suitable monovalent substituents on the ring formed together with their middle atom are independently halogen, -(CH2) 0-2 R · 、-(halogenated R · ), -(CH2) 0-2 OH, -(CH2) 0-2 OR · 、-(CH2) 0-2 CH(OR · )2、-O(halogenated R ·)、-CN、-N3、-(CH2) 0-2 C(O)R · 、-(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR · 、-(CH2) 0- 2SR · 、-(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR · 、-(CH2) 0-2 NR · 2. -NO2, -SiR · 3. -OSiR · 3. -C(O)SR · 、-(C 1-4 linear or branched alkylene)C(O)OR · or -SSR · , where each R · is unsubstituted, or in the case of "halo" preceding it, is substituted only with one or more halogens, and is independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 3- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. ○ Suitable divalent substituents on a saturated carbon atom of include =0 and =S.

[0081] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0 ("oxo"), =S, =NNR * 2. =NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O)2R * 、=NR * 、=NOR * 、-O(C(R * 2)) 2-3 O- or -S(C(R * 2)) 2-3 S-, where each independent occurrence of R * selected from hydrogen, C 1-6 aliphatic, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents attached to the vicinal substitutable carbon of an "optionally substituted" group include: -O(CR *2) 2-3 O-, where each independent occurrence of R * selected from hydrogen, C 1-6 aliphatic, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0082] R * Suitable substituents on the aliphatic group include halogen, -R · 、-(halogenated R · ), -OH, -OR · 、-O(halogenated R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · is unsubstituted, or in the case of being preceded by "halo" is substituted only by one or more halogens, and is independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5- to 6-membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0083] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include Each of these are independently hydrogen, C 1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the above definitions, two independent occurrences of Together with their central atoms, they form an unsubstituted 3- to 12-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0084] exist Suitable substituents on the aliphatic group are independently halogen, -R · 、-(halogenated R · ), -OH, -OR · 、-O(halogenated R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R· is unsubstituted, or in the case of being preceded by "halo" is substituted only by one or more halogens, and is independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5- to 6-membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0085] Halogen: As used herein, the term "halogen" or "halo" group is defined to include fluorine, chlorine, bromine, or iodine.

[0086] Partially unsaturated: As used herein, the term "partially unsaturated" refers to a ring group or moiety that includes at least one double or triple bond between ring atoms. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties as defined herein.

[0087] Binding: It will be understood that the term "binding," as used herein, generally refers to a non-covalent association between or among two or more entities. "Direct" binding involves physical contact between the entities or moieties; indirect binding involves physical interaction via physical contact with one or more intermediate entities. Binding between two or more entities can generally be assessed in any of a variety of situations, including studying the interacting entities or moieties in isolation or in more complex systems (e.g., when covalently or otherwise associated with a carrier entity and / or in a biological system or cell).

[0088] Biological sample: As used herein, the term "biological sample" generally refers to a sample obtained or derived from a biological source of interest (e.g., a tissue or organism or cell culture) as described herein. In some embodiments, the source of interest comprises an organism, such as an animal or a human. In some embodiments, the biological sample is or comprises a biological tissue or fluid. In some embodiments, the biological sample can be or comprises bone marrow; blood; blood cells; ascites; tissue or fine needle biopsy samples; body fluids containing cells; free nucleic acids; sputum; saliva; urine; cerebrospinal fluid; peritoneal fluid, pleural fluid; feces; lymph; gynecological fluid; skin swab; vaginal swab; oral swab; nasal swab; wash or lavage fluid, such as duct lavage fluid or bronchoalveolar lavage fluid; aspirate; scraping; bone marrow specimen; tissue biopsy specimen; surgical specimen; feces, other body fluids, secretions and / or excretions; and / or cells obtained therefrom, etc. In some embodiments, the biological sample is or comprises cells obtained from an individual. In some embodiments, the cell obtained is or includes the individual cell from which the sample is obtained. In some embodiments, sample is " original sample " obtained directly from the source of interest by any appropriate means. For example, in some embodiments, original biological sample is obtained by the method selected from biopsy (for example, fine needle aspiration or tissue biopsy), operation, collection of body fluids (for example, blood, lymph, feces, etc.). In some embodiments, as will be understood from the context, term " sample " refers to the prepared product obtained by processing original sample (for example, by removing one or more components of original sample and / or by adding one or more reagents thereto). For example, a semipermeable membrane is used to filter. Such " processed sample " can include, for example, nucleic acid or protein extracted from sample or obtained by carrying out the amplification or reverse transcription, separation and / or purification of some components such as mRNA to original sample.

[0089] Biomarker: The term "biomarker" is used herein to refer to an entity, event, or characteristic whose presence, level, extent, type, and / or form is associated with a particular biological event or state of interest, and is therefore considered a "marker" for that event or state. To name a few examples, in some embodiments, a biomarker can be or comprise a marker for a particular disease state, or a marker for the likelihood that a particular disease, disorder, or condition may develop, occur, or recur. In some embodiments, a biomarker can be or comprise a marker for a particular disease or its treatment outcome or likelihood. Thus, in some embodiments, a biomarker is a prediction of a relevant biological event or state of interest, in some embodiments, a biomarker is a prognosis of a relevant biological event or state of interest, and in some embodiments, a biomarker is a diagnosis of a relevant biological event or state of interest. A biomarker can be or comprise an entity of any chemical class, and can be or comprise a combination of entities. For example, in some embodiments, a biomarker can be or comprise a nucleic acid, a polypeptide, a lipid, a carbohydrate, a small molecule, an inorganic agent (e.g., a metal or ion), or a combination thereof. In some embodiments, a biomarker is a cell surface marker. In some embodiments, a biomarker is intracellular. In some embodiments, a biomarker is detected extracellularly (e.g., is secreted or otherwise produced or present extracellularly, such as in a body fluid, such as blood, urine, tears, saliva, cerebrospinal fluid, etc.). In some embodiments, a biomarker can be or comprise a genetic or epigenetic signature. In some embodiments, a biomarker can be or comprise a gene expression signature.

[0090] In some embodiments, biomarkers can be or include markers of neurodegeneration, or markers of the likelihood that a neurodegenerative disease, disorder, or condition may develop, occur, or recur. In some embodiments, biomarkers can be or include markers of neurodegeneration, its treatment outcome, or likelihood. Therefore, in some embodiments, biomarkers are predictions of neurodegenerative diseases, disorders, or conditions, in some embodiments, biomarkers are prognoses of neurodegenerative diseases, disorders, or conditions, and in some embodiments, biomarkers are diagnostics of neurodegenerative diseases, disorders, or conditions. In some embodiments, changes in biomarker levels can be detected by cerebrospinal fluid (CSF), plasma, and / or serum.

[0091] In some embodiments, neurodegeneration can be assessed, for example, by detecting an increase and / or decrease in the concentration of neurofilament light chain (NF-L) and / or neurofilament heavy chain (NF-H) in the cerebrospinal fluid of an individual. In some embodiments, the occurrence and / or progression of neurodegeneration can be assessed by positron emission tomography (PET) with synaptic vesicle glycoprotein 2a (SV2A) ligand. In some embodiments, detectable changes in constitutive NAD and / or cADPR levels in neurons can be used to assess neurodegeneration.

[0092] In some embodiments, relative to a healthy reference population, a detectable change in one or more neurodegeneration-related proteins in an individual can be used as a biomarker for neurodegeneration. Such proteins include, but are not limited to, albumin, amyloid-β (Aβ) 38, Aβ40, Aβ42, glial fibrillary acidic protein (GFAP), heart-type fatty acid binding protein (hFABP), monocyte chemoattractant protein (MCP) -1, neurogranulin, neuron-specific enolase (NSE), soluble amyloid precursor protein (sAPP) α, sAPPβ, soluble triggering receptor 2 (sTREM2) expressed on myeloid cells, phosphorylated tau and / or total tau. In some embodiments, an increase in cytokines and / or chemokines, including but not limited to Ccl2, Ccl7, Ccl12, Csf1 and / or Il6, can be used as a biomarker for neurodegeneration.

[0093] Carrier: As used herein, the term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a (pharmaceutical) composition is administered. In some exemplary embodiments, carriers can include sterile liquids such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. In some embodiments, a carrier is or includes one or more solid components.

[0094] Combination therapy: As used herein, the term "combination therapy" refers to those situations in which an individual is exposed to two or more treatment regimens (e.g., two or more therapeutic agents) at the same time. In some embodiments, two or more regimens can be administered simultaneously; in some embodiments, such regimens can be administered sequentially (e.g., all "doses" of the first regimen are administered before any doses of the second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, the "administration" of a combination therapy may involve administering one or more agents or characteristics to an individual receiving the other agents or characteristics in the combination. For clarity, combination therapy does not require that the individual agents be administered together in a single composition (or even must be administered simultaneously), however, in some embodiments, two or more agents or their active portions can be administered together in a combinatorial composition, or even in the form of a combinatorial compound (e.g., as part of a single chemical complex or covalent entity).

[0095] Composition: Those skilled in the art will appreciate that the term "composition" may be used to refer to a discrete physical entity comprising one or more specified components. Generally, unless otherwise specified, a composition can be in any form, such as gas, gel, liquid, solid, etc.

[0096] Domain: As used herein, the term "domain" refers to a segment or portion of an entity. In some embodiments, a "domain" is associated with a specific structural and / or functional characteristic of an entity, such that when the domain is physically separated from the remainder of its parent entity, it substantially or completely retains the specific structural and / or functional characteristic. Alternatively or additionally, a domain can be or include a portion of an entity that, when separated from the (parent) entity and attached to a different (receptor) entity, substantially retains and / or confers one or more structural and / or functional characteristics of the receptor entity that were characteristic of the parent entity. In some embodiments, a domain is a segment or portion of a molecule (e.g., a small molecule, carbohydrate, lipid, nucleic acid, or polypeptide). In some embodiments, a domain is a segment of a polypeptide; in some such embodiments, the domain is characterized by specific structural elements (e.g., specific amino acid sequences or sequence motifs, α-helical characteristics, β-sheet characteristics, coiled-coil characteristics, random coil characteristics, etc.), and / or by specific functional characteristics (e.g., binding activity, enzymatic activity, folding activity, signaling activity, etc.).

[0097] Dosage form or unit dosage form: Those skilled in the art will appreciate that the term "dosage form" can be used to refer to a physically discrete unit of an active agent (e.g., a therapeutic agent or diagnostic agent) for administration to an individual. Typically, each such unit contains a predetermined amount of the active agent. In some embodiments, such an amount is a unit dose (or fraction thereof) suitable for administration according to a dosing regimen (i.e., a therapeutic dosing regimen) that has been determined to be associated with a desired or beneficial outcome when administered to a relevant population. Those of ordinary skill in the art understand that the total amount of a therapeutic composition or medicament administered to a particular individual is determined by one or more attending physicians and may involve the administration of multiple dosage forms.

[0098] Dosing regimen or treatment regimen: Those skilled in the art will appreciate that the terms "dosing regimen" and "treatment regimen" can be used to refer to a group of unit doses (usually more than one) administered individually to an individual, the unit doses typically being separated by time periods. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, the dosing regimen includes multiple doses, each of which is separated in time from the other doses. In some embodiments, each dose is separated from another by a time period of the same length; in some embodiments, the dosing regimen includes multiple doses and at least two different time periods separating each dose. In some embodiments, all doses within a dosing regimen have the same unit dose amount. In some embodiments, different doses within a dosing regimen have different amounts. In some embodiments, a dosing regimen comprises a first dose in the amount of the first dose, followed by one or more additional doses in the amount of a second dose that is different from the amount of the first dose. In some embodiments, a dosing regimen comprises a first dose in the amount of the first dose, followed by one or more additional doses in the amount of the second dose that is the same as the amount of the first dose. In some embodiments, a dosing regimen is associated with a desired or beneficial outcome when administered to a relevant population (i.e., is a therapeutic dosing regimen).

[0099] Excipients: As used herein, the term "excipient" refers to non-therapeutic agents that may be included in pharmaceutical compositions, for example, to provide or promote desired consistency or stabilization. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene glycol, water, ethanol, and the like.

[0100] Inhibitor: As used herein, the term "inhibitor" refers to an entity, condition, or event whose presence, level, or extent is associated with a decrease in the level or activity of a target. In some embodiments, an inhibitor can act directly (in which case it exerts an effect on its target directly, such as by binding to the target); in some embodiments, an inhibitor can act indirectly (in which case it exerts an effect by interacting with and / or otherwise altering a modulator of the target, causing a decrease in the level and / or activity of the target). In some embodiments, an inhibitor is one whose presence or level is associated with a decrease in the level or activity of a target relative to a particular reference level or activity (e.g., a level or activity observed under appropriate reference conditions, such as the presence of a known inhibitor, or the absence of the inhibitor in question).

[0101] Neurodegeneration: As used herein, the term "neurodegeneration" refers to a reduction in one or more characteristics, structures or properties of neurons or neuronal tissue. In some embodiments, neurodegeneration is observed as a pathological reduction of an organism. Those skilled in the art will appreciate that neurodegeneration is associated with certain diseases, disorders and conditions, including those affecting humans. In some embodiments, neurodegeneration can be transient (e.g., sometimes occurring in association with certain infections and / or chemical or mechanical damage); in some embodiments, neurodegeneration can be chronic and / or progressive (e.g., often associated with certain diseases, disorders or conditions, such as, but not limited to, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease (Huntington disease) or Alzheimer's disease). In some embodiments, neurodegeneration can be assessed, for example, by detecting an increase in biomarkers associated with neurodegeneration in an individual. In some embodiments, neurodegeneration can be assessed, for example, by detecting a reduction in biomarkers associated with neurodegeneration in an individual. Alternatively or additionally, in some embodiments, neurodegeneration can be assessed by magnetic resonance imaging (MRI), cerebrospinal fluid containing biomarkers, or other biomarkers observed in patients. In some embodiments, neurodegeneration is defined as a score of less than 24 on the Mini-Mental State Examination. In some embodiments, neurodegeneration refers to the loss of synapses. In some embodiments, neurodegeneration refers to a reduction in neural tissue associated with traumatic injury (e.g., exposure to external forces that destroy the integrity of neural tissue). In some embodiments, neurodegeneration refers to a reduction in peripheral neural tissue. In some embodiments, neurodegeneration refers to a reduction in central nervous tissue.

[0102] Oral: As used herein, the phrases "oral administration" and "administered orally" have their art-understood meanings and refer to administration of a compound or composition via the mouth.

[0103] Parenteral: As used herein, the phrases "parenteral administration" and "administered parenterally" have their art-understood meanings and refer to modes of administration other than enteral and topical administration (usually by injection), and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.

[0104] Patient: As used herein, the term "patient" refers to any organism to which a provided composition is or can be administered, e.g., for experimental, diagnostic, preventive, cosmetic, and / or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is human. In some embodiments, the patient suffers from or is susceptible to one or more disorders or conditions. In some embodiments, the patient displays one or more symptoms of a disorder or condition. In some embodiments, the patient has been diagnosed with one or more disorders or conditions. In some embodiments, the patient is receiving or has received certain therapies to diagnose and / or treat the disease, disorder, or condition.

[0105] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent formulated with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in an amount suitable for a unit dose administered in a treatment or dosing regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition can be specifically formulated for administration in solid or liquid form, including pharmaceutical compositions suitable for: oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets, such as tablets targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes applied to the tongue; parenteral administration, such as as a sterile solution or suspension or sustained release formulation, by subcutaneous, intramuscular, intravenous, or epidural injection; topical administration, such as as a cream, ointment, or controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or rectally, such as as a pessary, cream, or foam; sublingually; ophthalmically; transdermally; or nasally, pulmonary, and other mucosal surfaces.

[0106] Pharmaceutically acceptable: As used herein, the phrase "pharmaceutically acceptable" refers to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without causing excessive toxicity, irritation, allergic response, or other problems or complications, and are commensurate with a reasonable benefit / risk ratio.

[0107] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, component, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, that is involved in carrying or transporting the subject compound from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; pH buffered solutions; polyesters, polycarbonates, and / or polyanhydrides; and other nontoxic, compatible substances employed in pharmaceutical formulations.

[0108] Pharmaceutically acceptable salts: As used herein, the term "pharmaceutically acceptable salts" refers to salts of compounds of this class that are suitable for use in a pharmaceutical setting, i.e., salts that are suitable for use in contact with the tissues of humans and lower animals, within the scope of sound medical judgment, without producing excessive toxicity, irritation, allergic reactions, etc., and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19 (1977). In some embodiments, pharmaceutically acceptable salts include, but are not limited to, non-toxic acid addition salts, which are salts of an amino group with inorganic acids or organic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or salts formed by other methods used in the art, such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. In some embodiments, pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyl groups having 1 to 6 carbon atoms, sulfonates, and arylsulfonates, as appropriate.

[0109] Stereoisomers: The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In compounds with one or more (e.g., 1, 2, 3, or 4) asymmetric centers, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers can be produced. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds provided herein can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, and the like. It is to be understood that the scope of this application encompasses all such isomers or mixtures thereof in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%).

[0110] "Diastereoisomers" refer to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of one another. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereoisomers can be separated by high-resolution analytical methods such as electrophoresis and chromatography.

[0111] "Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another.

[0112] The term "chiral" refers to molecules that have the property of non-superimposability of their mirror image pairs, whereas the term "achiral" refers to molecules that are superimposable on their mirror image pairs.

[0113] The compounds of the present invention may be prepared in racemic form, or individual enantiomers may be prepared by enantioselective synthesis or by resolution.

[0114] As used herein, the term "cis-trans isomers" or "geometric isomers" is caused by the inability to rotate freely about double bonds or single bonds of ring-forming carbon atoms. The compounds provided herein include all cis, trans, syn, anti, entgegen (E) and zusammen (Z) isomers and their corresponding mixtures.

[0115] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.

[0116] In this article, solid lines (——), solid wedges or virtual wedge Depict the chemical bonds of the compounds provided herein. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers (e.g., specific enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of real or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the stereoisomers shown are present. When present in a racemic mixture, real and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds provided herein are intended to exist in the form of stereoisomers (which include cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof). The compounds provided herein may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereoisomer pairs).

[0117] Polymorphs: The present disclosure encompasses all possible crystalline forms or polymorphs of the compounds provided herein, which may be single polymorphs or mixtures of more than one polymorph in any ratio.

[0118] Solvates, Metabolites, or Prodrugs: It should also be understood that certain compounds provided herein may exist in free form for therapeutic use or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. For purposes of this disclosure, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, solvates, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound provided herein or a metabolite or residue thereof. Therefore, reference herein to a "compound provided herein" is intended to encompass the various derivative forms of the compound described above.

[0119] The compounds provided herein may exist in the form of solvates (preferably hydrates), wherein the compounds provided herein comprise a polar solvent, such as water, methanol or ethanol, as a structural element of the crystal lattice of the compound. The amount of the polar solvent, particularly water, may be present in a stoichiometric or non-stoichiometric ratio.

[0120] N-oxides: Those skilled in the art will appreciate that not all nitrogen-containing heterocycles are capable of forming N-oxides due to the nitrogen requiring an available lone pair of electrons to oxidize to the oxide; those skilled in the art will recognize nitrogen-containing heterocycles that are capable of forming N-oxides. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides. Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art and include oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic acid and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; and GWH Cheeseman and ESGWerstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.

[0121] Also included within the scope of the present disclosure are metabolites of the compounds provided herein, i.e., substances formed in vivo upon administration of the compounds provided herein. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound. Thus, the present disclosure includes metabolites of the compounds provided herein, including compounds produced by contacting the compounds provided herein with a mammal for a period of time sufficient to produce a metabolic product thereof.

[0122] The present disclosure further includes within its scope prodrugs of the compounds provided herein, which are certain derivatives of the compounds provided herein that may have less pharmacological activity or no pharmacological activity themselves, and when administered to the body or on the body, can be converted into compounds provided herein with the desired activity by, for example, hydrolytic cleavage. Typically, such prodrugs will be functional group derivatives of the compounds that are easily converted into the desired therapeutically active compounds in vivo. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems," Volume 14, ACS Symposium Series (T. Higuchi and V. Stella) and "Bioreversible Carriers in Drug Design," Pergamon Press, 1987 (E.B. Roche, ed., American Pharmaceutical Association). Prodrugs provided herein can be prepared, for example, by replacing appropriate functional groups present in compounds provided herein with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in "Design of Prodrugs," H. Bundgaard (Elsevier, 1985)).

[0123] The present invention also includes all pharmaceutically acceptable isotopically labeled compounds that are identical to the compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of suitable isotopes for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium (D, 2H), tritium (T, 3H)); isotopes of carbon (e.g., 11C, 13C, and 14C); isotopes of chlorine (e.g., 36Cl); isotopes of fluorine (e.g., 18F); isotopes of iodine (e.g., 123I and 125I); isotopes of nitrogen (e.g., 13N and 15N); isotopes of oxygen (e.g., 15O, 17O, and 18O); isotopes of phosphorus (e.g., 32P); and isotopes of sulfur (e.g., 35S). Certain isotopically labeled compounds of the present invention (e.g., those incorporating radioisotopes) can be used in drug and / or substrate tissue distribution studies (e.g., analysis). The radioisotopes tritium (i.e., 3H) and carbon-14 (i.e., 14C) are particularly useful for this purpose because they are easy to incorporate and easy to detect. Substitution with positron-emitting isotopes (e.g., 11C, 18F, 15O, and 13N) can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds of the present invention can be prepared by methods similar to those described in the accompanying routes and / or examples and preparations by using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent can be isotopically substituted, for example, D2O, acetone-d6, or DMSO-d6. In some embodiments, the isotopically labeled compounds of the present invention are deuterated.

[0124] As used herein, the term "ester" refers to esters derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acid or alcohol). The compounds of the present invention themselves may also be esters.

[0125] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.

[0126] The present disclosure also encompasses compounds provided herein that contain protecting groups. In any process for preparing compounds provided herein, it may be necessary and / or desirable to protect sensitive or reactive groups on any related molecules, thereby forming a chemically protected form of the compounds provided herein. This can be achieved by conventional protecting groups, for example, those described in Protective Groups in Organic Chemistry, ed. JFW McOmie, Plenum Press, 1973; and TW Greene & P.GM Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.

[0127] The term "about" means within ±10%, preferably within ±5%, and more preferably within ±2% of the stated numerical value.

[0128] Prevent or prevention: As used herein, the terms "prevent" or "prevention," when used in connection with the occurrence of a disease, disorder, and / or condition, refer to reducing the risk of developing a disease, disorder, and / or condition and / or delaying the onset of one or more characteristics or symptoms of a disease, disorder, or condition. Prevention is considered accomplished when the onset of a disease, disorder, or condition has been delayed for a predetermined period of time.

[0129] Specificity: The term "specificity," when used herein to refer to an active agent, will be understood by those skilled in the art to mean that the agent discriminates against a potential target entity or state. For example, in some embodiments, an agent is said to "specifically" bind to a target if it preferentially binds to its target in the presence of one or more competing alternative targets. In many embodiments, specific interactions depend on the presence of specific structural features (e.g., epitopes, clefts, binding sites) of the target entity. It will be understood that specificity need not be absolute. In some embodiments, specificity can be assessed relative to the specificity of the binding agent for one or more other potential target entities (e.g., competitors). In some embodiments, specificity is assessed relative to the specificity of a reference specific binding agent. In some embodiments, specificity is assessed relative to the specificity of a reference nonspecific binding agent. In some embodiments, an agent or entity, under conditions in which it binds to its target entity, does not detectably bind to a competing alternative target. In some embodiments, a binding agent binds to its target entity with a higher on-rate, a lower off-rate, increased affinity, reduced dissociation, and / or increased stability compared to a competing alternative target.

[0130] Individual: As used herein, the term "individual" refers to an organism, typically a mammal (e.g., a human, including in some embodiments prenatal human forms). In some embodiments, the individual suffers from a relevant disease, disorder, or condition. In some embodiments, the individual is susceptible to a disease, disorder, or condition. In some embodiments, the individual displays one or more symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the individual does not display any symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the individual is a person with one or more characteristics of susceptibility or risk for a disease, disorder, or condition. In some embodiments, the individual is a patient. In some embodiments, the individual is an individual who is being and / or has been diagnosed and / or treated for the disease.

[0131] Therapeutic agent: As used herein, the phrase "therapeutic agent" generally refers to any agent that causes a desired pharmacological effect when administered to an organism. In some embodiments, an agent is considered a therapeutic agent if it shows a statistically significant effect in an appropriate population. In some embodiments, the appropriate population can be a population of a model organism. In some embodiments, the appropriate population can be defined by various criteria, such as a certain age group, gender, genetic background, pre-existing clinical condition, etc. In some embodiments, a therapeutic agent is a substance that can be used to alleviate, improve, alleviate, inhibit, prevent one or more symptoms or characteristics of a disease, disorder, and / or condition, delay its onset, reduce its severity, and / or reduce its incidence. In some embodiments, a "therapeutic agent" refers to an agent that has been or needs to be approved by a government agency before it can be sold to humans for administration. In some embodiments, a "therapeutic agent" is an agent that requires a medical prescription to be administered to humans.

[0132] Treatment: As used herein, the terms "treat," "treatment," or "treating" refer to any method used to partially or completely alleviate, ameliorate, alleviate, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a disease, disorder, and / or condition. Treatment can be administered to individuals who do not exhibit signs of the disease, disorder, and / or condition. In some embodiments, treatment can be administered to individuals who exhibit only early signs of a disease, disorder, and / or condition, for example, for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition. DETAILED DESCRIPTION

[0133] Programmed axonal degeneration and SARM1

[0134] Axonal degeneration is the main pathological feature of nervous system diseases, such as but not limited to Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, hereditary neuropathy, traumatic brain injury and / or glaucoma. Damaged or unhealthy axons are eliminated by an intrinsic self-destruction program, which is different from traditional cell death pathways, such as apoptosis (Gerdts, J. et al., Neuron, 2016, 89, 449-460; Whitmore, AV et al., Cell Death Differ., 2003, 10, 260-261) known as Wallerian degeneration. In Wallerian degeneration, peripheral nerves selectively decompose at the distal end of the axon segment, while the proximal axon segment and cell body remain intact. This degeneration is characterized by the initial depletion of nicotinamide mononucleotide adenylyltransferase (NMNAT), followed by nicotinamide adenine dinucleotide (NAD+) depletion, adenosine triphosphate (ATP) depletion, neurofilament proteolysis, and finally axonal degeneration approximately 8 to 24 hours after injury (Gerdts, J. et al., Neuron, 2016, 89, 449-460).

[0135] NAD+ is a ubiquitous metabolite that plays a key role in energy metabolism and cell signaling (Belenkey et al., Trends Biochem., 2007, 32, 12-19; ​​Chiarugi et al., Nat. Rev. Cancer, 2012, 12, 741-752). Homeostatic regulation of NAD+ levels is also responsible for maintaining axonal stability and integrity. Therefore, manipulations that increase NMNAT1 axonal localization confer axonal protection (Babetto et al., Cell Rep., 2010, 3, 1422-1429; Sasaki et al., J. Neurosci., 2009).

[0136] In a genome-wide RNAi screen of primary mouse neurons, SARM1 (Sterile Alpha and TIR motif-containing 1) was identified, wherein knockdown of SARM1 resulted in long-lasting protection of sensory neurons against injury-induced axonal degeneration (Gerdts et al., J. Neurosci., 2013, 33, 13569-13580). SARM1 belongs to a family of cytoplasmic adaptor proteins, but is unique among its members in that it is the most evolutionarily ancient adaptor, paradoxically inhibits TLR signaling, and has been identified as a core executor of injury-induced axonal death pathways (O'Neill, LA and Bowie, AG, Nat. Rev. Immunol., 2007, 7, 353-364; Osterloh, JM et al., Science, 2012, 337, 481-484; Gerdts, J. et al., J. Neurosci., 33, 2013, 13569-13580). Activation of SARM1 by axonal injury or forced dimerization of the SARM1-TIR domain promotes rapid and catastrophic depletion of nicotinamide adenine dinucleotide (NAD+), followed by axonal degeneration, highlighting the central role of NAD+ homeostasis in axonal integrity. (Gerdts, J. et al., Science, 2015, 348, 453-457). SARM1 is essential for this injury-induced NAD+ depletion both in vivo and in vitro, and activation of SARM1 locally triggers axonal degeneration via NAD(+) disruption (Gerdts et al., Science, 2015, 348, 452-457; Sasaki et al., J. Biol. Chem. 2015, 290, 17228-17238; both of which are hereby incorporated by reference in their entirety).

[0137] It is clear from the study of genetic loss of function that SARM1 acts as the core executor of the axonal degeneration pathway after injury. Genetic knockout of SARM1 can preserve axons after nerve transection for up to 14 days (Osterloh, JM et al., Science, 2012, 337, 481-484; Gerdts, J. et al., Journal of Neuroscience, 2013, 33, 13569-13580), and improve functional outcomes after traumatic brain injury in mice (Henninger, N. et al., Brain (Brain) 139, 2016, 1094-1105). In addition to the role of SARM1 in direct axonal injury, it has been observed that SARM1 is also essential for axonal degeneration in chemotherapy-induced peripheral neuropathy. Loss of SARM1 blocks chemotherapy-induced peripheral neuropathy, inhibiting both axonal degeneration and increased pain sensitivity following treatment with the chemotherapy vincristine (Geisler et al., Brain, 2016, 139, 3092-3108).

[0138] SARM1 contains multiple conserved motifs, including the SAM domain, the ARM / HEAT motif, and the TIR domain ( FIG1 ), which mediate oligomerization and protein-protein interactions (O'Neill, LA and Bowie, AG, Nat. Rev. Immunol., 2007, 7, 353-364; Tewari, R. et al., Trends Cell Biol., 2010, 20, 470-481; Qiao, F. and Bowie, JU, Sci. STKE, 2005, re7, 2005). TIR domains are commonly found in signaling proteins that function in innate immune pathways, where they serve as scaffolds for protein complexes (O'Neill, LA and Bowie, AG, Nat. Rev. Immunol., 2007, 7, 353-364). Interestingly, dimerization of the SARM1-TIR domain is sufficient to induce axonal degeneration and rapidly triggers the degradation of NAD+ by acting as an NAD+ lyase (Milbrandt et al., WO 2018 / 057989; Gerdts, J. et al., Science, 2015, 348, 453-457). Given the central role of SARM1 in the axonal degeneration pathway and its established NAD enzyme activity, much effort has been made to identify agents that can modulate SARM1 and may serve as useful therapeutic agents, for example, to prevent the occurrence of neurodegenerative diseases, including peripheral neuropathy, traumatic brain injury and / or neurodegenerative diseases.

[0139] The present disclosure provides certain compounds and / or compositions that are SARM1 inhibitors, and technologies related thereto.

[0140] Compound

[0141] In a first aspect, the present disclosure provides compounds of Formula I:

[0142] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof,

[0143] in:

[0144] R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a , a 3- to 7-membered saturated or partially unsaturated carbocyclic group, a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the carbocyclyl, heterocyclyl, aryl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace;

[0145] R 2 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 2a 、-S(O)2R 2a and -CO2R 2a ,

[0146] R 3 Yes - (CH2) n Cy, and n is 0, 1 or 2;

[0147] or

[0148] R 2 and R 3 Together with the nitrogen atom to which they are attached, they form a saturated or partially unsaturated 4- to 7-membered ring fused to Cy, or a saturated or partially unsaturated 4- to 7-membered ring substituted by Cy;

[0149] Cy is selected from 3 to 7 membered saturated or partially unsaturated carbocyclic groups, 8 to 10 membered saturated or partially unsaturated bicyclic heterocyclic groups having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8 to 10 membered bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the carbocyclyl, heterocyclyl, aryl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace;

[0150] R 4 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 4a 、-S(O)2R 4a 、-CO2R 4a , a 3- to 7-membered saturated or partially unsaturated carbocyclic group, a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are each separated by 0, 1, 2, 3, or 4 R x replace; and

[0151] Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 aliphatic, -SH, -S- optionally substituted C 1-6 Aliphatic, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、 -CONR 3a R 3b 、-N(R 3a )SO2R 3b 、-N(R 3a )C(O)R 3b , optionally substituted C 1-6 aliphatic, optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted 8- to 10-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0152] R 1a 、R 1b 、R 2a、R 3a 、R 3b and R 4a are each independently hydrogen, optionally substituted C 1-6 aliphatic, optionally substituted phenyl, or an optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclic ring; or

[0153] R 1a and R 1b , and / or R 3a and R 3b Together with the nitrogen atom to which they are attached, they form a 3- to 6-membered saturated or partially unsaturated heterocyclic ring;

[0154] Provided that the compound is not

[0155] In some embodiments, R 1 Selected from the following groups:

[0156] a)-CN;

[0157] b) -NO2;

[0158] c)-C(O)R 1a , where R 1a As defined above, preferably optionally substituted C 1-6 aliphatic, more preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably CH3;

[0159] d)-S(O)2R 1a , where R 1a As defined above, preferably optionally substituted C 1-6 aliphatic, more preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably CH3;

[0160] e)-CONR 1a R 1b , where R 1a and R 1b Each as defined above:

[0161] e1) In some such embodiments, R 1 Include-CONR 1a R 1b , where R 1a and R 1b are each selected from hydrogen and optionally substituted C 1-6 aliphatic, preferably hydrogen and optionally substituted C1-6 Alkyl, more preferably H and optionally substituted C 1-4 alkyl, even more preferably hydrogen and CH3. In some embodiments, R 1 Including -CONH2 and -CON(CH3)2. In some embodiments, R 1 Also includes

[0162] e2) In other such embodiments, R 1 Include-CONR 1a R 1b , where R 1a and R 1b Each is selected from hydrogen and an optionally substituted 3 to 7 membered saturated or partially unsaturated carbocyclic ring (preferably C 3-7 In some embodiments, R 1 include

[0163] e3) In other such embodiments, R 1 Including -C(O)NR 1a R 1b , where R 1a and R 1b Independently selected from optionally substituted C 1-6 aliphatic and optionally substituted phenyl, preferably optionally substituted C 1-6 alkyl and optionally substituted phenyl, more preferably optionally substituted C 1-4 alkyl and optionally substituted phenyl, even more preferably CH3 and phenyl. In some embodiments, R 1 include

[0164] e4) In other such embodiments, R 1 Including -C(O)NR 1a R 1b , where R 1a and R 1b Together with the nitrogen atom to which they are attached, they form: i) a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle, preferably a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 1-2 nitrogen heteroatoms and 0-1 heteroatoms selected from oxygen and sulfur, in particular a 6-membered saturated or partially unsaturated monocyclic heterocycle, preferably a pyrrolidinyl ring, a morpholinyl ring or a piperidinyl ring; ii) an 8- to 10-membered saturated or partially unsaturated bridged bicyclic heterocycle, preferably an 8- to 10-membered saturated or partially unsaturated bridged bicyclic heterocycle having 1 or 2 nitrogen heteroatoms and 0-1 heteroatoms independently selected from oxygen and sulfur, for example a 2-azabicyclo[2.2.2]octyl ring. In some embodiments, R 1 include

[0165] f)-S(O)2NR 1a R 1b , where R 1a and R 1b Each is as defined above, preferably selected from hydrogen and optionally substituted C 1-6 aliphatic, more preferably hydrogen and optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 alkyl, even more preferably hydrogen and CH3. In some such embodiments, R 1 Including -S(O)2NH2 and -S(O)2N(CH3)2;

[0166] g)-C(=NR 1a )NR 1a R 1b , where R 1a and R 1b Each as defined above:

[0167] g1) In some such embodiments, R 1 Including -C(=NR 1a )NR 1a R 1b , where R 1a and R 1b are each selected from hydrogen and optionally substituted C 1-6 aliphatic, preferably hydrogen and optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 alkyl, even more preferably hydrogen and CH3. In some embodiments, R 1 Including -C(=NH)NHCH3, -C(=NH)N(CH3)2. In other embodiments, R 1 Including -C(=NR 1a )NR 1a R 1b , where R 1a and R 1b Each is selected from hydrogen and -(CH2) 0-4 OR ○ Substituted C 1-6 Alkyl, preferably hydrogen and C substituted by -OH 1-6 In some embodiments, R 1 include In other embodiments, R 1 Including -C(=NR 1a )NR 1a R 1b, where R 1a and R 1b Each selected from H, CH3 and -OR ○ Substituted C 1-6 In some embodiments, R 1 include

[0168] g2) In other such embodiments, R 1 Including -C(=NH)NR 1a R 1b , where R 1a and R 1b Together with the nitrogen atom to which they are attached, they form a 3- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 include

[0169] h)-CO2R 1a , where R 1a and R 1b Each is as defined above, preferably selected from hydrogen and optionally substituted C 1- 6 aliphatic, more preferably hydrogen and optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 In some such embodiments, R 1 Including -CO2H and -CO2CH3;

[0170] i) 0, 1, 2, 3 or 4 R x Substituted 3 to 7 membered saturated or partially unsaturated carbocyclic group (preferably C 3-7 cycloalkyl);

[0171] j) 0, 1, 2, 3 or 4 R x Substituted C 6-10 aryl (e.g., phenyl or naphthyl);

[0172] k) is 0, 1, 2, 3 or 4 R x substituted 5- or 6-membered heteroaryl rings having 1-3 (e.g., 1, 2, or 3) heteroatoms independently selected from nitrogen, oxygen, and sulfur, preferably unsubstituted 5-membered heteroaryl rings having 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, more preferably and

[0173] l) 0, 1, 2, 3 or 4 R x Substituted 8- to 10-membered bicyclic heteroaryl having 1-4 (eg, 1, 2, or 3) heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0174] In some embodiments as described above, R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a 、C 3-7 cycloalkyl, 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, phenyl, naphthyl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, phenyl, naphthyl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace.

[0175] In some further embodiments, R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a , phenyl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the phenyl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace.

[0176] In some further embodiments, R 1 Selected from: -CN,

[0177] In any of the above embodiments, R 2 is selected from H, optionally substituted C 1-6 Alkyl, -C(O)R 2a 、-S(O)2R 2a and -CO2R 2a In some embodiments, R 2 is selected from H, optionally substituted C 1-6 Alkyl, -C(O)R 2a and -S(O)2R 2aIn any of the above embodiments, R 2a is optionally substituted C 1-6 aliphatic, preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 alkyl, even more preferably CH3. In some embodiments, R 2 Yes-C(O)R 2a , such as -C(O)CH3. In some embodiments, R 2 is optionally substituted C 1-6 In some preferred embodiments, R 2 It’s H.

[0178] In any of the above embodiments, R 3 In other embodiments, R 3 In some preferred embodiments, R 3 It's -Cy.

[0179] In any of the above embodiments, Cy is selected from C 3-7 Cycloalkyl, 8-10 membered saturated or partially unsaturated bicyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8 to 10 membered bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each separated by 0, 1, 2, 3 or 4 R x replace.

[0180] In any of the above embodiments, R 4 Selected from the following groups:

[0181] a)H;

[0182] b) optionally substituted C 1-6 Aliphatic, preferably:

[0183] b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 Alkyl, such as -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2;

[0184] b2) C substituted by a group selected from the following 1-6 Aliphatic: halogen, -(CH2) 0-4 R ○ 、-(CH2) 0-4 OR ○ 、-(CH2) 0-4N(R ○ )2、-(CH2) 0-4 S(O)2R ○ 、-(CH2) 0-4 C(O)R ○ 、-(CH2) 0-4 C(O)N(R ○ )2 or -(CH2) 0- 4C(O)OR ○ .

[0185] In some such embodiments, R 4 Including -(CH2) 0-4 R ○ Substituted C 1-6 In some such embodiments, R ○ is a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 4 Including C substituted by phenyl 1-6 In some embodiments, R 4 Including Substituted C 1-6 In some embodiments, R 4 including C substituted with a 5-membered heteroaryl group having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur 1-6 In some embodiments, R 4 Including Substituted C 1-6 In some embodiments, R 4 including C substituted with a 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur 1-6 In some embodiments, R 4 Including Substituted C 1-6 In some embodiments, R 4 including C substituted with 8-10 membered bicyclic heteroaryl having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur 1-6 In some embodiments, R 4 Including Substituted C 1-6 In some embodiments, R 4 including C substituted by a 5-membered saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur 1-6 In some embodiments, R 4 Including Substituted C 1-6Fatty.

[0186] In other such embodiments, R 4 Including -(CH2) 0-4 OR ○ Substituted C 1-6 In some embodiments, R 4 Including -OR ○ Substituted C 1-6 In some embodiments, R 4 Including C substituted by -OH 1-6 In some embodiments, R 4 Including C substituted by -OCH3 1-6 In some embodiments, R 4 Including C substituted by -OCH2CH2OCH2C≡CH 1-6 Fatty.

[0187] In other such embodiments, R 4 Including -(CH2) 0-4 N(R ○ )2 substituted C 1-6 In some embodiments, R 4 Including -N(R ○ )2 substituted C 1-6 In some embodiments, R 4 Including C substituted by -NH2 1-6 In some embodiments, R 4 Including C substituted by -N(CH3)2 1-6 Fatty.

[0188] In other such embodiments, R 4 Including -(CH2) 0-4 S(O)2R ○ Substituted C 1-6 In some embodiments, R 4 Including -S(O)2R ○ Substituted C 1-6 In some embodiments, R 4 Including C substituted by -S(O)2CH3 1-6 Fatty.

[0189] In other such embodiments, R 4 Including -(CH2) 0-4 C(O)N(R ○ )2 substituted C 1-6 Fatty.

[0190] In some embodiments, R 4 Including -C(O)N(R ○ )2 substituted C 1-6 In some embodiments, R 4 Including C substituted by -C(O)NH2 1-6 In some embodiments, R 4 Including -C(O)N(R ○ )2 substituted C 1-6 Aliphatic, where two independent occurrences of R ○ Together with their intermediate atoms, they form a 3- to 12-membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 4 Including -C(O)N(R ○ )2 substituted C 1-6 Aliphatic, where two independent occurrences of R ○ Together with their intermediate atoms, they form a 5- to 6-membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 4 Including Substituted C 1-6 In some embodiments, R 4 Including Substituted C 1-6 In some embodiments, R 4 Including Substituted C 1-6 Fatty.

[0191] In other such embodiments, R 4 Including -(CH2) 0-4 C(O)OR ○ Substituted C 1-6 In some embodiments, R 4 Including -C(O)OR ○ Substituted C 1-6 In some embodiments, R 4 Including C substituted by -C(O)OH 1-6 Fatty.

[0192] In any of the above embodiments, the C 1-6 The aliphatic group is preferably C 1-6 Alkyl, more preferably C 1-3 Alkyl, such as -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2;

[0193] c)-C(O)R 4a 、-S(O)2R 4a 、-CO2R 4a , where R 4a As defined above, preferably optionally substituted C 1-6 aliphatic, more preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably CH3;

[0194] d) Each is 0, 1, 2, 3 or 4 R x Substituted with the following groups:

[0195] d1) a 3- to 7-membered saturated or partially unsaturated carbocyclic group, preferably C 3-7 Cycloalkyl;

[0196] d2) a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably a 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclic group;

[0197] d3)C 6-10 Aryl, preferably phenyl and naphthyl;

[0198] d4) a 5- or 6-membered heteroaryl group having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0199] In some further embodiments, R 4 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 4a 、-S(O)2R 4a 、-CO2R 4a 、C 3-7 Cycloalkyl, 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl, heterocyclyl, aryl, and heteroaryl groups are each substituted by 0, 1, 2, 3, or 4 R x replace.

[0200] In some embodiments, R 4 is H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 or a group selected from the following:

[0201] In any of the above embodiments, R x Selected from the following groups:

[0202] a) halogen, -CN, -NO2, -OH and -SH;

[0203] b) -O- optionally substituted C 1-6 aliphatic and -S- optionally substituted C 1-6 aliphatic, wherein the optionally substituted C 1-6 The aliphatic group is preferably an optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably CH3;

[0204] c)-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-NR 3a R 3b 、-CONR 3a R 3b 、-CO2R 3a 、-N(R 3a )SO2R 3b and -N(R 3a )C(O)R 3b , where R 3a 、R 3b Each is as defined above, preferably selected from H and optionally substituted C 1-6 aliphatic, more preferably H and optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 In some such embodiments, R x Including -COCH3, -SO2CH3, -SO2NHCH3, -SO2N(CH3)2, -NH2, -NH(C 1-6 alkyl) (especially -NHCH3), -CONH2, -CO2H, -CO2CH3, -NHSO2CH3, -N(CH3)SO2CH3;

[0205] d) optionally substituted C 1-6 aliphatic, preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably optionally substituted CH3;

[0206] e) an optionally substituted 5-membered or 6-membered saturated or partially unsaturated heterocyclic group having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, for example and

[0207] f) optionally substituted 8- to 10-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably optionally substituted 9-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, for example

[0208] In some further embodiments, each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 Alkyl, -SH, -S- optionally substituted C 1-6 Alkyl, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b 、-N(R 3a )SO2R 3b 、-N(R 3a )C(O)R 3b and optionally substituted C 1-6 alkyl.

[0209] In some embodiments, R 3 Selected from

[0210] In any of the above embodiments, unless otherwise indicated, R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a may each independently be hydrogen or optionally substituted C 1-6 alkyl, optionally substituted phenyl, or optionally substituted C 3-7 In some embodiments, R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a may each independently be hydrogen or optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 Alkyl, even more preferably H and CH3.

[0211] In any of the above embodiments, unless otherwise indicated, when applicable, R1a and R 1b , and / or R 3a and R 3b Together with the nitrogen atom to which they are attached, they form: i) a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle, preferably a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 1-2 nitrogen heteroatoms and 0-1 heteroatoms selected from oxygen and sulfur, in particular a 6-membered saturated or partially unsaturated monocyclic heterocycle, preferably a pyrrolidinyl ring, a morpholinyl ring or a piperidinyl ring; ii) an 8- to 10-membered saturated or partially unsaturated bridged bicyclic heterocycle, preferably an 8- to 10-membered saturated or partially unsaturated bridged bicyclic heterocycle having 1 or 2 nitrogen heteroatoms and 0-1 heteroatoms independently selected from oxygen and sulfur, for example a 2-azabicyclo[2.2.2]octyl ring.

[0212] In some embodiments, R 2 and R 3 Together with the nitrogen atom to which they are attached, they form a saturated or partially unsaturated 4- to 7-membered ring fused to Cy, or a saturated or partially unsaturated 4- to 7-membered ring substituted by Cy. 2 and R 3 Together with the nitrogen atom to which they are attached, they form a ring selected from:

[0213] Cy is surrounded by 0-4 R x Replacement, R x and Cy are as defined above in any of the embodiments described herein.

[0214] In some embodiments, R 2 and R 3 Together with the nitrogen atom to which they are attached, they form a 5-membered saturated ring fused to Cy. In some such embodiments, Cy is phenyl. In some embodiments, R 2 and R 3 Together with the nitrogen atoms to which they are attached, they form

[0215] In a second aspect, as a subset of the first aspect, the present disclosure provides a compound as described above, or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug or pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound or prodrug thereof, wherein:

[0216] R 1 Selected from -CN, -NO2, -CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-CO2R1a , phenyl and 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the phenyl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace;

[0217] R 2 is selected from hydrogen, optionally substituted C 1-6 Alkyl, -C(O)R 2a and -S(O)2R 2a ;

[0218] R 3 Yes - (CH2) n Cy, and n is 0, 1 or 2, preferably 0;

[0219] Cy is selected from C 3-7 Cycloalkyl, 8-10 membered saturated or partially unsaturated bicyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace;

[0220] R 4 is selected from hydrogen, optionally substituted C 1-6 Alkyl, -C(O)R 4a 、-S(O)2R 4a 、C 3-7 Cycloalkyl, 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl, heterocyclyl, aryl, and heteroaryl groups are each substituted by 0, 1, 2, 3, or 4 R x replace; and

[0221] Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 Alkyl, -SH, -S- optionally substituted C 1-6 Alkyl, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR3a R 3b and optionally substituted C 1-6 alkyl;

[0222] R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a are each independently hydrogen, optionally substituted C 1-6 alkyl.

[0223] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, R 1 Selected from -CN, -NO2, -CONR 1a R 1b 、-S(O)2NR 1a R 1b and a 5- or 6-membered heteroaryl group having 1-3 (e.g., 1, 2, or 3) heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl group is surrounded by 0, 1, 2, 3, or 4 R x replace.

[0224] In some embodiments, R 1 Selected from -CONR 1a R 1b and -S(O)2NR 1a R 1b , especially -CONR 1a R 1b In some such embodiments, R 1a and R 1b are each independently H or optionally substituted C 1-4 Alkyl, preferably H or unsubstituted C 1-4 Alkyl, even more preferably H or CH3. In some embodiments R 1 Selected from -CONH2 and -CON(CH3)2.

[0225] In some preferred embodiments, R 1 is selected from -CN and an unsubstituted 5-membered heteroaryl ring having 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur. In some more preferred embodiments, R 1 Yes-CN, More preferably -CN or Even more preferred is -CN.

[0226] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, R 2 is selected from hydrogen, optionally substituted C 1-6Alkyl, -C(O)R 2a and -S(O)2R 2a In some embodiments, R 2 Yes-C(O)R 2a In some of the above embodiments, R 2a is independently optionally substituted C 1-4 Alkyl, preferably unsubstituted C 1-4 In some embodiments, R 2 It is -C(O)CH3.

[0227] In some preferred embodiments, R 2 is selected from hydrogen and optionally substituted C 1-4 Alkyl (preferably unsubstituted C 1- 4 alkyl, especially CH 3 ), more preferably H .

[0228] In some preferred embodiments, R 1 is -CN, and R 2 It’s H.

[0229] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, R 3 Yes - (CH2) n Cy, and n is 0. Therefore, in some preferred embodiments, R 3 It's Cy.

[0230] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, Cy is selected from C 3-6 cycloalkyl, 8- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, phenyl, naphthyl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, phenyl, naphthyl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace.

[0231] In some such embodiments, Cy comprises 0, 1, 2, or 3 R x Substituted C 3-6 Cycloalkyl, especially unsubstituted C 3-6 In some further embodiments, Cy comprises unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

[0232] In some preferred embodiments, Cy comprises 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3 R xIn some embodiments, Cy comprises an unsubstituted phenyl group. In some embodiments, Cy comprises an unsubstituted phenyl group. x In some embodiments, Cy comprises phenyl substituted by 2 R x substituted phenyl, particularly substituted at the 2- and 3-positions, 2- and 5-positions, or 2- and 6-positions. In some embodiments, Cy comprises substituted phenyl with 3 R x Substituted phenyl, particularly substituted at the 2-, 3- and 4-positions, or 2-, 3- and 5-positions, or 2-, 3- and 6-positions. In some preferred embodiments, Cy comprises:

[0233] Preferred embodiments are those wherein the phenyl group is unsubstituted or substituted with 1 or 2 R x Those embodiments that have been replaced.

[0234] In other preferred embodiments, Cy comprises 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3 R x In some embodiments, Cy comprises an unsubstituted naphthyl. In some embodiments, Cy comprises an unsubstituted naphthyl. x In some embodiments, Cy comprises two R x In some embodiments, Cy comprises 3 R x In some embodiments, Cy comprises:

[0235] In some preferred embodiments, Cy is More preferably

[0236] In other preferred embodiments, Cy includes a 5- or 6-membered heteroaryl group having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, which is separated by 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3 R x In some embodiments, Cy comprises a 5-membered heteroaryl group having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy comprises a 6-membered heteroaryl group having 1-3 nitrogen heteroatoms. In some embodiments, Cy comprises a 6-membered heteroaryl ring having 1-2 nitrogen heteroatoms. In some embodiments, Cy comprises a pyridyl group. In some such embodiments, Cy comprises a pyridin-2-yl group, preferably a pyridin-3-yl group or a pyridin-4-yl group. In some embodiments, Cy comprises a pyridazinyl group, particularly a pyridazin-4-yl group. In some embodiments, Cy comprises a pyrazinyl group. In some embodiments, Cy comprises a pyrimidinyl group. In any of the above embodiments, Cy is replaced by 1 or 2 R xIn some embodiments, Cy comprises:

[0237] Preferred

[0238] In other preferred embodiments, Cy includes an 8- to 10-membered bicyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, in particular an 8-membered, in particular a 9- or 10-membered bicyclic heteroaryl group having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, which is surrounded by 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3 R x In some such embodiments, the bicyclic heteroaryl is a fused ring system of a benzene ring and a 5- or 6-membered heteroaryl, wherein all heteroatoms are in the 5- or 6-membered heteroaryl ring and are not shared atoms. In some preferred embodiments, Cy includes a 9- or 10-membered bicyclic heteroaryl having 1-2 nitrogen heteroatoms. In some embodiments, Cy includes a 9-membered bicyclic heteroaryl having 1 or 2 nitrogen heteroatoms. In some embodiments, Cy includes a 10-membered bicyclic heteroaryl having 1 or 2 nitrogen heteroatoms. In some further embodiments, the bicyclic heteroaryl has only nitrogen atoms as heteroatoms. In some embodiments, Cy includes indolyl, indazolyl, benzimidazolyl, quinolinyl, or quinazolinyl. In some embodiments, Cy includes indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, or indol-7-yl. In some embodiments, Cy comprises indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol-6-yl, or indazol-7-yl. In some embodiments, Cy comprises quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, or quinolin-8-yl. In some preferred embodiments, Cy is replaced by 1 R x replace.

[0239] In some particular embodiments, Cy comprises:

[0240] Preferred

[0241] In other preferred embodiments, Cy includes an 8- to 10-membered (particularly 9- or 10-membered) bicyclic heterocyclic group having 1-3 (e.g., 1, 2, or 3) heteroatoms independently selected from nitrogen, oxygen, and sulfur, which is surrounded by 0, 1, 2, or 3 R xSubstitution. In some such embodiments, the bicyclic heterocyclyl is a fused ring system of a benzene ring and a 5- or 6-membered saturated or partially unsaturated heterocyclyl, wherein all heteroatoms are in the 5- or 6-membered saturated or partially unsaturated heterocyclyl ring and are not shared atoms. In some embodiments, the bicyclic heterocyclyl is a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the bicyclic heterocyclyl is a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 heteroatoms independently selected from oxygen and sulfur. In some preferred embodiments, the bicyclic heterocyclyl is a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2, preferably 1 oxygen heteroatom. In some embodiments, the bicyclic heterocyclyl is a 9-membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2, preferably 1 sulfur heteroatom. In some embodiments, the bicyclic heterocyclyl is a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms. In some preferred embodiments, the bicyclic heterocyclyl is a 9-membered saturated or partially unsaturated bicyclic heterocyclyl having 1 nitrogen heteroatom and 0 or 1, preferably 0, oxygen or sulfur heteroatoms. In some embodiments, Cy includes 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, indolinyl, 2,3-dihydrobenzoindazolyl, 2,3-dihydrobenzimidazolyl, chromanyl, dihydrobenzothiopyran, tetrahydroquinolinyl. In some embodiments, Cy includes 2,3-dihydrobenzofuranyl-4-yl, 2,3-dihydrobenzofuranyl-6-yl. In some embodiments, Cy includes 2,3-dihydrobenzothienyl-4-yl, 2,3-dihydrobenzothienyl-6-yl. In some embodiments, Cy includes indolin-4-yl, indolin-6-yl. In some such embodiments, Cy is replaced by 1 R x In some embodiments, Cy comprises:

[0242] Preferably

[0243] In some preferred embodiments, Cy is selected from:

[0244] Unsubstituted or as described above with 1, 2 or 3 R x substituted phenyl;

[0245] By 1 R x substituted naphthyl;

[0246] a 5- or 6-membered heteroaryl group having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably a 5-membered heteroaryl group having 1 nitrogen heteroatom and 0 or 1 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a 6-membered heteroaryl group having 1 or 2 nitrogen heteroatoms (especially pyridyl, pyridazinyl or pyrimidinyl), more preferably pyridin-2-yl, even more preferably pyridin-3-yl, pyridin-4-yl or pyridazin-4-yl, each of which is replaced by 1 or 2 R x replace;

[0247] 9- or 10-membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, more preferably a bicyclic heteroaryl fused with a benzene ring and a 5- or 6-membered heteroaryl as described above, even more preferably a 9- or 10-membered bicyclic heteroaryl having 1-2 nitrogen heteroatoms (especially quinolinyl and indazolyl), each of these groups being replaced by 0, 1, 2 or 3 R x Replacement; and

[0248] a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclic group having 1, 2 or 3, preferably 1 or 2, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably a fused bicyclic heterocyclic group of a benzene ring as described above and a 5- or 6-membered saturated or partially unsaturated heterocyclic group, more preferably a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclic group having 1 or 2 (especially 1) heteroatoms independently selected from oxygen and sulfur, or a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclic group having 1 or 2 (especially 1) nitrogen heteroatoms and 0 or 1 (especially 0) oxygen or sulfur heteroatoms, each of which is replaced by 0, 1, 2 or 3 R x replace;

[0249] More preferably selected from:

[0250] Preferred Preferred

[0251] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, R 4 Selected from the following groups:

[0252] a)H;

[0253] b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 Alkyl, such as -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2;

[0254] b2) C substituted by a group selected from the following 1-6Alkyl (preferably C 1-4 Alkyl): -OH, -SH, and 1, 2, 3 or more halogens.

[0255] In some such embodiments, R 4 including C substituted by 1, 2, 3 or more halogens 1-6 Alkyl, for example (methyl substituted by 1, 2 or preferably 3 halogen)-C 0-5 Alkyl-, for example (methyl substituted by 1, 2 or preferably 3 halogen)-C 0-3 In some embodiments, the halogen is F, Cl or Br, preferably F or Cl, more preferably F. In some embodiments, R 4 Including -CF3, -CH2CF3, -CH2CH2CF3 or -CH2CH2CH2CF3.

[0256] In other such embodiments, R 4 Including OH substituted C 1-6 Alkyl (preferably C 1-4 In other such embodiments, R 4 Including SH substituted C 1-6 Alkyl (preferably C 1-4 Alkyl), for example -CH2-SH, -CH2CH2-SH, -CH2CH2CH2-SH or -CH2CH2CH2CH2-SH;

[0257] c)-C(O)R 4a and -S(O)2R 4a , where R 4a As defined above, preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably CH3;

[0258] d) Each is 0, 1, 2, 3 or 4 R x Substituted with the following groups:

[0259] d1)C 3-7 Cycloalkyl, preferably C 4-6 cycloalkyl groups such as cyclobutyl, cyclopentyl, and cyclohexyl;

[0260] d2) a 4-, 5- or 6-membered saturated or partially unsaturated monocyclic heterocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, for example azetidinyl;

[0261] d3)C 6-10Aryl, preferably phenyl and naphthyl;

[0262] d4) 5- or 6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, for example pyrazolyl;

[0263] Preferably, the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are unsubstituted.

[0264] In some embodiments, R 4 Is H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -CH2CH2CF3, -CH2CH2CH2CF3, -CH2-OH, -CH2CH2-OH, -CH2CH2CH2-OH, -C(O)CH3, -S(O)2CH3,

[0265] In some embodiments, when R 4 As defined above, R 1 In some embodiments, R 4 is H, and R 1 As mentioned above about R 1 Defined -CONR 1a R 1b or 5- or 6-membered heteroaryl, such as -CONH2, -CON(CH3)2, or

[0266] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, R x Selected from the following groups:

[0267] a) halogen (e.g., F, Cl, or Br), -CN, -NO2, -OH, and -SH;

[0268] b) -O- optionally substituted C 1-4 Alkyl and -S- optionally substituted C 1-4 Alkyl, preferably -O-CH3 and -S-CH3;

[0269] c)-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-NR 3a R 3b 、-CONR 3a R 3b and -CO2R 3a , where R 3a 、R 3bEach is as defined above, preferably selected from H and optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 In some such embodiments, R x Including -COCH3, -SO2CH3, -SO2NHCH3, -SO2N(CH3)2, -NH2, -NH(C 1-6 alkyl) (especially -NHCH3), -CONH2, -CO2H or -CO2CH3.

[0270] d) unsubstituted or substituted by 1, 2, 3 or more halogens 1-6 Alkyl (preferably C 1-4 alkyl, such as CH3), such as CF3.

[0271] In some preferred embodiments, R x Selected from F, Cl, -CN, CF3, -O-CH3, -SO2CH3 or -CO2CH3.

[0272] In any and all embodiments described above according to the first and second aspects, unless otherwise indicated, R 3 Selected from:

[0273] In a third aspect, as a subset of any one of the first and second aspects, the present disclosure provides a compound as described above, or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof,

[0274] in:

[0275] R 1 is -CN;

[0276] R 2 is hydrogen;

[0277] R 3 It's Cy;

[0278] Cy is as defined above in any embodiment according to the first aspect, especially the second aspect, and is preferably selected from an 8- to 10-membered saturated or partially unsaturated bicyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10aryl, 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8 to 10 membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the heterocyclic group, aryl and heteroaryl are as defined in any embodiment described above according to the first aspect, especially the second aspect, and wherein the heterocyclic group, aryl and heteroaryl are each replaced by 0, 1, 2 or 3 R x replace;

[0279] R 4 is selected from hydrogen, optionally substituted C 1-6 Alkyl and 0, 1, 2 or 3 R x Substituted C 4-6 cycloalkyl; and

[0280] Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 Alkyl, -SH, -S- optionally substituted C 1-6 Alkyl, -C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b and optionally substituted C 1-6 alkyl;

[0281] R 3a and R 3b are each independently hydrogen or optionally substituted C 1-6 alkyl.

[0282] In some preferred embodiments, Cy is surrounded by 0, 1, 2 or 3 R x In some embodiments, Cy is unsubstituted phenyl. In some embodiments, Cy is substituted with 1 R x In some embodiments, Cy is substituted with 2 R x In some embodiments, Cy is substituted with 3 R x Substituted phenyl, in particular substituted at the 2-, 3- and 4-positions, or 2-, 3- and 5-positions, or 2-, 3- and 6-positions. In some preferred embodiments, Cy is:

[0283] In some preferred embodiments, Cy is separated by 1 R xIn some preferred embodiments, Cy is Preferably

[0284] In some preferred embodiments, Cy is a 5- or 6-membered heteroaryl group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably a 5-membered heteroaryl group having 1 nitrogen heteroatom and 0 or 1 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a 6-membered heteroaryl group having 1 or 2 nitrogen heteroatoms (particularly pyridyl, pyridazinyl or pyrimidinyl), more preferably pyridin-2-yl, even more preferably pyridin-3-yl, pyridin-4-yl or pyridazin-4-yl, each of which is replaced by 1 or 2 R x In some preferred embodiments, Cy is:

[0285] Preferred

[0286] In some preferred embodiments, Cy is a 9- or 10-membered bicyclic heteroaryl group having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, which is surrounded by 1, 2, or 3 R x In some preferred embodiments, Cy is a 9-membered bicyclic heteroaryl with 1 or 2 nitrogen atoms. In some preferred embodiments, Cy is a 10-membered bicyclic heteroaryl with 1 or 2 nitrogen atoms. In some preferred embodiments, Cy is replaced by 1 R x In some preferred embodiments, Cy is Preferred

[0287] In some preferred embodiments, Cy is a 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclic group having 1, 2, or 3, preferably 1 or 2, heteroatoms independently selected from nitrogen, oxygen, and sulfur, which is surrounded by 0, 1, 2, or 3 R xSubstituted, wherein the bicyclic heterocyclyl is a fused ring system of a benzene ring and a 5- or 6-membered saturated or partially unsaturated heterocyclyl, wherein all heteroatoms are in the 5- or 6-membered saturated or partially unsaturated heterocyclyl ring and are not shared atoms. Such bicyclic heterocyclyls include 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indolinyl, 2,3-dihydrobenzidinazolyl, 2,3-dihydrobenzimidazolyl, chromanyl, dihydrochromanthiopyran and tetrahydroquinolinyl. In some such embodiments, the bicyclic heterocyclic group is preferably a 9- or 10-membered (especially 9-membered) saturated or partially unsaturated bicyclic heterocyclic group having 1 or 2 (especially 1) heteroatoms independently selected from oxygen and sulfur, preferably a 2,3-dihydrobenzofuranyl group, especially a 2,3-dihydrobenzofuran-4-yl group; or a 9- or 10-membered (especially 9-membered) saturated or partially unsaturated bicyclic heterocyclic group having 1 or 2 (especially 1) nitrogen heteroatoms and 0 or 1 (especially 0) oxygen or sulfur heteroatoms, preferably an indolin-4-yl group. In some preferred embodiments, Cy is replaced by 1 R x In some preferred embodiments, Cy is:

[0288] Preferred

[0289] In some preferred embodiments, R 4 Selected from the following groups:

[0290] a)H;

[0291] b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 Alkyl, such as -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2;

[0292] b2) C substituted by a group selected from the following 1-4 Alkyl: -OH and 1, 2, 3 or more halogens.

[0293] In some preferred embodiments, R 4 is C substituted by 1, 2, 3 or more halogens 1-4 Alkyl, for example (methyl substituted by 1, 2 or preferably 3 halogen)-C 0-5 Alkyl-, for example (methyl substituted by 1, 2 or preferably 3 halogen)-C 0-3 In some embodiments, R 4 is -CF3, -CH2CF3, -CH2CH2CF3 or -CH2CH2CH2CF3. In some preferred embodiments, R 4 It is C substituted with OH 1-6 Alkyl (preferably C 1-4Alkyl), for example -CH2-OH, -CH2CH2-OH, -CH2CH2CH2-OH or -CH2CH2CH2CH2-OH;

[0294] d1) Unsubstituted C 4-6 Cycloalkyl groups such as cyclobutyl, cyclopentyl and cyclohexyl.

[0295] In some preferred embodiments, R 4 is H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -CH2CH2CF3, -CH2CH2CH2CF3, -CH2-OH, -CH2CH2-OH, -CH2CH2CH2-OH,

[0296] In some preferred embodiments, R x Selected from the following groups:

[0297] a) halogen (such as F, Cl or Br), -CN;

[0298] b) -O- optionally substituted C 1-4 Alkyl and -S- optionally substituted C 1-4 Alkyl, preferably -O-CH3 and -S-CH3;

[0299] c)-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a and-CONR 3a R 3b , where R 3a 、R 3b are each independently H or optionally substituted C 1-6 Alkyl, preferably H or optionally substituted C 1-4 Alkyl, more preferably H or CH3; and

[0300] d) C substituted by 1, 2, 3 or more halogens 1-6 Alkyl, preferably CF3.

[0301] In some more preferred embodiments, R x Selected from the following groups:

[0302] a) F, Cl, -CN;

[0303] b) -O- optionally substituted C 1-4 Alkyl, preferably -O-CH3; and

[0304] c)-SO2R 3a and -CO2R 3a , where R 3a is independently H or optionally substituted C 1-6 Alkyl, preferably H or CH3. In some preferred embodiments, R x It is -SO2CH3 or -CO2CH3.

[0305] d) C substituted by 1, 2, 3 or more halogens 1-4 Alkyl, preferably CF3.

[0306] In some preferred embodiments, R x Selected from F, Cl, -CN, CF3, -O-CH3, -SO2CH3 or -CO2CH3.

[0307] In some embodiments, R 3 Selected from:

[0308] It is understood that the compound of formula I having the structure

[0309] When R 4 When H is present, it can exist in two tautomeric forms:

[0310] Therefore, it should be understood that when R 4 When is H, the compound of Formula I may be drawn in either tautomeric form.

[0311] In a fourth aspect, the present disclosure provides a compound of formula I according to the first, second and third aspects above, which has a structure shown in one of the following formulas Ia, Iai, Ia-ii or Ia-iii to Ia-xiv,

[0312] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound, or prodrug thereof.

[0313] In some embodiments, R 1 Thus, in some embodiments, the present disclosure provides compounds of Formula Ia:

[0314] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof, wherein R2 、R 3 and R 4 Each of is as defined in any of the embodiments above and described herein.

[0315] In some embodiments of Formula Ia, R 2 is H. Thus, the present disclosure provides compounds of Formula Iai:

[0316] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof, wherein R 3 and R 4 Each of is as defined in any of the embodiments above and described herein.

[0317] In some embodiments of Formula Iai, R 3 is Cy. Therefore, the present disclosure provides compounds of Formula Ia-ii:

[0318] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof, wherein Cy and R 4 Each of is as defined in any of the embodiments above and described herein.

[0319] In some embodiments of Formula Ia-ii, the present disclosure provides compounds of Formulas Ia-iii to Ia-xiv:

[0320] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof, wherein R 4 and R x Each of is as defined in any of the embodiments above and described herein.

[0321] In a fifth aspect, as a subset of any one of the first, second, third and fourth aspects, the present disclosure provides a compound of Formula I as described above, or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug or pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound or prodrug thereof, wherein:

[0322] R 1 is -CN;

[0323] R 2 is hydrogen;

[0324] R 3 It's Cy;

[0325] Cy is 1 or 2 R x substituted phenyl;

[0326] R 4 is selected from hydrogen and optionally substituted C 1-6 alkyl; and

[0327] Each R x independently selected from halogen, -CN and optionally substituted C 1-6 alkyl.

[0328] Such compounds can be represented by the structures of Formulas Ia-xv below, which are a subset of the compounds of Formulas Ia-iii:

[0329] in

[0330] R 4 is selected from hydrogen and optionally substituted C 1-6 alkyl; and

[0331] Each R x independently selected from halogen, -CN and optionally substituted C 1-6 alkyl.

[0332] In some preferred embodiments, Cy is separated by 1 R x In some preferred embodiments, Cy is substituted by two R x Substituted phenyl, in particular substituted at the 2- and 3-positions, 2- and 5-positions, or 2- and 6-positions. In some preferred embodiments, Cy is:

[0333] In some preferred embodiments, R 4 Selected from the following groups:

[0334] a)H;

[0335] b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 Alkyl, such as -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2;

[0336] b2) C substituted by 1, 2, 3 or more halogens1-4 Alkyl, such as -CF3, -CH2CF3, -CH2CH2CF3 or -CH2CH2CH2CF3, preferably -CF3, -CH2CF3, -CH2CH2CF3.

[0337] In some preferred embodiments, R 4 It is H, -CH3, -CF3, -CH2CF3, -CH2CH2CF3.

[0338] In some preferred embodiments, R x Selected from: halogen (such as F, Cl or Br); -CN; C substituted by 1, 2, 3 or more halogens 1-6 Alkyl, preferably CF3.

[0339] In some preferred embodiments, R x Selected from F, Cl, -CN and CF3.

[0340] In some embodiments, R 3 Selected from:

[0341] In any of the embodiments described above, halogen is F, Cl or Br, preferably F or Cl.

[0342] In some embodiments, the present disclosure provides a compound selected from the group consisting of:

[0343] Tool compounds

[0344] In some embodiments, one or more compounds of Formula I are tethered to a detectable moiety to form a tool compound. In some embodiments, the tool compound comprises a compound of Formula I, a detectable moiety, and a tethering moiety that links the detectable moiety to the compound of Formula I. In some embodiments, the tool compound comprises a compound of Formula I and a moiety comprising a functional group capable of binding to or reacting with a detectable moiety.

[0345] In some embodiments, the present disclosure provides compounds of Formula II:

[0346] or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof, wherein R 1 、R 2 and R 3Each of the following is as defined above with respect to Formula I and subgroups thereof, and described in various aspects and subgroups herein; T is a divalent tethering moiety; and R t is the detectable portion.

[0347] In some embodiments, R t is a detectable moiety selected from a primary label or a secondary label. t The detectable moiety is selected from the group consisting of a fluorescent label (eg, a fluorescent dye or chromophore), a mass tag, a chemiluminescent group, a chromophore, an electron-dense group, and an energy transfer agent.

[0348] As used herein, the term "detectable moiety" is used interchangeably with the terms "label" and "reporter molecule" and refers to any moiety capable of being detected, such as primary and secondary labels. The presence of a detectable moiety can be measured using methods that quantify (in absolute, approximate, or relative terms) the detectable moiety in the system under investigation. In some embodiments, such methods are well known to those of ordinary skill in the art and include any method of quantifying a reporter moiety (e.g., a label, a dye, a photocrosslinker, a cytotoxic compound, a drug, an affinity label, a photoaffinity label, a reactive compound, an antibody or antibody fragment, a biomaterial, a nanoparticle, a spin label, a chromophore, a metal-containing moiety, a radioactive moiety, a quantum dot, a novel functional group, a group that covalently or non-covalently interacts with other molecules, a photocaged moiety, an actinic radiation excitable moiety, a ligand, a photoisomerizable moiety, biotin, a biotin analog (e.g., biotin sulfoxide), a moiety incorporating a heavy atom, a chemically cleavable group, a photocleavable group, a redox-active agent, an isotopically labeled moiety, a biophysical probe, a phosphorescent group, a chemiluminescent group, an electron dense group, a magnetic group, an intercalating group, a chromophore, an energy transfer agent, a biologically active agent, a detectable label, and any combination of the foregoing).

[0349] Primary labels, such as radioisotopes (e.g. tritium, 32 P. 33 P. 35 S. 14 C. 123 I. 124 I. 125 I or 131 I), mass labels, including but not limited to stable isotopes (e.g. 13 C. 2 H. 17 O. 18 O. 15 N. 19 F and 127 I), positron-emitting isotopes (e.g. 11 C. 18 F.13 N. 124 I and 15 (O) and fluorescent labels are signal-generating reporter groups that can be detected without further modification. The detectable moiety can be analyzed by methods including, but not limited to, fluorescence, positron emission tomography, SPECT medical imaging, chemiluminescence, electron spin resonance, UV / visible absorption spectroscopy, mass spectrometry, nuclear magnetic resonance, magnetic resonance, flow cytometry, autoradiography, scintillation counting, phosphorimaging, and electrochemical methods.

[0350] As used herein, the term "secondary label" refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate to produce a detectable signal. For biotin, the second intermediate may include a streptavidin-enzyme conjugate. For antigen labels, the second intermediate may include an antibody-enzyme conjugate. Some fluorescent groups act as secondary labels because they transfer energy to another group in a non-radiative fluorescence resonance energy transfer (FRET) process, and this second group produces the detection signal.

[0351] As used herein, the terms "fluorescent label," "fluorescent dye," and "chromophore" refer to a moiety that absorbs light energy at a defined excitation wavelength and emits light energy at a different wavelength. Examples of fluorescent labels include, but are not limited to, Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 493 / 503, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665), carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), dansyl, Dapoxyl, dialkylaminocoumarins, 4',5'-dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, eosin, erythrosine, fluorescein, FAM, hydroxycoumarins, IRDye (IRD40, IRD 700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue, methoxycoumarin, naphthylfluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue Blue), PyMPO, pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'-tetra-bromosulfone-fluorescein, tetramethyl-rhodamine (TMR), carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X, 5(6)-carboxyfluorescein, 2,7-dichlorofluorescein, N,N-bis(2,4,6-trimethylphenyl)-3,4:9,10-Perylenebis(dicarboximide), HPTS, Ethyl Eosin, DY-490XLMegaStokes, DY-485XL MegaStokes, Adirondack Green 520, ATTO 465, ATTO 488, ATTO 495, YOYO-1, 5-FAM, BCECF, dichlorofluorescein, Rhodamine 110, Rhodamine 123, YO-PRO-1, SYTOX Green, Sodium Green, SYBR Green I, Alexa Fluor 500, FITC, Fluo-3, Fluo-4, fluoro-emerald, YoYo-1ssDNA, YoYo-1dsDNA, YoYo-1, SYTO RNASelect, Diversa Green-FP, Dragon Green Green), EvaGreen, Surf Green EX, Spectrum Green, NeuroTrace 500525, NBD-X, MitoTracker Green FM, LysoTracker Green DND-26, CBQCA, PA-GFP (activated), WEGFP (activated), FlASH-CCXXCC, Azami Green monomeric, Thistle Green, Green Fluorescent Protein (GFP), EGFP (Campbell Tsien 2003), EGFP (Patterson 2001), Kaede Green, 7-benzylamino-4-nitrobenzo-2-oxa-1,3-diazole, Bexl, Doxorubicin, LumioGreen, and SuperGlo GFP.

[0352] As used herein, the term "mass tag" refers to any moiety that can be uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques. Examples of mass tags include electrophoretically releasable tags such as N-[3-[4'-[(p-methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceryl]isonipic acid, 4'-[2,3,5,6-tetrafluoro-4-(pentafluorophenoxy)]methylacetophenone, and derivatives thereof. The synthesis and utility of these mass tags are described in U.S. Patents 4,650,750, 4,709,016, 5,360,8191, 5,516,931, 5,602,273, 5,604,104, 5,610,020, and 5,650,270. Other examples of mass tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying lengths and base compositions, oligopeptides, oligosaccharides, and other synthetic polymers of varying lengths and monomer compositions. Various neutral and charged organic molecules (biomolecules or synthetic compounds) in the appropriate mass range (100-2000 Daltons) can also be used as mass labels. Stable isotopes (e.g. 13 C. 2 H. 17 O. 18 O and 15 N) can also be used as a quality label.

[0353] As used herein, the term "chemiluminescent group" refers to a group that emits light due to a chemical reaction without the addition of heat. For example, luminol (5-amino-2,3-dihydro-1,4-phthalhydrazide) reacts with an oxidizing agent such as hydrogen peroxide (H2O2) in the presence of a base and a metal catalyst to produce an excited-state product (3-aminophthalic acid, 3-APA).

[0354] As used herein, the term "chromophore" refers to a molecule that absorbs light at visible, UV, or IR wavelengths.

[0355] As used herein, the term "dye" refers to a soluble colored substance containing a chromophore.

[0356] As used herein, the term "electron-dense group" refers to a group that scatters electrons when irradiated with an electron beam. Such groups include, but are not limited to, ammonium molybdate, bismuth subnitrate, cadmium iodide, carbohydrazide, ferric chloride hexahydrate, hexamethylenetetramine, anhydrous indium trichloride, lanthanum nitrate, lead acetate trihydrate, lead citrate trihydrate, lead nitrate, periodic acid, phosphomolybdic acid, phosphotungstic acid, potassium ferrocyanide, potassium ferrocyanide, ruthenium red, silver nitrate, silver protein (Ag assay: 8.0-8.5%) "Strong", silver tetraphenylporphine (S-TPPS), sodium chloroaurate, sodium tungstate, thallium nitrate, thiosemicarbazide (TSC), uranyl acetate, uranyl nitrate, and vanadyl sulfate.

[0357] As used herein, the term "energy transfer agent" refers to a molecule that donates energy to or accepts energy from another molecule. By way of example only, fluorescence resonance energy transfer (FRET) is a dipole-dipole coupling process by which the excited state energy of a fluorescent donor molecule is nonradiatively transferred to an unexcited acceptor molecule, which then emits the donated energy as a fluorescent light at a longer wavelength.

[0358] As used herein, the term "moiety incorporating a heavy atom" refers to a group that incorporates an ion of an atom, typically heavier than carbon. In some embodiments, such ions or atoms include, but are not limited to, silicon, tungsten, gold, lead, and uranium.

[0359] As used herein, the term "photoaffinity label" refers to a label with a group that, upon exposure to light, forms a bond with a molecule that has an affinity for the label.

[0360] As used herein, the term "photocaging moiety" refers to a group that covalently or non-covalently binds to other ions or molecules under irradiation of certain wavelengths.

[0361] As used herein, the term "photo-isomerisable moiety" refers to a group that changes from one isomeric form to another when irradiated with light.

[0362] As used herein, the term "radioactive moiety" refers to a group whose nucleus spontaneously emits nuclear radiation, such as alpha, beta, or gamma particles; where alpha particles are helium nuclei, beta particles are electrons, and gamma particles are high-energy photons.

[0363] The term "spin label" as used herein refers to a molecule containing an atom or group of atoms exhibiting an unpaired electron spin (i.e., a stable paramagnetic group) that is detected by electron spin resonance spectroscopy in some embodiments and is attached to another molecule in other embodiments. Such spin label molecules include, but are not limited to, nitroxyl radicals and nitroxides, and in some embodiments are single spin labels or dual spin labels.

[0364] As used herein, the term "quantum dots" refers to colloidal semiconductor nanocrystals that, in some embodiments, are detected in the near-infrared and have extremely high quantum yields (ie, are very bright under moderate illumination).

[0365] Those of ordinary skill in the art will recognize that the detectable portion can be connected to the provided compound through a suitable substituent. As used herein, the term "suitable substituent" refers to a portion that can be covalently linked to the detectable portion. Such portions are well known to those of ordinary skill in the art and include groups containing, for example, carboxylate moieties, amino moieties, sulfhydryl moieties, or hydroxyl moieties (just to name a few). It should be understood that such portions can be connected to the provided compound directly or through a tethered portion (such as a divalent saturated or unsaturated hydrocarbon chain).

[0366] In some embodiments, -T- is selected from -(CH2CH2O) m -、-(C 1-6 alkyl)N(R)C(O)(C 1-6 alkyl)- and -(CH2CH2O) m (C 1-6 alkyl)N(R)C(O)(C 1-6 alkyl)-, wherein m is 1-4. In some embodiments, -T- is selected from -(CH2CH2O) m -、-(C 3-5 alkyl)N(R)C(O)(C 2-4 alkyl)- and -(CH2CH2O) m (C 3-5 alkyl)N(R)C(O)(C 2- 4-alkyl)-, wherein m is 2-3. In some embodiments, -T- is selected from:

[0367] In some embodiments, the detectable moiety R t The compound of Formula I is linked to the compound of Formula I by click chemistry. In some embodiments, the compound of Formula I is linked to -TR by 1,3-cycloaddition of an azide and an alkyne (optionally in the presence of a copper catalyst). t Methods using click chemistry are known in the art and include methods described by Rostovtsev et al., Angew.Chem.Int.Ed., 2002, 41, 2596-99 and Sun et al., Bioconjugate Chem., 2006, 17, 52-57. In some embodiments, the compound of formula IV is a click ready inhibitor. In some such embodiments, the click ready inhibitor of formula IV is combined with click ready-TR tAs used herein, "click-ready" refers to a moiety containing an azide or alkyne for use in click chemistry reactions. In some embodiments, the click-ready inhibitor moiety comprises an azide. In certain embodiments, the click-ready inhibitor moiety comprises an azide. t Partially comprised strained cyclooctynes ​​for copper-free click chemistry reactions (eg, using the methods described in Baskin et al., Proc. Natl. Acad. Sci. USA, 2007, 104, 16793-16797).

[0368] In some embodiments, one or more compounds of Formula I covalently inhibit SARM1. In some embodiments, one or more compounds of Formula I covalently modify a cysteine ​​residue of SARM1. In some embodiments, one or more compounds of Formula I covalently modify Cys635 of SARM1. In some embodiments, one or more compounds of Formula I covalently modify Cys629 of SARM1. In some embodiments, one or more compounds of Formula I covalently modify Cys649 of SARM1. Without wishing to be bound by any particular theory, in some embodiments, one or more compounds of Formula I denature the SARM1 protein by covalent modification of a cysteine ​​residue. In some embodiments, one or more compounds of Formula I denature the SARM1 protein by covalent modification of Cys635. In some embodiments, one or more compounds of Formula I denature the SARM1 protein by covalent modification of Cys629. In some embodiments, one or more compounds of Formula I denature the SARM1 protein by covalent modification of Cys649.

[0369] Preparation of compounds of formula I

[0370] The compounds of formula I can be prepared as shown in the following Schemes 1-4.

[0371] Route 1

[0372] where R 1 and R 4 As defined in any of the embodiments above.

[0373] As shown in Scheme 1, a compound of Formula A is reacted with Lawesson's reagent in a suitable organic solvent at elevated temperature to obtain a compound of Formula B. The organic solvent includes, but is not limited to, toluene and xylene, preferably toluene. The elevated temperature can be, for example, 80-140° C., particularly 90-120° C., or 100-110° C.

[0374] Route 2

[0375] where R 3 As defined in any of the embodiments above.

[0376] As shown in Scheme 2, in the presence of a suitable base, an amine of formula C is reacted with thiophosgene D in a suitable organic solvent at a suitable temperature to obtain an isocyanate of formula E. The suitable temperature can be, for example, about 0°C. The base is, for example, an organic amine, particularly an alkylamine, such as triethylamine. The organic solvent includes dichloromethane (DCM). The reaction can be carried out under an inert atmosphere, for example, under nitrogen protection.

[0377] Route 3

[0378] As shown in Scheme 3, in the presence of a suitable base, the compound of formula B is reacted with isocyanate E at a suitable temperature in a suitable organic solvent to obtain a compound of formula I' (ie, wherein R 2 The base may be an inorganic base, in particular an alkali metal hydroxide, such as NaOH or KOH. The organic solvent may include N,N-dimethylformamide (DMF). The suitable temperature may be, for example, room temperature (20-35° C.).

[0379] Route 4

[0380] As shown in Scheme 4, in the presence of a suitable base, compound I' is reacted with an acid anhydride of formula F in a suitable organic solvent at a suitable temperature to obtain a compound of formula I, wherein R 2 It is C 1-6 The base may be an inorganic base, in particular an alkali metal carbonate, such as sodium bicarbonate or potassium bicarbonate. The organic solvent may include, for example, DCM. The suitable temperature may be, for example, about 0°C.

[0381] Composition

[0382] In some embodiments, a compound of Formula I can be provided as a composition, for example, in combination (eg, admixture) with one or more other components.

[0383] In some embodiments, the present disclosure provides compositions comprising and / or delivering a compound of Formula I, e.g., when contacted with or otherwise administered to a system or environment, e.g., that system or environment may include SARM1 NAD enzyme activity; in some embodiments, administering the composition to the system or environment can achieve inhibition of SARM1 activity as described herein.

[0384] In some embodiments, the compositions described herein can be pharmaceutical compositions, wherein the pharmaceutical compositions comprise an active agent and one or more pharmaceutically acceptable carriers. In some such embodiments, the pharmaceutical compositions comprise a compound of Formula I and / or deliver the compound of Formula I to a relevant system or environment as described herein (e.g., to an individual in need thereof).

[0385] In some embodiments, one or more compounds of Formula I are provided and / or utilized in the form of a pharmaceutically acceptable salt.

[0386] The present disclosure also provides (drug) compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle. The amount of the compound in the composition is such that axonal degeneration in a biological sample or patient is effectively and measurably suppressed. In certain embodiments, the compound or composition is formulated for use in patients in need of such compositions. According to the method of the present disclosure, the compound and composition can be administered using any amount and any route of administration effective for treating or alleviating the severity of any disease or condition described herein. The compound is preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression "unit dosage form" used herein refers to a physically discrete dosage unit suitable for a patient to be treated. However, it should be understood that the total daily dosage of the compound and composition will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism will vary from individual to individual, depending on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific compound employed; the specific composition employed and its route of administration; the species, age, weight, sex, and diet of the patient; the general condition of the individual; the time of administration; the excretion rate of the specific compound employed; the duration of treatment; drugs used in combination or concomitantly with the specific compound employed, and the like.

[0387] The compositions provided by the present disclosure can be administered orally, parenterally, by inhalation or nasal spray, topically (e.g., by powders, ointments, or drops), rectally, buccally, vaginally, intraperitoneally, intracisternalally, or by implanted reservoirs, depending on the severity of the condition being treated. Preferably, the composition is administered orally, intraperitoneally, or intravenously. In certain embodiments, the compound is administered orally or parenterally at a dosage level of about 0.01 mg / kg to about 50 mg / kg of individual body weight, once or more per day to obtain the desired therapeutic effect.

[0388] The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. The sterile injectable form of the composition can be an aqueous or oily suspension. These suspensions can be formulated using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. Sterile injectable preparations can also be sterile injectable solutions or suspensions in non-toxic parenteral acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media.

[0389] For this purpose, any mild fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives can be used to prepare injectables, as can natural pharmaceutically acceptable oils, such as olive oil or castor oil, particularly their polyoxyethylated forms. These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose or similar dispersants, which are commonly used in the preparation of pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifiers or bioavailability enhancers, which are commonly used in the manufacture of pharmaceutically acceptable solids, liquids or other dosage forms, can also be used for formulation purposes.

[0390] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0391] In order to prolong the effect of the compound, it is generally desirable to slow down the absorption of the compound injected subcutaneously or intramuscularly. This can be achieved by using a liquid suspension of a crystalline or amorphous material with poor water solubility. The absorption rate of the compound then depends on its solubility, which in turn can depend on the crystal size and crystalline form. Alternatively, delayed absorption of the compound form administered parenterally can be achieved by dissolving or suspending the compound in an oily vehicle. Injectable depot forms are made by forming a microcapsule matrix of the compound in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the release rate of the compound can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations can also be prepared by encapsulating the compound in liposomes or microemulsions compatible with body tissues.

[0392] The pharmaceutically acceptable compositions provided by the present disclosure can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions. In such solid dosage forms, the active compound can be mixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can also contain additional substances other than the inert diluent, such as lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose, as is normal practice. When an oral aqueous suspension is desired, the active ingredient is combined with an emulsifier and a suspending agent. If desired, certain sweeteners, flavorings or coloring agents can also be added.

[0393] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; c) humectants, such as glycerol; d) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarders, such as paraffin; f) absorption accelerators, such as quaternary ammonium compounds; g) wetting agents, such as cetyl alcohol and glyceryl monostearate; h) absorbents, such as kaolin and bentonite; and / or i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain a buffer. The active compounds can also be in microencapsulated form with one or more excipients as noted above.

[0394] Solid compositions of similar types can also be used as fillers for soft and hard filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings (i.e., buffers) and other coatings well known in pharmaceutical formulation technology. They may optionally contain opacifiers and may also be compositions that release the active ingredient only or preferably in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0395] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings, and aromatics.

[0396] Alternatively, the pharmaceutically acceptable compositions provided by the present disclosure can be used in the form of suppositories for rectal or vaginal administration. These can be prepared by mixing the compounds of the present disclosure with suitable non-irritating excipients or carriers, which are solid at room temperature but liquid at body temperature (e.g., rectal or vaginal temperature) and will therefore melt in the rectum or vaginal cavity to release the active compound. Such materials include cocoa butter, suppository waxes (e.g., beeswax), and polyethylene glycol.

[0397] The pharmaceutically acceptable compositions provided by the present disclosure can also be administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, skin, or lower intestinal tract. Topical administration to the lower intestinal tract can be achieved in the form of a rectal suppository formulation (see above) or a suitable enema formulation.

[0398] The dosage form for topical or transdermal administration of the compound provided by the present disclosure includes ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant or patch. The active ingredient is mixed with a pharmaceutically acceptable carrier and any required preservative or buffer that may be needed under aseptic conditions. Ophthalmic preparations, ear drops and eye drops are also considered within the scope of the present disclosure. In addition, the present disclosure also contemplates the use of transdermal patches, which have the additional advantage of controllably delivering the compound to the body. This type of dosage form can be made by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Rate control can be achieved by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or gel.

[0399] For topical application, the pharmaceutically acceptable compositions provided by the present disclosure can be formulated into a suitable ointment containing an active ingredient suspended or dissolved in one or more carriers. Carriers for topical application of the compounds of the present disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the pharmaceutically acceptable compositions provided can be formulated into a suitable lotion or cream containing an active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0400] For ophthalmic use, the pharmaceutically acceptable compositions provided herein can be formulated as micronized suspensions in isotonic, pH-adjusted sterile saline, or preferably as solutions in isotonic, pH-adjusted sterile saline, with or without preservatives such as benzalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutically acceptable compositions can be formulated in an ointment such as petrolatum.

[0401] The pharmaceutically acceptable compositions of the present disclosure may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in normal saline using benzyl alcohol or other suitable preservatives, absorption enhancers to improve bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0402] Most preferably, the pharmaceutically acceptable compositions of the present disclosure are formulated for oral administration.

[0403] Identification and / or characterization of compounds and / or compositions

[0404] Among other things, the present disclosure provides various techniques for identifying and / or characterizing the compounds and / or compositions described herein.For example, the present disclosure provides various assays for evaluating SARM1 inhibitory activity, in particular for evaluating SARM1 inhibitory activity.

[0405] In some embodiments, the performance of one or more compounds of interest or compositions in assays described herein is compared with the performance of appropriate references. For example, in some embodiments, reference can be to the absence of a related compound or composition. Alternatively or additionally, in some embodiments, reference can be to the presence of an alternative compound or composition, for example, the alternative compound or composition has a known performance (for example, as a positive control or negative control, as understood in the art) in a related assay. In some embodiments, reference can be to a set of alternative but comparable conditions (for example, temperature, pH value, salt concentration, etc.). In some embodiments, reference can be to the performance of a compound or composition relative to a SARM1 variant.

[0406] Further alternatively or additionally, in some embodiments, the performance of one or more compounds or compositions of interest can be assessed in the presence of an appropriate reference compound or composition in an assay described herein, e.g., to determine the ability of the compound or composition to compete with a reference.

[0407] In some embodiments, multiple compounds or compositions of interest can be analyzed and / or compared to the same reference in a particular assay. In some embodiments, such multiple compounds or compositions can be or include a group of compounds or compositions that are considered a "library" because multiple members share one or more characteristics (e.g., structural elements, source characteristics, synthetic similarity, etc.).

[0408] Certain exemplary assays that can be used in the practice of the present disclosure are described in the Examples below. Those skilled in the art reading this disclosure will appreciate that useful or relevant systems for identifying and / or characterizing compounds and / or compositions according to the present disclosure are not limited to those included in the Examples, or those otherwise discussed below.

[0409] In some embodiments, compounds and / or compositions can be identified and / or characterized based on one or more activities or characteristics, such as promoting axonal integrity, cytoskeletal stability, and / or neuronal survival. In some embodiments, provided SARM1 inhibitors inhibit the catabolism of NAD+ by SARM1. In some embodiments, provided SARM1 inhibitors slow the rate of NAD+ catabolism.

[0410] In some embodiments, provided SARM1 inhibitors reduce or inhibit SARM1 binding to NAD+. In some embodiments, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., the catalytic cleft of SARM1). Examples of such catalytic residues include glutamic acid at position 642 (E642).

[0411] In some embodiments, provided SARM1 inhibitors disrupt and / or prevent multimerization of the TIR1 domain of SARM1. In some embodiments, provided SARM1 inhibitors disrupt multimerization of the SAM domain. In some embodiments, provided SARM1 inhibitors disrupt the axonal signaling cascade that leads to NAD+ depletion.

[0412] In some embodiments, the present disclosure provides assays that can be used to identify and / or characterize one or more activities and / or characteristics of a compound and / or composition of interest. For example, in some embodiments, the present disclosure provides in vitro, cellular, and / or in vivo systems for evaluating one or more such activities and / or characteristics.

[0413] SARM1 activity assay

[0414] In some embodiments, a method of identifying a SARM1 inhibitor comprises: a) providing a mixture comprising i) a mutant or fragment of SARM1, ii) NAD+, and iii) a candidate inhibitor, wherein the mutant or fragment is constitutively active; b) incubating the mixture; c) quantifying NAD+ in the mixture after the incubation; and d) identifying the candidate inhibitor compound as an inhibitor if the amount of NAD+ is greater than that of a control mixture that does not comprise the candidate inhibitor.

[0415] In some embodiments, a method of identifying a SARM1 inhibitor is provided, comprising: a) providing a mixture comprising i) full-length SARM1, ii) NAD+, and iii) a candidate inhibitor, wherein the full-length SARM1 is constitutively active; b) incubating the mixture; c) quantifying NAD+ and ADPR (or cADPR) in the mixture after the incubation; d) determining the molar ratio of NAD+:ADPR (or cADPR); and e) identifying the candidate inhibitor compound as an inhibitor if the molar ratio is greater than the molar ratio of a control mixture without the candidate inhibitor.

[0416] In some embodiments, a method of identifying a SARM1 inhibitor is provided, comprising: a) providing a mixture comprising a solid support bound to i) full-length SARM1 and at least one tag, ii) NAD+, and iii) a candidate inhibitor; b) incubating the mixture; c) quantifying NAD+ after the incubation; and d) if the concentration of NAD+ is greater than that of a control, identifying the candidate inhibitor compound as a SARM1 inhibitor.

[0417] SARM1 binding assay

[0418] In some embodiments, the efficacy of a provided SARM1 inhibitor can be determined according to an assay, for example, as described in WO 2018 / 057989, published on March 29, 2018, which is incorporated herein by reference in its entirety. In some embodiments, a provided SARM1 inhibitor can be applied to a solution containing SARM1 or a fragment thereof. In some embodiments, a provided SARM1 inhibitor can be applied to an in vitro system. In some embodiments, a provided SARM1 inhibitor can be applied to an in vivo system. In some embodiments, a provided SARM1 inhibitor can be applied to a patient. In some embodiments, a SARM1 inhibitor can be mixed with a SARM1 or a fragment thereof that has been labeled with an epitope tag. In some embodiments, the amount of bound SARM1 inhibitor can be compared to the amount of unbound SARM1 inhibitor to derive affinity for the SARM1 inhibitor.

[0419] In some embodiments, the mutant or fragment of SARM1 is a constitutively active SAM-TIR fragment. Constitutively active SARM1 fragments include, for example, but are not limited to, SARM1 lacking the autoinhibitory domain; at least one point mutation in SARM1 that inactivates the autoinhibitory domain; a SARM1 fragment containing a TIR domain; or a SARM1 fragment consisting of both a SAM and a TIR domain. In some embodiments, the SARM1 polypeptide may include one or more additional amino acid sequences that may function as a tag, such as a His tag, a streptavidin tag, or a combination thereof. In some embodiments, the SARM1 polypeptide may include a tag at the amino terminus, the carboxyl terminus, or a combination thereof. In some embodiments, SARM1 or a fragment thereof tagged with an epitope tag may be used to measure the binding efficacy of a provided SARM1 inhibitor.

[0420] Purification of SARM1-TIR domain

[0421] In some embodiments, the SARM1-TIR domain can be engineered with various protein tags or epitope tags, which can be used, for example, for purification. In some embodiments, the present disclosure also provides NRK1-HEK293T cell lines, which comprise HEK293T cells transformed with nicotinamide riboside kinase 1 (NRK1). In some embodiments, HEK293T cells are transformed or transfected with a DNA sequence encoding nicotinamide riboside kinase 1 (NRK1). In some embodiments, the DNA encoding NRK1 can be genomic or cDNA. In some embodiments, HEK293T cells are stably or transiently transfected with DNA encoding NRK1 exogenously from the host cell. In some embodiments, HEK293T cells are stably or transiently transfected with DNA encoding NRK1 so that the cells express NRK1 at an elevated level compared to control cells. In some embodiments, the DNA encoding NRK1 is under the control of one or more exogenous regulatory DNA sequences (such as promoters, enhancers, or a combination thereof). In some embodiments, the combination of the DNA sequence encoding NRK1 and the regulatory sequence is a non-naturally occurring combination. In some embodiments, the DNA encoding NRK1, whether genomic or cDNA, comprises an expression vector, such as an FCIV expression vector. In some embodiments, the DNA encoding NRK1 is derived from genomic DNA or cDNA from a vertebrate or invertebrate species, such as, but not limited to, human, mouse, zebrafish, or fruit fly. In some configurations, the NRK1 DNA is human NRK1 DNA.

[0422] Applications and uses

[0423] The present disclosure provides various uses and applications of the compounds and / or compositions described herein, for example, based on the activity and / or characteristics of these compounds and / or compositions as described herein. In some embodiments, such uses may include therapeutic and / or diagnostic uses. Alternatively, in some embodiments, such uses may include research, production, and / or other technical uses.

[0424] In one aspect, the present disclosure provides methods comprising administering to an individual one or more compounds of Formula I, e.g., to treat, prevent, or reduce the risk of one or more diseases, disorders, or conditions characterized by axonal degeneration. In some such embodiments, the compound of Formula I is a SARM1 inhibitor.

[0425] Another embodiment of the present disclosure is directed to a method of inhibiting SARM1 activity in a patient, comprising the step of administering to the patient a provided compound or a composition comprising the compound.

[0426] Inhibiting enzymes in biological samples is useful for a variety of purposes known to those skilled in the art. Examples of such purposes include, but are not limited to, bioassays, gene expression studies, and biological target identification.

[0427] In certain embodiments, the present disclosure relates to a method for treating axonal degeneration in a biological sample, comprising contacting the biological sample with a compound or composition of Formula I. In some embodiments, one or more compounds and / or compositions described herein can be used, for example, to inhibit the degeneration of neurons derived from an individual. In some embodiments, one or more compounds and / or compositions described herein can be used to inhibit the degeneration of neurons cultured in vitro or a portion thereof. In some embodiments, one or more compounds and / or compositions described herein can be used as stabilizers to promote neuronal survival in vitro.

[0428] In some embodiments, provided compounds and / or compositions inhibit the NAD enzyme activity of SARM1. Alternatively or additionally, in some embodiments, provided compounds alleviate one or more attributes of neurodegeneration. In some embodiments, the present disclosure provides methods for treating neurodegenerative diseases, disorders, or conditions associated with axonal degeneration.

[0429] In some embodiments, one or more compounds and / or compositions as described herein can be used in, for example, medical practice. In some embodiments, one or more compounds and / or compositions as described herein can be used in, for example, treating, preventing or improving axonal degeneration (e.g., one or more features or characteristics thereof). In some embodiments, one or more compounds and / or compositions as described herein can be used in, for example, suppressing axonal degeneration, including axonal degeneration caused by reduction or depletion of NAD+. In some embodiments, one or more compounds and / or compositions as described herein can be used in, for example, preventing axonal degeneration at the distal end of axonal injury.

[0430] In some embodiments, one or more compounds as described herein and / or compositions can be used for example to suppress the method for peripheral nervous system neuron or its part degeneration.In some embodiments, one or more compounds as described herein and / or compositions can be used for example to suppress or prevent the method for central nervous system (neuron) or its part degeneration.In some embodiments, one or more compounds as described herein or compositions are characterized in that, when applied to individual colonies, reduce one or more symptoms or features of neurodegeneration.For example, in some embodiments, relevant symptoms or features can be selected from the group consisting of degree, rate and / or opportunity of neuron destruction.

[0431] In certain embodiments, the present disclosure provides compounds according to the present disclosure for use as analytical tools, as probes in biological assays, or as therapeutic agents. The compounds provided herein can also be used to study SARM1 activity in biological and pathological phenomena and for comparative evaluation of new SARM1 activity inhibitors in vitro or in vivo. In certain embodiments, the present disclosure provides assays for identifying and / or characterizing the compounds and / or compositions provided herein. In some embodiments, the assays provided utilize specific reagents and / or systems (e.g., certain vector constructs and / or polypeptides) that can be used to assay SARM1 activity. For example, in some embodiments, the assays provided can utilize, for example, a SAM-TIR lacking the SARM1 N-terminal autoinhibitory domain, and / or one or more tagged versions of the TIR domain.

[0432] In some embodiments, one or more compounds and / or compositions described herein can be used, for example, in methods for inhibiting neuronal degeneration in an individual. In some embodiments, one or more compounds and / or compositions described herein can be used to inhibit the degeneration of neurons cultured in vitro or a portion thereof. In some embodiments, one or more compounds and / or compositions described herein can be used as stabilizers to promote neuronal survival in vitro.

[0433] In some embodiments, one or more compounds and / or compositions as described herein can be used to, for example, affect biomarkers associated with neurodegeneration. In some embodiments, the change of biomarkers can be detected systemically or with samples from individual cerebrospinal fluid (CSF), plasma, serum and / or tissue. In some embodiments, one or more compounds and / or compositions can be used to affect the concentration changes of neurofilament light chain (NF-L) and / or neurofilament heavy chain (NF-H) contained in the cerebrospinal fluid of an individual. In some embodiments, one or more compounds and / or compositions as described herein can affect constitutive NAD and / or cADPR levels in neurons and / or axons.

[0434] In some embodiments, one or more compounds as described herein and / or compositions can affect the detectable change of one or more neurodegeneration-related protein levels in individual.Such proteins include but are not limited to albumin, amyloid-β (Aβ) 38, Aβ40, Aβ42, glial fibrillary acidic protein (GFAP), heart-type fatty acid binding protein (hFABP), monocyte chemoattractant protein (MCP) -1, neurogranulin, neuron-specific enolase (NSE), soluble amyloid precursor protein (sAPP) α, sAPPβ, soluble triggering receptor (sTREM) 2 expressed on myeloid cells, phosphorylation tau and / or total tau (total-tua).In some embodiments, one or more compounds as described herein and / Or compositions can affect the change of cytokines and / or chemokines, including but not limited to Ccl2, Ccl7, Ccl12, Csf1 and / or Il6.

[0435] Diseases, disorders, and conditions

[0436] In some embodiments, the compounds and / or compositions described herein may be administered to an individual suffering from one or more diseases, disorders, or conditions.

[0437] In some embodiments, the disease, disorder, or condition is acute. In some embodiments, the disease, disorder, or condition is chronic.

[0438] In some embodiments, the disease, disorder, or condition is characterized by axonal degeneration of the central nervous system, peripheral nervous system, optic nerves, cranial nerves, or a combination thereof.

[0439] In some embodiments, the disease, disorder, or condition is or comprises acute injury to the central nervous system, such as injury to the spinal cord and / or traumatic brain injury. In some embodiments, the disease, disorder, or condition is or comprises chronic injury to the central nervous system, such as injury to the spinal cord, traumatic brain injury, and / or traumatic axonal injury. In some embodiments, the disease, disorder, or condition is or comprises chronic traumatic encephalopathy (CTE).

[0440] In some embodiments, the disease, disorder, or condition is a chronic condition affecting the central nervous system, such as Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, or Huntington's disease, Alzheimer's disease.

[0441] In some embodiments, the disease, disorder or condition is acute peripheral neuropathy. Chemotherapy-induced peripheral neuropathy (CIPN) is an example of acute peripheral neuropathy. CIPN can be associated with a variety of drugs, such as, but not limited to, thalidomide, epothilone (epothilone) (e.g., ixabepilone), taxane (taxane) (e.g., paclitaxel and docetaxel), vinca alkaloid (vinca alkaloid) (e.g., vinblastine, vinorelbine, vincristine and vindesine), proteasome inhibitors (e.g., bortezomib), platinum drugs (e.g., cisplatin, oxaliplatin and carboplatin).

[0442] In some embodiments, the disease, disorder, or condition is a chronic condition affecting the peripheral nervous system, such as diabetic neuropathy, HIV neuropathy, Charcot-Marie-Tooth disease, or amyotrophic lateral sclerosis.

[0443] In some embodiments, the disease, disorder, or condition is an acute condition affecting the optic nerve, such as acute optic neuropathy (AON) or acute angle-closure glaucoma.

[0444] In some embodiments, the disease, disorder, or condition is a chronic condition affecting the optic nerve, such as Leber's congenital amaurosis, Leber's hereditary optic neuropathy, primary open-angle glaucoma, and autosomal dominant optic atrophy.

[0445] In some embodiments, one or more compounds and / or compositions as described herein can be used for example to treat one or more neurodegenerative diseases, disorders or conditions selected from neuropathy or axonopathy. In some embodiments, one or more compounds and / or compositions as described herein can be used for example to treat neuropathy or axonopathy associated with axonal degeneration. In some embodiments, the neuropathy associated with axonal degeneration is a hereditary or congenital neuropathy or axonopathy. In some embodiments, the neuropathy associated with axonal degeneration is caused by newborn or somatic mutation. In some embodiments, the neuropathy associated with axonal degeneration is selected from the list contained herein. In some embodiments, neuropathy or axonopathy is associated with axonal degeneration, including but not limited to Parkinson's disease, non-Parkinson's disease, Alzheimer's disease, herpes infection, diabetes, amyotrophic lateral sclerosis, demyelinating disease, ischemia or stroke, chemical injury, thermal injury and AIDS.

[0446] In some embodiments, one or more compounds or compositions described herein are characterized in that, when applied to an individual population, one or more symptoms or features of neurodegeneration are reduced. For example, in some embodiments, relevant symptoms or features can be selected from the group consisting of the degree, rate and / or timing of neuronal destruction. In some embodiments, neuronal destruction can be or include axonal degeneration, synapse loss, dendrite loss, synaptic density loss, dendrite arbour loss, axonal branching loss, neuronal density loss, myelination loss, neuronal cell body loss, synaptic potentiation loss, action potential potentiation loss, cytoskeletal stability loss, axonal transport loss, ion channel synthesis and turnover loss, neurotransmitter synthesis loss, neurotransmitter release and reuptake capacity loss, axonal potential propagation loss, neuronal hyperexcitability and / or neuronal hypoexcitability. In some embodiments, neuronal destruction is characterized by the inability to maintain an appropriate resting neuronal membrane potential. In some embodiments, neuronal destruction is characterized by the occurrence of inclusion bodies, plaques and / or neurofibrillary tangles. In some embodiments, neuronal destruction is characterized by the occurrence of stress granules. In some embodiments, the feature of neuronal destruction is the intracellular activation of one or more members of the cysteine-aspartic acid protease (Caspase) family. In some embodiments, the feature of neuronal destruction is that neurons undergo programmed cell death (e.g., apoptosis, pyrolysis, ferroptosis, and / or necrosis) and / or inflammation.

[0447] In some embodiments, the neurodegenerative or nervous system disease, disorder or condition is associated with axonal degeneration, axonal damage, axonopathy, demyelinating disease, central pontine myelinolysis, a nerve damaging disease or disorder, a metabolic disease, a mitochondrial disease, metabolic axonal degeneration, axonal damage due to a leukoencephalopathy or leukodystrophy. In some embodiments, the neurodegenerative or nervous system disease, disorder, or condition is selected from the group consisting of spinal cord injury, stroke, multiple sclerosis, progressive multifocal leukoencephalopathy, congenital hypomyelination, encephalomyelitis, acute disseminated encephalomyelitis, central pontine myelinolysis, osmotic hyponatremia, anoxic demyelination, ischemic demyelination, adrenoleukodystrophy, Alexander's disease, Niemann-Pick disease, Pelizaeus-Merzbacher disease, periventricular leukomalacia, globoid cell leukodystrophy (Krabbe's disease), Wallerian degeneration, optic neuritis, transverse myelitis, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), disease), Huntington disease, Alzheimer's disease, Parkinson's disease, Tay-Sacks disease, Gaucher's disease, Hurler syndrome, traumatic brain injury, post-radiation injury, neurologic complications of chemotherapy (chemotherapy-induced neuropathy; CIPN), neuropathy, acute ischemic optic neuropathy, vitamin B 12deficiency, monovitamin E deficiency syndrome, Bassen-Kornzweig syndrome, glaucoma, Leber's hereditary optic atrophy (neuropathy), Leber's congenital amaurosis, neuromyelitis optica, metachromatic leukodystrophy, acute hemorrhagic leukoencephalitis, trigeminal neuralgia, Bell's palsy, cerebral ischemia, multiple system atrophy, traumatic glaucoma, tropical spastic paraplegia, human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy, West Nile virus encephalopathy, La Crosse virus encephalitis, Bunyavirus encephalitis encephalitis), pediatric viral encephalitis, essential tremor, Charcot-Marie-Tooth disease, motor neuron disease, spinal muscular atrophy (SMA), hereditary sensory and autonomic neuropathy (HSAN), adrenoleukodystrophy, progressive supranuclear palsy (PSP), Friedrich's ataxia, hereditary ataxias, noise-induced hearing loss, congenital hearing loss, Lewy Body Dementia, frontotemporal dementia, amyloidosis, diabetic neuropathy, HIV neuropathy, enteric neuropathy and axonopathy, Guillain-Barré syndrome, severe acute motor axonal neuropathy (AMAN), Creutzfeldt-Jakob disease, transmissible spongiform encephalopathies, spinocerebellar ataxias, preeclampsia, hereditary spastic paraplegia, spastic paraplegia, familial spastic paraplegia, French settlement disease), Strumpell-Lorrain disease, and nonalcoholic steatohepatitis (NASH).

[0448] In some embodiments, the present disclosure provides a SARM1 activity inhibitor for treating a neurodegenerative or nervous system disease or condition involving axonal degeneration or axonopathy. The present disclosure also provides methods of using a SARM1 activity inhibitor to treat, prevent or ameliorate axonal degeneration, axonopathy and a neurodegenerative or nervous system disease, disorder or condition involving axonal degeneration.

[0449] In some embodiments, the present disclosure provides methods of treating a neurodegenerative or nervous system disease, disorder or condition associated with axonal degeneration, axonal injury, axonopathy, demyelinating disease, central pontine myelinolysis, a nerve damaging disease or disorder, a metabolic disease, a mitochondrial disease, metabolic axonal degeneration, axonal injury due to a leukoencephalopathy or leukodystrophy.

[0450] In some embodiments, neuropathy and axonopathy include any disease, disease or the patient's condition related to neurons and / or supporting cells, such as glial cells, muscle cells or fibroblasts, particularly those diseases, diseases or the patient's condition related to axonal injury. Axonal injury can be caused by traumatic injury or by disease, disease or the patient's condition or by exposure to non-mechanical damage caused by toxic molecules or drugs. The result of this damage can be the degeneration or dysfunction of axons and the loss of functional neuronal activity. The disease, disease and the patient's condition produced or related to this axonal injury are one of many neurological diseases, diseases and the patient's condition. Such neuropathy can include peripheral neuropathy, central neuropathy and combinations thereof. In addition, peripheral neurological manifestations can be mainly produced by diseases concentrated in the central nervous system, and central nervous system manifestations can be produced basically by peripheral or systemic diseases.

[0451] In some embodiments, peripheral neuropathy can be related to damage to peripheral nerves, and / or can be caused by nerve diseases or due to systemic diseases.Some such diseases can include diabetes, uremia, infectious diseases such as AID or leprosy, nutritional deficiencies, vascular or collagen disorders such as atherosclerosis, and autoimmune diseases such as systemic lupus erythematosus, scleroderma, sarcoidosis, rheumatoid arthritis and polyarteritis nodosa. In some embodiments, peripheral nerve degeneration is caused by traumatic (mechanical) damage to nerves and chemical or thermal damage to nerves. Such conditions that damage peripheral nerves include compression or pinching, such as glaucoma, carpal tunnel syndrome, direct trauma, penetrating trauma, contusion, fracture or bone dislocation; Pressure related to superficial nerves (ulnar, radial or peroneal nerves), which may be due to long-term use of crutches or staying too long in one position, or due to tumors; Intraneural hemorrhage; Local ischemia; Exposure to cold or radiation or certain drugs or toxic substances, such as herbicides or pesticides. In particular, nerve damage may be due to chemical damage from cytotoxic anticancer agents, such as paclitaxel, cisplatin, proteasome inhibitors, or vinca alkaloids, such as vincristine. Typical symptoms of this type of peripheral neuropathy include weakness, numbness, paresthesia (abnormal sensations such as burning, itching, tingling, or numbness) and pain in the arms, hands, legs, and / or feet. In some embodiments, neuropathy is associated with mitochondrial dysfunction. This neuropathy can manifest as a decrease in energy levels, i.e., a decrease in NAD and ATP levels.

[0452] In some embodiments, peripheral neuropathy is a metabolic and endocrine neuropathy, which includes a wide range of peripheral nerve disorders associated with systemic diseases of metabolic origin. These diseases include, for example, diabetes, hypoglycemia, uremia, hypothyroidism, liver failure, polycythemia, amyloidosis, acromegaly, porphyria, lipid / glycolipid metabolism disorders, nutritional / vitamin deficiencies, and mitochondrial disorders. The common feature of these diseases is that the structure or function of myelin and axons is altered due to metabolic pathway disorders, resulting in involvement of peripheral nerves.

[0453] In some embodiments, neuropathy includes optic neuropathy, such as glaucoma; retinal ganglion degeneration, such as retinal ganglion degeneration associated with retinitis pigmentosa and outer retinal neuropathy; optic nerve neuritis and / or degeneration, including optic neuritis and / or degeneration associated with multiple sclerosis; traumatic injury to the optic nerve, which may include, for example, injury during tumor resection; hereditary optic neuropathies, such as Kjer's disease and Leber's hereditary optic neuropathy; ischemic optic neuropathy, such as optic neuropathy secondary to giant cell arteritis; metabolic optic neuropathy, such as neurodegenerative diseases, including the aforementioned Leber's neuropathy, nutritional deficiencies, such as vitamin B12 or folic acid deficiency, and poisoning, such as due to ethambutol or cyanide; neuropathy caused by adverse drug reactions and neuropathy caused by vitamin deficiency. Ischemic optic neuropathy also includes non-arteritic anterior ischemic optic neuropathy.

[0454] In some embodiments, the neurodegenerative diseases associated with neuropathy or axonopathy in the central nervous system include a variety of diseases. Such diseases include diseases involving progressive dementia, such as Alzheimer's disease, senile dementia, Pick's disease (Pick's disease) and Huntington's disease; central nervous system diseases that affect muscle function, such as Parkinson's disease, motor neuron disease and progressive ataxia, such as amyotrophic lateral sclerosis; demyelinating diseases, such as multiple sclerosis; viral encephalitis, such as viral encephalitis caused by enterovirus, arbovirus and herpes simplex virus; and prion disease. Mechanical damage, such as glaucoma or traumatic injury to the head and spine, can also cause nerve damage and degeneration of the brain and spinal cord. In addition, ischemia and stroke and conditions such as nutritional deficiencies and chemical toxicity (such as chemotherapeutic agents) can also cause central nervous system neuropathy.

[0455] In some embodiments, the present disclosure provides a method for treating a neuropathy or axonopathy associated with axonal degeneration. In some such embodiments, the neuropathy or axonopathy associated with axonal degeneration can be any of a variety of neuropathy or axonopathy, such as those that are hereditary or congenital or are associated with Parkinson's disease, Alzheimer's disease, herpes infection, diabetes, amyotrophic lateral sclerosis, demyelinating disease, ischemia or stroke, chemical injury, thermal injury, and AIDS. In addition, neurodegenerative diseases not mentioned above and subsets of the diseases mentioned above can also be treated with the methods of the present disclosure. Such disease subsets can include Parkinson's disease or non-Parkinson's disease, or Alzheimer's disease.

[0456] individual

[0457] In some embodiments, the compounds and / or compositions described herein are administered to an individual suffering from or susceptible to a disease, disorder, or condition described herein; in some embodiments, such a disease, disorder, or condition is characterized by axonal degeneration, such as one of the diseases, disorders, or conditions mentioned herein.

[0458] In some embodiments, the individual to whom a compound or composition described herein is administered exhibits one or more signs or symptoms associated with axonal degeneration; in some embodiments, the individual does not exhibit any signs or symptoms of neurodegeneration.

[0459] In some embodiments, provided methods comprise administering a compound of Formula I to a patient in need thereof. In some such embodiments, the patient is at risk for a disease, disorder, or condition characterized by axonal degeneration. In some embodiments, the patient has a disease, disorder, or condition characterized by axonal degeneration. In some embodiments, the patient has been diagnosed with a disease, disorder, or condition characterized by axonal degeneration.

[0460] In some embodiments, the methods provided include administering a composition as described herein to a patient population in need thereof. In some embodiments, the population is individuals from activities in which the likelihood of traumatic neuronal injury is high. In some embodiments, the population is athletes from activities in which contact sports or other high-risk activities are involved.

[0461] In some embodiments, the individual is at risk for a disease, disorder, or condition characterized by axonal degeneration. In some embodiments, the individual is identified as being at risk for axonal degeneration, e.g., based on the individual's genotype, diagnosis of a disease, disorder, or condition associated with axonal degeneration, and / or exposure to agents and / or conditions that induce axonal degeneration.

[0462] In some embodiments, the patient is at risk for a neurodegenerative disorder. In some embodiments, the patient is elderly. In some embodiments, the patient is known to have a genetic risk factor for neurodegeneration. In some embodiments, the patient has a family history of a neurodegenerative disease. In some embodiments, the patient expresses one or more copies of a known genetic risk factor for neurodegeneration. In some embodiments, the patient is from a high-risk population for neurodegeneration. In some embodiments, the patient has a hexanucleotide repeat expansion in chromosome 9 open reading frame 72. In some embodiments, the patient has one or more copies of the ApoE4 allele.

[0463] In some embodiments, the individual to whom the compounds or compositions described herein are administered may be or include an individual suffering from or susceptible to a neurodegenerative disease, disorder, or condition. In some embodiments, the neurodegenerative disease, disorder, or condition may be or include traumatic neuronal injury. In some embodiments, the traumatic neuronal injury is blunt force trauma, closed head injury, open head injury, exposure to concussive and / or explosive forces, penetrating injury to the brain cavity or the innervated area of ​​the body. In some embodiments, the traumatic neuronal injury is a force that causes axonal deformation, stretching, squeezing, or shearing.

[0464] In some embodiments, the individual engages in an activity identified as a risk factor for neuronal degeneration, for example, an individual who plays a contact sport or has an occupation with a high chance of traumatic neuronal injury.

[0465] For example, the individual can be a patient who is receiving or has been prescribed chemotherapy associated with peripheral neuropathy. Examples of chemotherapeutic agents include, but are not limited to, thalidomide, epothilones (e.g., ixabepilone), taxanes (e.g., paclitaxel and docetaxel), vinca alkaloids (e.g., vinblastine, vinorelbine, vincristine, and vindesine), proteasome inhibitors (e.g., bortezomib), platinum drugs (e.g., cisplatin, oxaliplatin, and carboplatin).

[0466] In some embodiments, provided methods comprise administering a composition described herein to a patient or patient population based on the presence or absence of one or more biomarkers. In some embodiments, provided methods further comprise monitoring the levels of biomarkers in the patient or patient population and adjusting the dosing regimen accordingly.

[0467] Drug administration

[0468] It will be understood by those skilled in the art that, in some embodiments, the precise amount of a particular compound included in a pharmaceutical composition or regimen described herein and / or delivered by administration may be selected by a medical practitioner and may vary for different individuals, e.g., after considering one or more of the species, age, and general condition of the individual, and / or the characteristics of the particular compound or composition, its mode of administration, etc. Alternatively, in some embodiments, the amount of a particular compound included in a pharmaceutical composition or regimen as described herein and / or delivered by administration may be standardized across a relevant patient population (e.g., all patients, all patients of a particular age or disease stage, or all patients expressing a particular biomarker, etc.).

[0469] The compounds or compositions provided by the present disclosure are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression "unit dosage form" as used herein refers to a physically discrete dosage unit suitable for the patient to be treated. However, it should be understood that the total daily dosage of the compounds and compositions provided by the present disclosure will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism will depend on a variety of factors, including the severity of the condition being treated and the condition; the clinical condition of the individual patient; the cause of the condition; the activity of the specific compound employed; the specific composition employed; the patient's age, weight, general health, sex and diet; the administration time of the specific compound employed, the delivery site of the agent, the route of administration and the excretion rate; the duration of treatment; the drugs used in combination with or concurrently with the specific compound employed, and similar factors well known in the medical art. The effective amount of the compound to be administered will be determined by these considerations and is the minimum amount required to inhibit SARM1 activity to prevent or treat an undesirable disease or condition, such as neurodegeneration or traumatic nerve injury.

[0470] The pharmaceutically acceptable compositions of the present invention can be administered to humans and other animals orally, rectally, intravenously, parenterally, intracisternal, intravaginal, intraperitoneally, topically (such as powders, ointments or drops), buccally, as an oral or nasal spray, etc., depending on the severity of the disease, condition or infection being treated. In certain embodiments, the daily dose is given as a single daily dose or divided doses twice to six times a day, or in a sustained release form. This dosing regimen can be adjusted to provide the optimal therapeutic response. The compound can be administered on a regimen of 1 to 4 times a day, preferably once or twice a day.

[0471] In some embodiments, the compositions of the present disclosure can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intradermal, intraocular, intralesional, and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally, or intravenously.

[0472] In some embodiments, the pharmaceutically acceptable compositions of the present disclosure can also be administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, skin, or lower intestinal tract. Topical formulations suitable for use in each of these areas or organs are readily prepared.

[0473] Most preferably, the pharmaceutically acceptable compositions of the present disclosure are formulated for oral administration. Such formulations can be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions of the present disclosure are not administered with food. In other embodiments, the pharmaceutically acceptable compositions of the present disclosure are administered with food.

[0474] Those additional agents can be administered separately from the provided compounds or compositions thereof as part of a multiple-dose regimen. Alternatively, those agents can be part of a single dosage form, mixed together with the provided compounds in a single composition. If administered as part of a multiple-dose regimen, the two active agents can be administered simultaneously, sequentially, or within a period of time of each other (generally within five hours of each other).

[0475] It will also be understood that the specific dosage and treatment regimen for any particular patient may depend on a variety of factors, including the activity of the specific compound employed, age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the specific disease being treated. In some embodiments, the amount of the compound of the present disclosure in the composition will also depend on the specific compound in the composition.

[0476] In some embodiments, the SARM1 inhibitors described herein can be used in combination with one or more other therapies to treat related diseases, disorders or conditions. In some embodiments, compared to when used as monotherapy, when using combination therapy, the dosage of the SARM1 inhibitor is changed; alternatively or additionally, in some embodiments, the therapy administered in combination with the SARM1 inhibition described herein is administered according to a regimen or treatment process different from that when it is administered alone or in combination with one or more therapies other than SARM1 inhibition. In some embodiments, the composition comprising an additional therapeutic agent, the additional therapeutic agent and the compound provided can act synergistically. In some embodiments, one or both therapies used in the combination regimen are administered at a lower level or less frequently than when used as monotherapy.

[0477] In some embodiments, the compounds and / or compositions described herein are administered with a chemotherapeutic agent, including but not limited to alkylating agents, anthracyclines, taxanes, epothilones, histone deacetylase inhibitors, topoisomerase inhibitors, kinase inhibitors, nucleotide analogs, peptide antibiotics, platinum agents, retinoids, vinca alkaloids, and derivatives. In some embodiments, the compounds and / or compositions described herein are administered in combination with a PARP inhibitor.

[0478] Advantageous Effects of the Invention

[0479] The present inventors surprisingly found that the compounds provided by the present disclosure obtained by replacing the oxo group (=O) on 2,3-dihydroisothiazole with a thio group (=S) have significantly improved SARM1 inhibitory activity compared to the corresponding compounds disclosed in WO2019236890A1 (e.g., positive controls 1 and 2 determined in the biological examples below). The compounds disclosed herein also have a variety of excellent properties, such as good physicochemical properties (e.g., solubility, physical and / or chemical stability), good pharmacokinetic properties (e.g., excellent drug exposure and excellent oral absorption effect), and good safety (lower toxicity and / or fewer side effects, and a wider therapeutic window).

[0480] Example

[0481] The embodiments of the present invention will be described in detail below with reference to the examples, but those skilled in the art will appreciate that the following examples are intended only to illustrate the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all commercially available conventional products.

[0482] NMR was measured using a Bruker AVANCE-400 and Bruker AVANCE-500 nuclear magnetic spectrometer. The measurement solvents included deuterated dimethyl sulfoxide (DMSO-d6), deuterated acetone (CD3COCD3), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). Tetramethylsilane (TMS) was used as the internal standard, and chemical shifts were measured in parts per million (ppm).

[0483] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1260 mass spectrometer. HPLC analysis was performed using an Agilent 1100 high pressure chromatograph (Microsorb 5 micron C18 100×3.0 mm column).

[0484] TLC silica gel plates used were Qingdao GF254 silica gel plates, with a diameter of 0.15-0.20 mm for TLC and 0.4-0.5 mm for preparative thin layer chromatography. Column chromatography generally used Qingdao 200-300 mesh silica gel as a carrier.

[0485] Abbreviations in the context of this disclosure have the following meanings:

[0486] Example 1: Synthesis of 5-((2-chlorophenyl)amino)-3-mercaptoisothiazole-4-carbonitrile (5)

[0487] 1-Chloro-2-isocyanatobenzene (300 mg, 1.95 mmol) and 2-cyanoethanethioamide (227 mg, 1.95 mmol) were added to DMF (5 mL), followed by the addition of KOH (219 mg, 3.90 mmol). The mixture was reacted at room temperature for 5 hours. EtOAc (20 mL) and H2O (20 mL) were added for dilution, and the pH was adjusted to 5 with aqueous hydrochloric acid (1N). The mixture was washed with H2O (20 mL × 2) and saturated NaCl solution (20 mL) in sequence, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (DCM / MeOH (v / v) = 20 / 1) to give 5-((2-chlorophenyl)amino)-3-mercaptoisothiazole-4-carbonitrile (5) (50 mg, 10%).

[0488] MS (ESI, pos.ion) m / z: 268.1 [M+1] + .

[0489] 1HNMR (DMSO-d6) δ: 8.82 (s, 2H), 7.50 (d, J = 7.8 Hz, 1H), 7.28-7.36 (m, 1H), 7.10-7.18 (m, 1H), 7.04 (d, J = 7.8 Hz, 1H).

[0490] Example 2: Synthesis of 5-((2-chlorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (30)

[0491] Step 1: Synthesis of 2-cyano-N-methylthioamide

[0492] 2-Cyano-N-methylacetamide (2.0 g, 20.39 mmol) was dissolved in toluene (20 mL), and Lawesson's reagent (4.10 g, 10.19 mmol) was added at 25°C. The reaction solution was stirred at 110°C for 0.5 h. After the reaction was complete, the reaction solution was directly spin-dried and purified by silica gel column chromatography (SiO2, PE:EA (v / v) = 2:1) to obtain compound 30-1 (1.21 g, 52%).

[0493] MS (ESI, pos.ion) m / z: 115.1 [M+1] + .

[0494] Step 2: Synthesis of 5-((2-chlorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (30)

[0495] 2-Cyano-N-methylacetamide (300 mg, 2.63 mmol) and 1-chloro-2-isothiocyanatobenzene (446 mg, 2.63 mmol) were dissolved in DMF (5 mL), and KOH (221 mg, 3.94 mmol) was added portionwise. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water, adjusted to pH 7 with HCl (1 mol / L), extracted with ethyl acetate (20 mL × 3), and washed with water (20 mL × 2) and saturated brine (20 mL × 2) in that order. The organic phases were combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 0 / 1) and preparative HPLC to give 5-((2-chlorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (30) (113 mg, 15%).

[0496] MS (ESI, pos.ion) m / z: 282.0 [M+1] + .

[0497] 1HNMR(400MHz, DMSO-d6)δ9.23(s,1H),7.50(dd,J=7.9,1.3Hz,1H),7.32(td,J=7.6 ,1.4Hz,1H),7.13(td,J=7.7,1.6Hz,1H),7.04(dd,J=7.9,1.6Hz,1H),3.01(s,3H).

[0498] Example 3: Synthesis of 2-ethyl-5-((2-fluorophenyl)amino)-3-thioxo-2,3-diisothiazole-4-carbonitrile (31A)

[0499] Step 1: Synthesis of 2-cyano-N-ethylthioamide

[0500] 2-Cyano-N-ethylacetamide (300 mg, 2.68 mmol) and Lawesson's reagent (541 mg, 1.19 mmol) were added to toluene (5 mL). The reaction was allowed to react at 110°C for 1 hour. The reaction solution was cooled to room temperature, diluted with EtOAc (50 mL), washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PET / EtOAc (v / v) = 4 / 1) to obtain compound 31-1 (330 mg, 96%).

[0501] Step 2: Synthesis of 2-ethyl-5-((2-fluorophenyl)amino)-3-thioxo-2,3-diisothiazole-4-carbonitrile (31A)

[0502] 1-Fluoro-2-isothiocyanatobenzene (119 mg, 0.78 mmol) and 2-cyano-N-ethylthioamide (100 mg, 0.78 mmol) were added to DMF (5 mL), and KOH (66 mg, 1.17 mmol) was added at room temperature. The mixture was stirred overnight. H2O (20 mL) was added for dilution, and the mixture was extracted with EA (20 mL × 3), washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by HPLC to give 2-ethyl-5-((2-fluorophenyl)amino)-3-thioxo-2,3-diisothiazole-4-carbonitrile (31A) (10 mg, 5%).

[0503] MS (ESI, pos.ion) m / z: 279.9 [M+1] + .

[0504] 1H NMR (DMSO-d6) δ: 9.26 (br s, 1H), 7.21-7.32 (m, 1H), 7.11-7.21 (m, 2H), 7.00-7.09 (m, 1H), 3.40-3.50 (m, 2H), 1.23 (t, J = 7.2Hz, 3H).

[0505] Example 4: Synthesis of 5-((2-chlorophenyl)amino)-2-isopropyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (32)

[0506] Step 1: Synthesis of 2-cyano-N-isopropylacetamide

[0507] Ethyl 2-cyanoacetate (1.06 g, 9.37 mmol) and isopropylamine (554 mg, 9.37 mmol) were added to EtOH (10 mL) and reacted overnight at 70°C. The reaction solution was cooled to room temperature and concentrated under reduced pressure to remove excess ethanol. EtOAc (50 mL) was added for dilution, and the solution was washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EA (v / v) = 3 / 1) to obtain compound 32-1 (800 mg, 68%).

[0508] Step 2: Synthesis of 2-cyano-N-isopropylethanesulfamide

[0509] 2-Cyano-N-isopropylacetamide (300 mg, 2.38 mmol) and Lawesson's reagent (481 mg, 1.19 mmol) were added to toluene (10 mL). The reaction was allowed to react at 110°C for 1 hour. The reaction solution was cooled to room temperature, diluted with EtOAc (20 mL), washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PET / EtOAc (v / v) = 4 / 1) to obtain compound 32-2 (300 mg, 89%).

[0510] Step 3: Synthesis of 5-((2-chlorophenyl)amino)-2-isopropyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (32)

[0511] 2-Cyano-N-isopropylethanesulfamide (300 mg, 2.11 mmol) and 1-chloro-2-isothiocyanatobenzene (0.28 mL, 2.11 mmol) were added to DMF (5 mL), and then KOH (178 mg, 3.16 mmol) was slowly added. Stir at room temperature overnight. After the reaction, water (10 mL) was added to dilute the mixture and the pH was adjusted to 6 with 1N hydrochloric acid. The mixture was extracted with EtOAc (30 mL), washed with saturated NaCl solution (15 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by HPLC to obtain 5-((2-chlorophenyl)amino)-2-isopropyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (32) (7.4 mg, 1%).

[0512] MS (ESI, pos.ion) m / z: 309.9 [M+1] + .

[0513] 1 HNMR(DMSO-d6)δ:9.18(br d,J=8.2Hz,1H),7.50(d,J=7.9Hz,1H),7.32(t,J=7.6Hz,1H),7.13(t,J=7.7Hz,1H),7.03(d,J=7.7Hz,1H),3.83(br s,1H),1.27(d,J=6.2Hz,6H).

[0514] Example 5: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclopropyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (33)

[0515] Step 1: Synthesis of 2-cyano-N-cyclopropylacetamide

[0516] Ethyl 2-cyanoacetate (1.06 g, 9.37 mmol) and cyclopropylamine (535 mg, 9.37 mmol) were added to EtOH (10 mL) and reacted at 70°C overnight. The reaction solution was cooled to room temperature and concentrated under reduced pressure to remove excess ethanol. EtOAc (50 mL) was added for dilution, and the solution was washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EA (v / v) = 3 / 1) to obtain compound 33-1 (820 mg, 70%).

[0517] Step 2: Synthesis of 2-cyano-N-cyclopropylethylthioamide

[0518] 2-Cyano-N-cyclopropylacetamide (200 mg, 1.61 mmol) and Lawesson's reagent (326 mg, 0.81 mmol) were added to toluene (10 mL). The mixture was heated at 110°C for 1 hour. The reaction solution was cooled to room temperature, diluted with EtOAc (20 mL), washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EA (v / v) = 4 / 1) to obtain compound 33-2 (180 mg, 80%).

[0519] Step 3: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclopropyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (33)

[0520] 2-Cyano-N-cyclopropylethanethioamide (140 mg, 1.00 mmol) and 1-chloro-2-isothiocyanatobenzene (0.13 mL, 1.00 mmol) were added to DMF (5 mL), and then KOH (84 mg, 1.50 mmol) was slowly added. The mixture was stirred at room temperature overnight. After completion of the reaction, it was diluted with water (10 mL) and the pH was adjusted to 6 with 1N hydrochloric acid. The mixture was extracted with EtOAc (30 mL), washed with saturated NaCl solution (15 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by HPLC to give 5-((2-chlorophenyl)amino)-2-cyclopropyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (33) (17 mg, 6%).

[0521] MS (ESI, pos.ion) m / z: 307.8 [M+1] + .

[0522] 1 HNMR(DMSO-d6)δ:9.56(br s,1H),7.50(dd,J=8.0,1.2Hz,1H),7.31(td,J=7.6,1.3Hz,1H),7.12(td,J=7.7,1.5Hz,1H),7.02(dd,J=7.9,1.3Hz,1H),2.79(br s,1H),0.78-0.86(m,4H).

[0523] Example 6: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclobutyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (34)

[0524] Step 1: Synthesis of 2-cyano-N-cyclobutylacetamide

[0525] Ethyl 2-cyanoacetate (2.00 g, 17.68 mmol) and cyclobutylamine (1.89 g, 26.52 mmol) were added to EtOH (15 mL) and reacted at 70°C for 12 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure to remove excess ethanol. The residue was slurried with a mixed solvent of ethyl acetate and petroleum ether (1:10, 10 mL), filtered, and washed with petroleum ether (10 mL) to obtain compound 34-1 (2.00 g, yield: 81%).

[0526] Step 2: Synthesis of 2-cyano-N-cyclobutylethylthioamide

[0527] 2-Cyano-N-cyclobutylacetamide (500 mg, 3.62 mmol) and Lawesson's reagent (730 mg, 1.81 mmol) were added to toluene (5 mL). The reaction was allowed to react at 110°C for 0.5 h. The reaction solution was cooled to room temperature, diluted with EtOAc (20 mL), washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EA (v / v) = 4 / 1) to obtain compound 34-2 (360 mg, 65%).

[0528] Step 3: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclobutyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (34)

[0529] 2-Cyano-N-cyclobutylethanethioamide (200 mg, 1.30 mmol) and 1-chloro-2-isothiocyanatobenzene (220 mg, 1.30 mmol) were added to DMF (5 mL), and then KOH (110 mg, 1.95 mmol) was slowly added. The mixture was stirred at room temperature overnight. After the reaction, it was diluted with water (10 mL) and the pH was adjusted to 6 with 1N hydrochloric acid. The mixture was extracted with EtOAc (30 mL), washed with saturated NaCl solution (15 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by HPLC to obtain 5-((2-chlorophenyl)amino)-2-cyclobutyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (34) (8.6 mg, 2%).

[0530] L MS(ESI,pos.ion)m / z:321.8[M+H] + .

[0531] 1HNMR (400MHz, DMSO-d6) δ9.54(d,J=7.0Hz,1H),7.51(dd,J=8.0,1.4Hz,1H),7.32(td,J=7.6,1.4Hz,1H),7.14( td,J=7.7,1.6Hz,1H),7.03(dd,J=7.9,1.6Hz,1H),4.14(d,J=9.5Hz,1H),2.38–2.14(m,4H),1.80–1.62(m,2H).

[0532] Example 7: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclopentyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (35)

[0533] Step 1: Synthesis of 2-cyano-N-cyclopentylacetamide

[0534] Ethyl 2-cyanoacetate (2.00 g, 17.68 mmol) and cyclopentylamine (2.26 g, 26.52 mmol) were added to EtOH (15 mL) and reacted at 70°C overnight. The reaction solution was cooled to room temperature and concentrated under reduced pressure to remove excess ethanol. The residue was slurried with a mixed solvent of ethyl acetate and petroleum ether (1:10, 10 mL), filtered, and washed with petroleum ether (10 mL) to obtain compound 35-1 (2.6 g, yield: 96%).

[0535] Step 2: Synthesis of 2-cyano-N-cyclopentylethylthioamide

[0536] 2-Cyano-N-cyclopentylacetamide (500 mg, 3.62 mmol) and Lawesson's reagent (660 mg, 1.64 mmol) were added to toluene (5 mL). The reaction was allowed to react at 110°C for 0.5 h. The reaction solution was cooled to room temperature, diluted with EtOAc (20 mL), washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EA (v / v) = 4 / 1) to obtain compound 35-2 (450 mg, 82%).

[0537] Step 3: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclopentyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (35)

[0538] 2-Cyano-N-cyclopentylethanethioamide (200 mg, 1.19 mmol) and 1-chloro-2-isothiocyanatobenzene (200 mg, 1.19 mmol) were added to DMF (5 mL), and then KOH (100 mg, 1.78 mmol) was slowly added. The mixture was stirred at room temperature overnight. After completion of the reaction, it was diluted with water (10 mL) and the pH was adjusted to 6 with 1N hydrochloric acid. The mixture was extracted with EtOAc (30 mL), washed with saturated NaCl solution (15 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by HPLC to give 5-((2-chlorophenyl)amino)-2-cyclopentyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (35) (4.7 mg, 1%).

[0539] L MS(ESI,pos.ion)m / z:335.8[M+H] + .

[0540] 1 HNMR(400MHz,DMSO-d6)δ9.27(d,J=7.7Hz,1H),7.51(dd,J=8.0,1.4Hz,1H),7.32(td,J=7.6,1.4Hz,1H),7.14(td,J=7.7,1.6Hz,1H) ,7.04(dd,J=7.8,1.6Hz,1H),4.04(s,1H),2.04–1.93(m,2H),1.70(dtt,J=13.0,6.3,3.6Hz,4H),1.56(dp,J=10.8,3.9,3.0Hz,2H).

[0541] Example 8: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclohexyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (36)

[0542] Step 1: Synthesis of 2-cyano-N-cyclohexylacetamide

[0543] Ethyl 2-cyanoacetate (1.00 g, 8.84 mmol) and cyclohexylamine (1.75 g, 17.68 mmol) were added to EtOH (20 mL). The reaction was allowed to proceed at 70°C for 25 h. The mixture was concentrated under reduced pressure, and EA (10 mL) was added. PE was then added dropwise until a large amount of solid precipitated. Filter the mixture to obtain a yellow solid (1.20 g, 81%).

[0544] MS (ESI, pos.ion) m / z: 167.1 [M+1] + .

[0545] Step 2: Synthesis of 2-cyano-N-cyclohexylethylthioamide

[0546] 2-Cyano-N-cyclohexylacetamide (740 mg, 4.45 mmol) and Lawesson's reagent (900 mg, 2.23 mmol) were added to toluene (20 mL) and reacted at 110°C for 0.5 h. The mixture was concentrated under reduced pressure, and the crude product was separated by column chromatography (PE / EtOAc (v / v) = 3 / 1) to give a light yellow solid (600 mg, 74%).

[0547] MS (ESI, pos.ion) m / z: 183.1 [M+1] + .

[0548] Step 3: Synthesis of 5-((2-chlorophenyl)amino)-2-cyclohexyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (36)

[0549] 2-Cyano-N-cyclohexylethanethioamide (300 mg, 1.65 mmol) and 1-chloro-2-isothiocyanatobenzene (279 mg, 1.65 mmol) were added to DMF (10 mL), followed by KOH (139 mg, 2.47 mmol) and allowed to react at room temperature for 12 h. EtOAc (20 mL) was added for dilution, and the mixture was washed with H2O (20 mL × 2) and saturated NaCl solution (20 mL) in sequence, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (DCM / MeOH (v / v) = 20 / 1) to give 5-((2-chlorophenyl)amino)-2-cyclohexyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (36) (18 mg, 3%).

[0550] MS (ESI, pos.ion) m / z: 350.1 [M+1] + .

[0551] 1 H NMR (400MHz, DMSO-d6) δ9.19(d,J=8.0Hz,1H),7.51(dd,J=8.0,1.4Hz,1H),7.32(td,J=7.6,1.4Hz,1H),7.14(td,J=7.6,1.6Hz,1H),7.04(dd,J=8.0, 1.6Hz, 1H), 1.93 (d, J = 12.1Hz, 2H), 1.75 (d, J = 12.8Hz, 2H), 1.60 (d, J = 12. 8Hz,1H),1.44(q,J=11.8Hz,2H),1.37–1.20(m,3H),1.12(t,J=12.4Hz,1H)

[0552] Example 9: Synthesis of 5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile

[0553] 1-Fluoro-2-isothiocyanatobenzene (125 mg, 0.82 mmol) and 3-amino-3-thiopropionitrile (82 mg, 0.82 mmol) were added to DMF (5 mL), and KOH (69 mg, 1.23 mmol) was added portionwise at room temperature. The mixture was stirred overnight at room temperature. 20 mL of water was added to the reaction solution, and the pH of the aqueous phase was adjusted to 7 with HCl (1 N). The mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative TLC (DCM / MeOH (v / v) = 20 / 1) and preparative HPLC, and lyophilized to give 5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (37) (10 mg, 5%).

[0554] MS (ESI, pos.ion) m / z: 251.9 [M+1] + .

[0555] 1 H NMR (400MHz, DMSO-d6) δ8.81(s,2H),7.25(ddd,J=10.9,7.5,2.4Hz,1H),7.20–7.09(m,2H),7.04(ddd,J=9.4,6.8,2.5Hz,1H).

[0556] Example 10: Synthesis of 3-thioxo-5-((2-(trifluoromethyl)phenyl)amino)-2,3-dihydroisothiazole-4-carbonitrile (38-A)

[0557] 1-Isothiocyanato-2-(trifluoromethyl)benzene (100 mg, 0.49 mmol) and 2-cyanoethylthioamide (49 mg, 0.49 mmol) were added to DMF (5 mL). KOH (41 mg, 0.74 mmol) was added portionwise at room temperature and stirred overnight at room temperature. 20 mL of water was added to the reaction solution, and the aqueous phase was adjusted to pH 7 with HCl (1N). The mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative TLC (DCM / MeOH (v / v) = 20 / 1) and preparative HPLC, and lyophilized to give 3-thioxo-5-((2-(trifluoromethyl)phenyl)amino)-2,3-dihydroisothiazole-4-carbonitrile (38) (7 mg, 5%).

[0558] MS (ESI, pos.ion) m / z: 301.8 [M+1] + .

[0559] 1 H NMR (400MHz, DMSO-d6) δ8.82(s,2H),7.71(dd,J=7.9,1.5Hz,1H),7.62(td,J=7.7,1.5Hz,1H),7.28(t,J=7.6Hz,1H),7.15(d,J=7.9Hz,1H).

[0560] Example 11: Synthesis of 5-((2-chloronaphthalen-1-yl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (39-A)

[0561] Step 1: Synthesis of 2-chloronaphthalene-1-amine

[0562] Dissolve 1-naphthaleneamine (1000 mg, 6.98 mmol) in THF (15 mL), and add 1-chloropyrrolidine-2,5-dione (930 mg, 6.98 mmol) portionwise at 0°C. The mixture is allowed to react for 1 h at 0°C. The reaction mixture is quenched with water and extracted with ethyl acetate (50 mL x 3). The organic phase is dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product is analyzed by preparative TLC (PE:EA (v / v) = 5 / 1) to afford compound 39-1 (525 mg, 42%).

[0563] MS (ESI, pos.ion) m / z: 177.9 [M+1] + .

[0564] Step 2: Synthesis of 2-chloro-1-isothiocyanatonaphthalene

[0565] 2-Chloronaphthalen-1-amine (525 mg, 2.96 mmol) was dissolved in DCM (5 mL). A solution of thiophosgene (408 mg, 3.55 mmol) in DCM (5 mL) was added dropwise at 0°C under nitrogen. The mixture was allowed to react for 0.5 h at the same temperature. The pH of the reaction mixture was adjusted to acidic with 1N HCl (20 mL), and the mixture was extracted with DCM (10 mL x 3). The organic phase was washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product (497 mg, 76.5%) was used directly in the next reaction.

[0566] Step 3: Synthesis of 5-((2-chloronaphthalen-1-yl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (39)

[0567] 2-Chloro-1-isothiocyanatonaphthalene (497 mg, 2.26 mmol) and 3-amino-3-thiopropionitrile (227 mg, 2.26 mmol) were dissolved in DMF (5 mL). KOH (126 mg, 2.26 mmol) was added portionwise and stirred at room temperature overnight. The reaction mixture was diluted with water, adjusted to pH 7 with HCl (1N), and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, DCM / MeOH = 1 / 0 to 40 / 1) and preparative HPLC to give 5-((2-chloronaphthalen-1-yl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (39) (117 mg, 16%).

[0568] MS (ESI, pos.ion) m / z: 317.8 [M+1] + .

[0569] 1 H NMR (400MHz, DMSO-d6) δ7.06(ddt,J=14.8,8.4,4.1Hz,2H),6.86(d,J=8.8Hz,1H),6.71(ddt,J=13.2,9.0,3.9Hz,3H).

[0570] Example 12: Synthesis of 5-(phenylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (54)

[0571] Isothiocyanatobenzene (300 mg, 2.22 mmol) and 2-cyanoethylthioamide (222 mg, 2.22 mmol) were dissolved in DMF (3 mL), and KOH (187 mg, 3.33 mmol) was added portionwise, and the mixture was stirred at room temperature overnight. The reaction solution was diluted with water, adjusted to pH 7 with HCl (1 mol / L), extracted with ethyl acetate (20 mL×3), and washed with water (20 mL×2) and saturated brine (20 mL×2) in that order. The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-(phenylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (54) (17 mg, 3%).

[0572] MS (ESI, pos.ion) m / z: 234.0 [M+1]+ .

[0573] 1 HNMR (400MHz, DMSO-d6) δ8.75(s,2H),7.36(t,J=7.9Hz,2H),7.12(t,J=7.4Hz,1H),6.96(d,J=7.1Hz,2H).

[0574] Example 13: Synthesis of 5-((2-methoxyphenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (55)

[0575] 1-Isothiocyanato-2-methoxybenzene (200 mg, 1.21 mmol) and 2-cyanoethylthioamide (121 mg, 1.21 mmol) were dissolved in DMF (5 mL), and KOH (102 mg, 1.8 mmol) was added portionwise and stirred at room temperature for 5 h. The reaction solution was diluted with water, adjusted to pH 7 with HCl (1 mol / L), extracted with ethyl acetate (20 mL×3), and washed with water (20 mL×2) and saturated brine (20 mL×2), respectively. The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((2-methoxyphenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (55) (10 mg, 3%).

[0576] MS (ESI, pos.ion) m / z: 264.0 [M+1] + .

[0577] 1 H NMR (400MHz, DMSO-d6) δ9.86(s,1H),7.47–7.38(m,1H),7.31(d,J=7.7Hz,1H),7.23(dd,J=8.4,1.2Hz,1H),7.06(td,J=7.6,1.2Hz,1H),3.85(s,3H).

[0578] Example 14: Synthesis of 5-((2,6-difluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (56)

[0579] 1,3-Difluoro-2-isothiocyanatobenzene (200 mg, 1.17 mmol) and 2-cyanoethylthioamide (222 mg, 1.17 mmol) were dissolved in DMF (3 mL), and KOH (98 mg, 1.75 mmol) was added portionwise, and the mixture was stirred at room temperature overnight. The reaction solution was diluted with water, adjusted to pH 7 with HCl (1 mol / L), extracted with ethyl acetate (20 mL×3), and washed with water (20 mL×2) and saturated brine (20 mL×2) in that order. The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((2,6-difluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (56) (11 mg, 3.5%).

[0580] MS (ESI, pos.ion) m / z: 270.0 [M+1] + .

[0581] 1 HNMR (500MHz, DMSO-d6) δ8.92 (s, 2H), 7.15 (m, J = 8.8Hz, 3H).

[0582] Example 15: Synthesis of 5-(cyclohexylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (57)

[0583] 3-Amino-3-thiopropionitrile (0.16 mL, 2.00 mmol) and isothiocyanatocyclohexane (0.27 mL, 2.00 mmol) were added to DMF (3 mL). The mixture was reacted at 25°C for 5 hours. The mixture was extracted with ethyl acetate (20 mL × 3), washed with water (20 mL × 2) and saturated brine (20 mL × 2), respectively. The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was slurried with dichloromethane and filtered to obtain a brown solid. The solid was then purified by HPLC to give 5-(cyclohexylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (57) (20 mg, 5%).

[0584] MS (ESI, pos.ion) m / z: 240 [M-1] + .

[0585] 1HNMR (400MHz, DMSO-d6) δ8.49(s,1H),4.87–4.77(m,1H),1.94(d,J=10.6Hz,2H),1.79(d,J=11.8Hz,2H),1.62(d,J=12.6Hz,1H),1.44–1.13(m,6H).

[0586] Example 16: Synthesis of N-(4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)-N-phenylacetamide (59)

[0587] Step 1: Synthesis of 5-(phenylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile

[0588] Isothiocyanatobenzene (1.0 g, 9.99 mmol) and 2-cyanoethylthioamide (1.35 g, 9.99 mmol) were dissolved in DMF (10 mL). KOH (0.84 g, 14.98 mmol) was added portionwise and stirred at room temperature overnight. The reaction mixture was diluted with water, adjusted to pH 7 with HCl (1 mol / L), and extracted with ethyl acetate (50 mL × 3). The organic phase was washed sequentially with water (50 mL × 2) and saturated brine (50 mL × 2). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 0 / 1) to give 5-(phenylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (322 mg, 14%).

[0589] MS (ESI, pos.ion) m / z: 234.0 [M+1] + .

[0590] Step 2: Synthesis of N-(4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)-N-phenylacetamide (59)

[0591] 5-(Phenylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (40 mg, 0.17 mmol) and sodium bicarbonate (126 mg, 1.49 mmol) were dissolved in DCM (3 mL). Acetic anhydride (18 mg, 0.23 mmol) was slowly added dropwise at 0°C, and the reaction was stirred at room temperature for 1 h. The reaction solution was diluted with water and extracted with DCM (20 mL × 3). The organic phase was washed once with water (20 mL) and saturated brine (20 mL). The organic phases were combined and dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 1 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give N-(4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)-N-phenylacetamide (59) (10 mg, 21%).

[0592] MS (ESI, pos.ion) m / z: 276.0 [M+1] + .

[0593] H NMR(500MHz,DMSO-d6)δ12.03(br,1H),7.65–7.00(m,5H),2.28(s,3H).

[0594] Example 17: Synthesis of N-(2-acetyl-4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)-N-phenylacetamide (59c)

[0595] Dissolve 5-(phenylamino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (40 mg, 0.17 mmol) and sodium bicarbonate (126 mg, 1.49 mmol) in DCM (3 mL). Slowly add acetic anhydride (18 mg, 0.23 mmol) dropwise at 0°C. Stir and react at room temperature for 1 h. The reaction solution is diluted with water and extracted with DCM (20 mL x 3). The organic phase is washed sequentially with water (20 mL) and saturated brine (20 mL). The organic phases were combined and dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (SiO2, PE / EA (v / v) = 1 / 0 to 3 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give N-(2-acetyl-4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)-N-phenylacetamide (59c) (6 mg, 11%).

[0596] MS (ESI, pos.ion) m / z: 318.0 [M+1] + .

[0597] 1 HNMR (400MHz, DMSO-d6) δ7.72(d,J=6.9Hz,2H),7.60(dt,J=14.4,7.0Hz,3H), 2.25(s,3H),2.03(s,3H).

[0598] Example 18: Synthesis of 5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carboxamide (60)

[0599] Step 1: Synthesis of 5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile

[0600] 1-Fluoro-2-isothiocyanatobenzene (300 mg, 1.96 mmol) and 3-amino-3-thiopropionitrile (196 mg, 1.96 mmol) were added to DMF (3 mL). KOH (165 mg, 2.94 mmol) was added portionwise at room temperature and stirred overnight at room temperature. 20 mL of water was added to the reaction solution, and the aqueous phase was adjusted to pH 7 with HCl (1N). The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative TLC (DCM / MeOH (v / v) = 20 / 1) to obtain compound 60-1 (235 mg, 39%).

[0601] MS (ESI, pos.ion) m / z: 251.9 [M+1] + .

[0602] Step 2: Synthesis of 5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carboxamide (60)

[0603] 5-((2-Fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (100 mg, 0.40 mmol) was added to H2SO4 (1 mL). The reaction was allowed to proceed at 50°C for 30 min. After the reaction solution was cooled to room temperature, the reaction solution was added dropwise to a cooled saturated sodium bicarbonate solution. After the reaction was quenched, the aqueous phase was extracted with DCM (10 mL × 2). The organic phase was washed with saturated brine and dried over anhydrous Na2SO4. The crude product was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carboxamide (60) (37 mg, 34%).

[0604] MS (ESI, pos.ion) m / z: 271[M+1] + .

[0605] 1 H NMR (500MHz, DMSO-d6) δ9.99(s,1H),9.05(d,J=4.0Hz,2H),7.40(d,J=3.9Hz,1H),7.27(ddd,J=10.6,7.6,2.0Hz,1H),7.20–7.09(m,3H).

[0606] Example 19: Synthesis of 5-((6-chloroquinolin-5-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (63)

[0607] Step 1: Synthesis of 6-chloro-5-isothiocyanatoquinoline

[0608] 5-Amino-6-chloroquinoline (200 mg, 1.12 mmol) was dissolved in DCM (3 mL). DIEA and thiophosgene (453 mg, 3.94 mmol, 0.3 mL) in DCM (1 mL) were added dropwise at 0°C. The mixture was allowed to react for 0.5 h at the same temperature. The pH of the reaction mixture was adjusted to acidic with 1N HCl (10 mL) and extracted with DCM (10 mL x 3). The organic phase was washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product (200 mg, 81%) was used directly in the next reaction.

[0609] Step 2: Synthesis of 5-((6-chloroquinolin-5-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (63)

[0610] Dissolve 6-chloro-5-isothiocyanatoquinoline (200 mg, 0.91 mmol) and 2-cyano-N-methylthioacetamide (124 mg, 1.09 mmol) in DMF (4 mL). Add KOH (76 mg, 1.35 mmol) in portions and stir at room temperature overnight. The reaction mixture is diluted with water, adjusted to pH 7 with HCl (1N), and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA=1 / 0 to 90 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((6-chloroquinolin-5-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (63) (43 mg, 14%).

[0611] MS (ESI, pos.ion) m / z: 333 [M+1] + .

[0612] 1 H NMR(DMSO-d6)δ:9.37(br d,J=3.8Hz,1H),8.85-8.97(m,1H),8.17(br d,J=8.3Hz,1H),7.72-7.88(m,2H),7.56(dd,J=8.4,4.3Hz,1H),3.03(br d,J=3.4Hz,3H)

[0613] Example 20: Synthesis of 5-((6-fluoroquinolin-5-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (64)

[0614] Step 1: Synthesis of 6-fluoro-5-nitroquinoline

[0615] H2SO4 (4 mL) was added dropwise to HNO3 (0.67 mL, 10.19 mmol) at 0°C. The mixed acid was then added dropwise to 6-fluoroquinoline (0.83 mL, 6.80 mmol) at 0°C. The reaction was stirred overnight at room temperature. TLC monitored the completion of the reaction. The reaction solution was slowly poured into crushed ice water, and the pH was adjusted to 6 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure to yield compound 64-1 (1080 mg, 83%).

[0616] Step 2: Synthesis of 6-fluoro-5-aminoquinoline

[0617] 6-Fluoro-5-nitroquinoline (881 mg, 4.58 mmol) was dissolved in ethanol (30 mL) and water (10 mL). Iron powder (1.53 g, 27.51 mmol) and NH₄Cl (1.47 g, 27.48 mmol) were added with stirring. The reaction was stirred at 75°C overnight. TLC monitored the reaction completion. The reaction solution was cooled to room temperature, filtered through celite, and the filtrate was concentrated under reduced pressure and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO₂, PE / EA = 1 / 0 to 3 / 1) to yield compound 64-2 (327 mg, 44%).

[0618] MS (ESI, pos.ion) m / z: 163.1 [M+1] + .

[0619] Step 3: Synthesis of 6-fluoro-5-isothiocyanatoquinoline

[0620] 6-Fluoro-5-aminoquinoline (197 mg, 1.21 mmol) was added to water (2 mL), followed by concentrated HCl (1 mL, 1.21 mmol) and thiophosgene (168 mg, 0.22 mmol, 0.02 mL). The reaction was stirred at room temperature for 2 h. Completion of the reaction was monitored by TLC. The mixture was extracted with ethyl acetate (10 mL × 3), and the organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain compound 64-3 (332 mg, crude product).

[0621] MS (ESI, pos.ion) m / z: 205.1 [M+1] + .

[0622] Step 4: Synthesis of 5-((6-fluoroquinolin-5-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (64)

[0623] Dissolve 6-fluoro-5-isothiocyanatoquinoline (332 mg, 1.63 mmol) and 2-cyano-N-methylthioacetamide (222.73 mg, 1.95 mmol) in DMF (5 mL). Add KOH (137 mg, 2.44 mmol) in portions and stir at room temperature for 5 hours. The reaction mixture is diluted with water, adjusted to pH 6 with HCl (1N), and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA=1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((6-fluoroquinolin-5-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (64) (245 mg, 48%).

[0624] MS (ESI, pos.ion) m / z: 317.0 [M+1] + .

[0625] 1 H NMR(DMSO-d6)δ:9.36(br s,1H),8.91(dd,J=4.0,1.5Hz,1H),8.22(dd,J=8.4,1.0Hz,1H),7.81-7.86(m, 1H),7.71-7.78(m,1H),7.55(dd,J=8.5,4.0Hz,1H),3.32(s,2H),3.04(s,3H).

[0626] Example 21: Synthesis of 5-((2-fluorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (65)

[0627] Step 1: Synthesis of 2-cyano-N-methylthioacetamide

[0628] 2-Cyano-N-methylacetamide (500 mg, 5.10 mmol) was dissolved in toluene (5 mL), and the reaction solution was stirred at 110° C. for 1 h. The completion of the reaction was monitored by TLC. The crude product was separated by column chromatography (PE / EA=3:1) to obtain compound 65-1 (479 mg, 81%).

[0629] MS (ESI, pos.ion) m / z: 269.1 [M+1] + .

[0630] Step 2: Synthesis of 5-((2-fluorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (65)

[0631] Dissolve 2-cyano-N-methylthioacetamide (97.82 mg, 0.86 mmol) and 1-fluoro-2-isothiocyanatobenzene (0.10 mL, 0.82 mmol) in DMF (3 mL). Add KOH (68.68 mg, 1.22 mmol) in portions and stir at room temperature for 5 h. The reaction mixture is diluted with water, adjusted to pH 6 with HCl (1N), and extracted with ethyl acetate (10 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA=1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((2-fluorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (65) (23 mg, 10%).

[0632] MS (ESI, pos.ion) m / z: 266[M+1]+.

[0633] 1 H NMR(DMSO-d6)δ:9.22(br s,1H),7.22-7.29(m,1H),7.10-7.19(m,2H),7.01-7.07(m,1H),3.01(s,3H)

[0634] Example 22: Synthesis of 5-((3-fluoropyridin-4-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (67)

[0635] Step 1: Synthesis of 3-fluoro-4-isothiocyanatopyridine

[0636] 4-Amino-3-fluoropyridine (100 mg, 0.89 mmol) was dissolved in DCM (3 mL). DIEA (346 mg, 2.68 mmol, 0.44 mL) and thiophosgene (307 mg, 2.68 mmol, 0.20 mL) in DCM (3 mL) were added dropwise at 0°C. The mixture was allowed to react at 0°C for 2 h. The pH of the reaction mixture was adjusted to acidic with 1N HCl and extracted with DCM (10 mL x 3). The organic phase was washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product (99 mg, 71%) was used directly in the next reaction.

[0637] Step 2: Synthesis of 5-((3-fluoropyridin-4-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (67)

[0638] 3-Fluoro-4-isothiocyanatopyridine (99 mg, 0.64 mmol) and 2-cyano-N-methylthioacetamide (87.98 mg, 0.77 mmol) were dissolved in DMF (2 mL). KOH (54.05 mg, 0.96 mmol) was added portionwise at 0°C and stirred at room temperature overnight. The reaction mixture was diluted with water, adjusted to pH 6 with HCl (1N), and extracted with ethyl acetate (10 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA=1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((3-fluoropyridin-4-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (67) (6.5 mg, 4%).

[0639] MS (ESI, pos.ion) m / z: 267 [M+1] + .

[0640] 1 H NMR(DMSO-d6)δ:9.42(br s,1H),8.54(d,J=2.2Hz,1H),8.33(d,J=5.2Hz,1H),7.16(dd,J=7.2,5.3Hz,1H),3.00-3.07(m,1H),3.04(s,2H)

[0641] Example 23: Synthesis of 5-((5-cyano-2-fluorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (68)

[0642] Step 1: Synthesis of 4-fluoro-3-isothiocyanatobenzonitrile

[0643] 3-Amino-4-fluorobenzonitrile (500 mg, 3.67 mmol) was dissolved in DCM (3 mL). DIEA (2.13 mL, 12.85 mmol) and thiophosgene (1.48 g, 12.85 mmol, 0.98 mL) in DCM (3 mL) were added dropwise at 0°C. The mixture was allowed to react for 0.5 h at the same temperature. The pH of the reaction mixture was adjusted to acidic with 1N HCl and extracted with DCM (20 mL x 3). The organic phase was washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product (464 mg, 70%) was used directly in the next reaction.

[0644] Step 2: Synthesis of 5-((5-cyano-2-fluorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (68)

[0645] Dissolve 4-fluoro-3-isothiocyanatobenzonitrile (333 mg, 1.87 mmol) and 2-cyano-N-methylthioacetamide (256 mg, 2.24 mmol) in DMF (5 mL). Add KOH (157 mg, 2.80 mmol) in portions and stir at room temperature overnight. The reaction mixture is diluted with water, adjusted to pH 6 with HCl (1N), and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA=1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((5-cyano-2-fluorophenyl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (68) (95 mg, 17%).

[0646] MS (ESI, pos.ion) m / z: 291.1 [M+1] + .

[0647] 1 H NMR(DMSO-d6)δ:9.25-9.49(m,1H),7.62-7.69(m,1H),7.62-7.70(m,1H),7.52(dd,J=10.0,8.9Hz,1H),3.03(s,3H)

[0648] Example 24: Synthesis of 5-((2-(methylsulfonyl)phenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (1)

[0649] Step 1: Synthesis of 1-isothiocyanato-2-(methylsulfonyl)benzene

[0650] 2-(Methylsulfonyl)aniline (200 mg, 1.17 mmol) was added to water (4 mL), followed by concentrated HCl (1 mL) and thiophosgene (161 mg, 1.40 mmol, 0.11 mL). The reaction was stirred at room temperature for 2 h. After completion of the reaction monitored by TLC, the mixture was filtered to give compound 1-1 (200 mg, 80%).

[0651] Step 2: Synthesis of 5-((2-(methylsulfonyl)phenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (1)

[0652] 1-Isothiocyanato-2-(methylsulfonyl)benzene (200 mg, 0.94 mmol) and 2-cyanothioacetamide (113 mg, 1.13 mmol) were dissolved in DMF (4 mL). KOH (78.93 mg, 1.41 mmol) was added portionwise and stirred at 0°C for 5 hours. The reaction mixture was diluted with water, adjusted to pH 6 with HCl (1N), and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, DCM / MeOH=1 / 0 to 90 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((2-(methylsulfonyl)phenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (1) (18.6 mg, 6%).

[0653] MS (ESI, pos.ion) m / z: 312.0 [M+1] + .

[0654] 1H NMR(DMSO-d6)δ:8.91(s,2H),7.92(dd,J=8.0,1.5Hz,1H),7.68(td,J=7.8,1.5Hz,1H),7.30-7.35(m,1H),7.26(dd,J=8.0,0.9Hz,1H),3.32(s,2H)

[0655] Example 25: Synthesis of 5-((3-chloro-2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (2)

[0656] Step 1: Synthesis of 1-chloro-2-fluoro-3-isothiocyanatobenzene

[0657] In a 100 mL three-necked flask at 0°C, 3-chloro-2-fluoroaniline (1 g, 6.87 mmol) was dissolved in DCM (30 mL). DIEA (3.98 mL, 24.05 mmol) was then added dropwise. After stirring for 5 minutes, thiophosgene (2.37 g, 20.61 mmol) was slowly added. The reaction was allowed to react at room temperature for 2 hours. After completion, the reaction mixture was quenched with water, extracted with DCM (30 mL x 2), washed with saturated brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EtOAc (v / v) = 20 / 1) to yield 1-chloro-2-fluoro-3-isothiocyanatobenzene (1.15 g, 89%).

[0658] MS (ESI, pos.ion) m / z: 188.0 [M+1] + .

[0659] Step 2: Synthesis of 5-((3-chloro-2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (2)

[0660] 1-Chloro-2-fluoro-3-isothiocyanatobenzene (200 mg, 1.07 mmol) and 2-cyanoethanethioamide (107 mg, 1.07 mmol) were dissolved in DMF (5 mL), KOH (72 mg, 1.28 mmol) was added at 0°C, and the mixture was stirred at 0°C for 2 hours. After the reaction was completed, water was added to the reaction solution to quench the reaction mixture, and EtOAc (20 mL × 2) was added for extraction. The mixture was washed with H2O (20 mL × 2) and saturated NaCl solution (20 mL) in sequence, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (DCM / MeOH (v / v) = 20 / 1) to obtain a yellow solid, which was then purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((3-chloro-2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (2) (5.8 mg, 1.9%).

[0661] MS (ESI, pos.ion) m / z: 286.0 [M+1] + .

[0662] 1 H NMR (CD3OD_SPE) δ: 9.71 (s, 2H), 8.12 (td, J = 8.0, 1.0 Hz, 1H), 8.01 (td, J = 8.0, 1.0 Hz, 1H), 7.87 (td, J = 8.0, 1.0 Hz, 1H).

[0663] Example 26: Synthesis of 5-((5-chloro-2,3-dihydrobenzofuran-4-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (4A)

[0664] Step 1: Synthesis of 5-chloro-2,3-dihydrobenzofuran-4-amine

[0665] NCS (52 mg, 0.39 mmol) was added to 2,3-dihydrobenzofuran-4-amine (50 mg, 0.37 mmol) in dry dichloromethane (5 mL) at 0°C, and the reaction mixture was stirred at 0°C for 30 min. The reaction mixture was concentrated under reduced pressure, and the crude product was separated by column chromatography (PE / EtOAc (v / v) = 5 / 1) to obtain compound 4-1 (40 mg, 64%).

[0666] Step 2: Synthesis of 5-chloro-4-isothiocyanato-2,3-dihydrobenzofuran

[0667] 5-Chloro-2,3-dihydrobenzofuran-4-amine (52 mg, 0.29 mmol) and DIEA (133 mg, 1.03 mmol) were added to DCM (8 mL), the atmosphere was replaced with nitrogen, and thiophosgene (102 mg, 0.88 mmol) was added at 0°C. The mixture was then stirred at 0°C for 2 hours. After the reaction was complete, DCM (20 mL) was added to dilute the mixture, and the mixture was washed sequentially with H2O (20 mL × 2) and saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was separated by column chromatography (PE / EtOAc (v / v) = 10 / 1) to obtain compound 4-2 (52 mg, 83%).

[0668] Step 3: Synthesis of 5-((5-chloro-2,3-dihydrobenzofuran-4-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (4A)

[0669] 5-Chloro-4-isothiocyanato-2,3-dihydrobenzofuran (30 mg, 0.14 mmol) and 2-cyano-N-methylethanesulfamide (16 mg, 0.14 mmol) were added to DMF (5 mL), and KOH (12 mg, 0.21 mmol) was added at room temperature. The reaction was stirred at room temperature overnight. H2O (20 mL) was added for dilution, and the mixture was extracted with EA (20 mL × 3). The mixture was washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by HPLC to give 5-((5-chloro-2,3-dihydrobenzofuran-4-yl)amino)-2-methyl-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (4A) (6 mg, 14%).

[0670] MS (ESI, pos.ion) m / z: 323.9 [M+1] + .

[0671] 1 HNMR(DMSO-d6)δ:9.24(br s,1H),7.19(d,J=8.5Hz,1H),6.54(d,J=8.5Hz,1H),4.56(t,J=8.8Hz,2H),2.93-3.10(m,5H).

[0672] Example 27: Synthesis of tert-butyl 5-chloro-4-((4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)amino)indoline-1-carboxylate (7B)

[0673] Step 1: Synthesis of tert-butyl 4-nitro-1H-indole-1-carboxylate

[0674] 4-Nitro-1H-indole (2.00 g, 12.34 mmol) was added to DCM (20 ml) at room temperature, and DMAP (150 mg, 1.24 mmol) was slowly added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with water, extracted with dichloromethane (20 ml x 2), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain compound 7-1 (2.8 g, 90%).

[0675] MS(ESI,pos.ion)m / z:263.26[M+1] + .

[0676] Step 2: Synthesis of tert-butyl 4-aminoindoline-1-carboxylate

[0677] tert-Butyl 4-nitro-1H-indole-1-carboxylate (2.00 g, 7.63 mmol) was added to MeOH (20 mL), followed by Pd / C (200 mg, 1.88 mmol). The atmosphere was replaced with hydrogen three times and then reacted at 60°C for 2 h. The reaction solution was cooled to room temperature, filtered, and concentrated to obtain compound 7-2 (1.40 g, 78%).

[0678] MS (ESI, pos.ion) m / z: 235.1 [M+1] + .

[0679] Step 3: Synthesis of tert-butyl 4-amino-5-chloroindoline-1-carboxylate

[0680] tert-Butyl 4-aminoindoline-1-carboxylate (500 mg, 2.13 mmol) was added to DCM (5 mL), and NCS (284 mg, 2.13 mmol) was added at room temperature. The mixture was allowed to react at 25°C for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (20 mL x 2). The organic phase was collected and passed through a column chromatography column (PE / EA = 3:1) to obtain compound 7-3 (344 mg, 60%).

[0681] MS (ESI, negative ion) m / z: 269.7 [M-1] + .

[0682] Step 4: Synthesis of tert-butyl 5-chloro-4-isothiocyanatoindoline-1-carboxylate

[0683] tert-Butyl 4-amino-5-chloroindoline-1-carboxylate (100 mg, 0.37 mmol) was added to DCM (2 ml), followed by DIEA (95.64 mg, 0.74 mmol). The temperature was lowered to 0°C, and thiophosgene (76.19 mg, 0.74 mmol) was added. The mixture was stirred at 0°C for 2 hours, quenched with water, extracted with dichloromethane (20 mL x 2), dried over anhydrous sodium sulfate, concentrated, and filtered through a column chromatography column (PE / EA = 10:1) to obtain the title compound, tert-butyl 5-chloro-4-isothiocyanatoindoline-1-carboxylate (80 mg, 69%).

[0684] MS (ESI, pos.ion) m / z: 311.8 [M+1] + .

[0685] Step 5: Synthesis of tert-butyl 5-chloro-4-((4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)amino)indoline-1-carboxylate (7B)

[0686] 5-Chloro-4-isothiocyanatoindole-1-carboxylic acid tert-butyl ester (89 mg, 0.29 mmol) was added to DMF (2 ml), followed by addition of KOH (24.1 mg, 0.42 mmol) and 3-amino-3-thiopropionitrile (31.94 mg, 0.32 mmol). The mixture was stirred at 25° C. for 5 hours, quenched with water, extracted with ethyl acetate (20 mL×2), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated, and purified by HPLC to obtain the target compound 5-chloro-4-((4-cyano-3-thioxo-2,3-dihydroisothiazol-5-yl)amino)dihydroindole-1-carboxylic acid tert-butyl ester (30.91 mg, 27%).

[0687] MS (ESI, pos.ion) m / z: 409.1 [M+1] + .

[0688] 1H NMR(DMSO-d6)δ:8.27(s,1H),7.27-7.49(m,1H),7.25(d,J=8.4Hz,1H),3.91(br t,J=8.7Hz,1H),3.82-3.97(m,1H),2.85(br t,J=8.6Hz,2H),1.50(s,9H).

[0689] Example 28: Synthesis of 5-((2-fluorophenyl)amino)-2-(2-hydroxyethyl)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (13)

[0690] Step 1: Synthesis of 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine

[0691] To a solution of 2-aminoethane-1-ol (1.21 mL, 20 mmol) in DCM (20 mL) was slowly added dropwise TBSCl (3.46 mL, 20.00 mmol) at 0°C. The mixture was stirred at room temperature for 1 h. H₂O (20 mL) was added for washing. The organic layer was washed with saturated brine (10 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product (2.60 g, 74%).

[0692] Step 2: Synthesis of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-cyanoacetamide

[0693] 2-((tert-Butyldimethylsilyl)oxy)ethan-1-amine (2.60 g, 14.86 mmol) and ethyl cyanoacetate (1.59 mL, 14.86 mmol) were added to EtOH (20 mL) and reacted at 80°C for 12 h. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain the crude product (3.60 g, 99%).

[0694] Step 3: Synthesis of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-cyanoethylthioamide

[0695] N-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-cyanoacetamide (3.60 g, 14.85 mmol) and Lawesson's reagent (3.00 g, 7.43 mmol) were added to toluene (20 mL) and reacted at 120°C for 3 h. The reaction solution was diluted with H2O (20 mL) and extracted with ethyl acetate (20 mL x 2). The organic layer was washed with saturated brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA (v / v) = 4 / 1) to give N-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-cyanoethylthioamide (0.70 g, 18%).

[0696] MS (ESI, pos.ion) m / z: 259.2 [M+1] + .

[0697] Step 4: Synthesis of 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile

[0698] N-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-cyanoethylthioamide (0.7 g, 2.71 mmol) and 1-fluoro-2-isothiocyanatobenzene (0.30 mL, 2.46 mmol) were added to DMF (3 mL), followed by KOH (151 mg, 2.71 mmol) and stirring at room temperature for 18 h. The reaction mixture was diluted with H₂O (15 mL) and extracted with ethyl acetate (15 mL x 2). The organic layer was washed with saturated brine (15 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EA (v / v) = 10 / 1) to yield 2-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (67 mg, 7%).

[0699] MS (ESI, pos.ion) m / z: 410.1 [M+1] + .

[0700] Step 5: Synthesis of 5-((2-fluorophenyl)amino)-2-(2-hydroxyethyl)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (13) 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-((2-fluorophenyl)amino)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (20 mg, 0.05 mmol) was added to TBAF (2 mL, 6.81 mmol) and stirred at room temperature for 3 h. The reaction solution was diluted with H2O (10 mL) and extracted with ethyl acetate (10 mL×2). The organic layer was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative chromatography (formic acid conditions) to give compound 5-((2-fluorophenyl)amino)-2-(2-hydroxyethyl)-3-thioxo-2,3-dihydroisothiazole-4-carbonitrile (13) (8 mg, 55%).

[0701] MS (ESI, pos.ion) m / z: 296.0 [M+1] + .

[0702] 1 H NMR(DMSO-d6)δ:9.20(br s,1H),7.23-7.30(m,1H),7.11-7.21(m,2H),7.02-7.08(m,1H),3.59-3.61(m,2H),3.43(s,2H).

[0703] Example 29: Synthesis of 5-((2-fluorophenyl)amino)-3-thioxo-2-(2,2,2-trifluoroethyl)-2,3-dihydroisothiazole-4-carbonitrile (66A)

[0704] Step 1: Synthesis of 2-cyano-N-(2,2,2-trifluoroethyl)acetamide

[0705] 2-Cyanoacetic acid (250 mg, 2.94 mmol), 2,2,2-trifluoroethane-1-amine (437 mg, 4.41 mmol), 50% T3P in EA (2.55 g, 8.00 mmol), and DIEA (1.13 g, 8.82 mmol) were added to EA (5 mL) and stirred at room temperature overnight. The reaction mixture was extracted with EA (20 mL × 3). The combined organic phases were washed sequentially with water (20 mL × 2) and saturated brine (20 mL × 1), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 2-cyano-N-(2,2,2-trifluoroethyl)acetamide (519 mg, crude product).

[0706] MS (ESI, pos.ion) m / z: 167.0 [M+1] + .

[0707] Step 2: Synthesis of 2-cyano-N-(2,2,2-trifluoroethyl)ethanethioamide

[0708] 2-Cyano-N-(2,2,2-trifluoroethyl)acetamide (300 mg, 1.8 mmol) was dissolved in toluene (5 mL). Lawesson's reagent (364 mg, 0.9 mmol) was added at room temperature, and the reaction mixture was stirred at 110°C for 1 hour. After the reaction was complete, the reaction mixture was directly spin-dried, and the crude product was purified by silica gel column chromatography (PE:EA (v / v) = 2:1) to obtain 2-cyano-N-(2,2,2-trifluoroethyl)ethanethioamide (302 mg, 92%).

[0709] MS (ESI, pos.ion) m / z: 183.0 [M+1] + .

[0710] Step 3: Synthesis of 5-((2-fluorophenyl)amino)-3-thioxo-2-(2,2,2-trifluoroethyl)-2,3-dihydroisothiazole-4-carbonitrile (66A)

[0711] 2-Cyano-N-(2,2,2-trifluoroethyl)ethanethioamide (302 mg, 1.66 mmol) and 1-fluoro-2-isothiocyanatobenzene (254 mg, 1.66 mmol) were added to DMF (3 mL), followed by KOH (140 mg, 2.49 mmol) and stirred at room temperature overnight. The reaction mixture was diluted with water, adjusted to pH 7 with aqueous hydrochloric acid (1N), and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed sequentially with water (20 mL × 2) and saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated by silica gel column chromatography (PE / EA (v / v) = 3 / 1) and purified by preparative HPLC to give 5-((2-fluorophenyl)amino)-3-thioxo-2-(2,2,2-trifluoroethyl)-2,3-dihydroisothiazole-4-carbonitrile (66A) (58 mg, 30%).

[0712] MS (ESI, pos.ion) m / z: 334.0 [M+1] + .

[0713] 1HNMR(DMSO-d6)δ:9.69(br s,1H),7.26-7.36(m,1H),7.14-7.26(m,2H),7.04-7.13(m,1H),4.24-4.46(m,2H).

[0714] Example 30: Synthesis of 5-[(3-chloro-2-fluorophenyl)amino]-3-thioxo-2-(2,2,2-trifluoroethyl)-2,3-dihydroisothiazole-4-carbonitrile (71)

[0715] Step 1: Synthesis of 2-cyano-N-(2,2,2-trifluoroethyl)acetamide

[0716] Dissolve cyanoacetic acid (500 mg, 5.88 mmol), 2,2,2-trifluoroethylamine (0.70 mL, 8.82 mmol), DIEA (2.92 mL, 17.63 mmol), and 1-propylphosphoric anhydride (T3P) (4.24 mL, 15.99 mmol) in ethyl acetate (5 mL) and stir at room temperature overnight. After completion of the reaction, monitor the reaction by TLC. Add 20 mL of water and extract with ethyl acetate (20 mL x 3). The organic phase is washed with saturated NaCl solution (20 mL x 3), dried over anhydrous Na2SO4, and concentrated under reduced pressure to yield crude 2-cyano-N-(2,2,2-trifluoroethyl)acetamide (239 mg, 25%), which is used directly in the next step.

[0717] Step 2: Synthesis of 2-cyano-N-(2,2,2-trifluoroethyl)thioacetamide

[0718] 2-Cyano-N-(2,2,2-trifluoroethyl)acetamide (239 mg, 1.44 mmol) and Lawesson's reagent (291 mg, 0.72 mmol) were dissolved in 6 ml of toluene and stirred at 110°C for 1 hour. After completion of the reaction, the reaction solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA = 1 / 0 to 3 / 1) to give 2-cyano-N-(2,2,2-trifluoroethyl)acetamide (183 mg, 70%).

[0719] Step 3: Synthesis of 1-chloro-2-fluoro-3-isothiocyanatobenzene

[0720] 3-Chloro-2-fluoroaniline (150 mg, 1.03 mmol, 0.11 mL) was dissolved in 4 mL of dichloromethane. DIEA (0.60 mL, 3.61 mmol) and thiophosgene (355 mg, 3.09 mmol, 0.24 mL) in DCM (3 mL) were added dropwise at 0°C. The mixture was allowed to react at 0°C for 1 hour. The pH of the reaction mixture was adjusted to acidic with 1N HCl and extracted with DCM (20 mL x 3). The organic phase was washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford crude 1-chloro-2-fluoro-3-isothiocyanatobenzene (150 mg, 76%), which was used directly in the next reaction.

[0721] Step 4: Synthesis of 5-[(3-chloro-2-fluorophenyl)amino]-3-thioxo-2-(2,2,2-trifluoroethyl)-2,3-dihydroisothiazol-4-carbonitrile (71)

[0722] 1-Chloro-2-fluoroisothiocyanatobenzene (137 mg, 0.73 mmol) and 2-cyano-N-(2,2,2-trifluoroethyl)thioacetamide (153 mg, 0.84 mmol) were dissolved in DMF (4 mL). Potassium hydroxide (61 mg, 1.09 mmol) was added portionwise at 0°C, and the mixture was stirred at 0°C for 1 hour. After completion of the reaction, as monitored by TLC, the reaction solution was diluted with water, adjusted to pH 6 with HCl (1N), and extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA=1 / 0 to 0 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-[(3-chloro-2-fluorophenyl)amino]-3-thioxo-2-(2,2,2-trifluoroethyl)-2,3-isothiazole-4-carbonitrile (71) (4.2 mg, 2%).

[0723] MS (ESI, pos.ion) m / z: 368.0 [M+1] + .

[0724] 1 HNMR(DMSO-d6):9.76(br s,1H),7.34(br s,1H),7.22(t,J=8.0Hz,1H),7.09(br s,1H),4.32(br d,J=6.8Hz,2H)

[0725] Example 31: Synthesis of 5-((3-chloro-2-fluorophenyl)amino)-3-thioxo-2-(3,3,3-trifluoropropyl)-2,3-dihydroisothiazole-4-carbonitrile (69)

[0726] Step 1: Synthesis of 2-cyano-N-(3,3,3-trifluoropropyl)acetamide

[0727] 3,3,3-Trifluoropropan-1-amine hydrochloride (1 g, 6.69 mmol), cyanoacetic acid (854 mg, 10.04 mmol), and T3P (50% by mass in EA, 12.8 g, 20.07 mmol) were dissolved in EA (20 mL). DIEA (2.59 g, 20.07 mmol) was added dropwise and stirred at room temperature overnight. The reaction mixture was diluted with EA (50 mL), washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain crude 2-cyano-N-(3,3,3-trifluoropropyl)acetamide (756 mg, 62%), which was used directly in the next reaction.

[0728] Step 2: Synthesis of 2-cyano-N-(3,3,3-trifluoropropyl)thioacetamide

[0729] 2-Cyano-N-(3,3,3-trifluoropropyl)acetamide (756 mg, 4.2 mmol) and Lawesson's reagent (849 mg, 2.1 mmol) were added to 20 mL of toluene and reacted at 110°C for 1 hour. The mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (SiO2, PE / EA = 1 / 0 to 2 / 1) to give 2-cyano-N-(3,3,3-trifluoropropyl)thioacetamide (430 mg, 52%).

[0730] Step 3: Synthesis of 1-chloro-2-fluoro-3-isothiocyanatobenzene

[0731] 3-Chloro-2-fluoroaniline (500 mg, 3.43 mmol) was dissolved in DCM (10 mL). A solution of DIEA (474 ​​mg, 4.12 mmol) and thiophosgene (666 mg, 5.15 mmol) in DCM (3 mL) was added dropwise at 0°C under nitrogen. The mixture was allowed to react at 0°C for 30 min. The reaction solution was diluted with DCM (20 mL), washed with saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, PE / EA = 1 / 0 to 10 / 1) to give 1-chloro-2-fluoro-3-isothiocyanatobenzene (452 ​​mg, 70%).

[0732] Step 4: Synthesis of (Z)-3-((3-chloro-2-fluorophenyl)amino)-2-cyano-3-mercapto-N-(3,3,3-trifluoropropyl)prop-2-enethioamide

[0733] 1-Chloro-2-fluoro-3-isothiocyanatobenzene (411 mg, 2.19 mmol) and 2-cyano-N-(3,3,3-trifluoropropyl)thioacetamide (430 mg, 2.19 mmol) were dissolved in DMF (10 mL). Potassium hydroxide (185 mg, 3.29 mmol) was added portionwise and stirred at 0°C for 3 hours. The reaction mixture was diluted with water, the pH was adjusted to 6 with HCl (1N), and the mixture was extracted with EA (20 mL × 3) and washed with brine (50 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product (Z)-3-((3-chloro-2-fluorophenyl)amino)-2-cyano-3-mercapto-N-(3,3,3-trifluoropropyl)prop-2-enethioamide (50 mg, 6%).

[0734] MS (ESI, pos.ion) m / z: 384.0 [M+1] + .

[0735] Step 5: Synthesis of 5-((3-chloro-2-fluorophenyl)amino)-3-thioxo-2-(3,3,3-trifluoropropyl)-2,3-dihydroisothiazole-4-carbonitrile (69)

[0736] (Z)-3-((3-chloro-2-fluorophenyl)amino)-2-cyano-3-mercapto-N-(3,3,3-trifluoropropyl)prop-2-enethioamide (50 mg, 0.13 mmol) was dissolved in EA (10 mL), and iodine (66 mg, 0.26 mmol) was added at 0° C. The mixture was reacted at 0° C. for 2 h. The reaction solution was diluted with EA (20 mL), washed with aqueous sodium thiosulfate solution (20 mL), the organic phase was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (SiO2, DCM / MeOH=1 / 0 to 90 / 1) and preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water-ACN]; gradient: 15%-45% B over 8 min) to give 5-((3-chloro-2-fluorophenyl)amino)-3-thioxo-2-(3,3,3-trifluoropropyl)-2,3-dihydroisothiazole-4-carbonitrile (69) (9 mg, 55%).

[0737] MS (ESI, pos.ion) m / z: 382.0 [M+1] + .

[0738] 1HNMR(DMSO-d6)δ:9.38(br s,1H),7.27-7.40(m,1H),7.20(t,J=8.1Hz,1H),6.97-7.11(m,1H),3.63(br t,J=6.6Hz,2H),2.64-2.81(m,2H).

[0739] Biological Examples

[0740] Biological test methods and results

[0741] 1. Preparation of SAM-TIR Lysate

[0742] NRK1-HEK293T cells (HEK 293T cell line overexpressing mouse Nrk1 gene, a stable cell line customized by Beijing Sino Biological) were cultured at 10×10 6 Cells / plate were seeded into 150 mm culture dishes (Corning; 430599) containing 25 mL of growth medium. The next day, 15 μg of human SARM1 expression plasmid (SARM1408-724 expression plasmid customized by Sino Biologics) or control vector (pCMV3 control vector, Cat: CV011, Sino Biologics, https: / / cn.sinobiological.com / cdna-clone / contol-vector-pcmv3-untagged-cv011) was pre-mixed with 45 μl X-tremeGENE 9 DNA transfection reagent (Roche product #06365787001) and 750 μl OptiMEM (Gibco 31985062), and the mixture was then added directly to the cells for transfection. At the time of transfection, 250 μl of 100 mM nicotinamide riboside (Ron's reagent; R056456-1g; CAS: 23111-00-4; molecular weight: 290.7; stored at room temperature) was added to each dish to minimize toxicity from SAM-TIR overexpression. 48 hours after transfection, cells were washed 3-4 times with cold PBS and collected. Cells were resuspended in 0.5 ml PBS containing protease inhibitors (Complete Protease Inhibitor Cocktail, Roche product #11873580001). Cell lysates were prepared by sonication (Ningbo Xinzhi Ultrasonic Disruptor, power 14%, sonication for 5 min). Lysates were centrifuged at 12,500 rpm for 10 minutes at 4°C (Eppendorf Centrifuge 5425R) to remove cell debris. Protein concentration was determined by the bicinchoninic acid (BCA) method and used to normalize lysate concentrations. Aliquots of the supernatant were stored at -80°C until use.

[0743] NRK1-HEK293T cells:

[0744] Host cells: HEK293T cells

[0745] Transfer plasmid information: N-Flag-linker-mouse NRK1

[0746] Human SARM1 expression plasmid: Nt-Strep-TEV-human SARM1 (408-724)

[0747] 2. Luminescence-based SARM1 SAM-TIR NADase Activity Assay

[0748] This assay is an adjustment to the NAD+ / NADH-GLO™ assay (Promega G9071, Promega). In this assay, NAD+ cycling enzymes convert NAD+ into NADH. In the presence of NADH, a reductase enzymatically converts the pre-luciferin reductase substrate into luciferin. ULTRA-GLO™ rLuciferase is used to detect luciferin, and the chemiluminescence intensity is proportional to the amount of NAD+ and NADH in the sample. Under the conditions of this assay, the amount of NAD+ and NADH present in the lysate is not detected with this assay, eliminating any endogenous contribution to the final NAD+ detected.

[0749] The assay was set up as follows: 40 nl of candidate inhibitor (maximum concentration 200 μM, 0.4% DMSO), 0.25 μg of lysate (5 μl), and 5 μl of 400 nM NAD+. The reaction was incubated at 37°C for 60 minutes, followed by the addition of 10 μl of NAD+ / NADH-GLO™ detection reagent. After 30 minutes at room temperature, luminescence signals were read using Envision Xcite. GraphPad 8.0 was used to fit the % inhibition values ​​to the compound concentrations and to a logarithmic nonlinear regression (dose-response - variable slope) to calculate the IC50.

[0750] (WO2019236890)

[0751] result:

[0752] The above results indicate that the compounds of the present invention have SARM1 inhibitory activity. Compared with the positive controls 1 and 2, compounds 5 and 37 of the present invention exhibit significantly enhanced inhibitory activity (3.8-fold and 5.3-fold, respectively).

[0753] In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books, and any other disclosures) is incorporated herein by reference in its entirety.

Claims

1. Compounds of formula I: or an enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug, or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof, in: R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a , a 3- to 7-membered saturated or partially unsaturated carbocyclic group, a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the carbocyclyl, heterocyclyl, aryl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace; R 2 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 2a 、-S(O)2R 2a and -CO2R 2a ; R 3 Yes - (CH2) n Cy, and n is 0, 1 or 2; or R 2 and R 3 Together with the nitrogen atom to which they are attached, they form a saturated or partially unsaturated 4- to 7-membered ring fused to Cy, or a saturated or partially unsaturated 4- to 7-membered ring substituted by Cy; Cy is selected from 3 to 7 membered saturated or partially unsaturated carbocyclic groups, 8 to 10 membered saturated or partially unsaturated bicyclic heterocyclic groups having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8 to 10 membered bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the carbocyclyl, heterocyclyl, aryl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace; R 4 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 4a 、-S(O)2R 4a 、-CO2R 4a , a 3- to 7-membered saturated or partially unsaturated carbocyclic group, a 4- to 7-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the carbocyclyl, heterocyclyl, aryl, and heteroaryl are each separated by 0, 1, 2, 3, or 4 R x replace; and Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 aliphatic, -SH, -S- optionally substituted C 1-6 Aliphatic, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b 、-N(R 3a )SO2R 3b 、-N(R 3a )C(O)R 3b , optionally substituted C 1-6 aliphatic, optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted 8- to 10-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a are each independently hydrogen, optionally substituted C 1-6 aliphatic, optionally substituted phenyl, or an optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclic ring; or R 1a and R 1b , and / or R 3a and R 3b Together with the nitrogen atom to which they are attached, they form a 3- to 6-membered saturated or partially unsaturated heterocyclic ring; Provided that the compound is not 2. The compound according to claim 1, wherein R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a 、C 3-7 cycloalkyl, 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, phenyl, naphthyl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, phenyl, naphthyl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace; Preferably, R 1 Selected from -CN, -NO2, -C(O)R 1a 、-S(O)2R 1a 、-CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-C(=NR 1a )NR 1a R 1b 、-CO2R 1a , phenyl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the phenyl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace. Preferably, R 1 Selected from: -CN, -S(O)2NH2 and -S(O)2N(CH3)2, -CO2H, 3. The compound according to claim 1 or 2, wherein R 2 is selected from H, optionally substituted C 1-6 Alkyl, -C(O)R 2a 、-S(O)2R 2a and -CO2R 2a , preferably H.

4. The compound according to any one of claims 1 to 3, wherein R 3 It is -CH2-Cy, -(CH2)2-Cy or Cy.

5. The compound according to any one of claims 1 to 4, wherein Cy is selected from C 3-7 Cycloalkyl, 8-10 membered saturated or partially unsaturated bicyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8 to 10 membered bicyclic heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each separated by 0, 1, 2, 3 or 4 R x replace.

6. A compound according to any one of claims 1 to 5, wherein R 4 is selected from hydrogen, optionally substituted C 1-6 Aliphatic, -C(O)R 4a 、-S(O)2R 4a 、-CO2R 4a 、C 3-7 Cycloalkyl, 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl, heterocyclyl, aryl, and heteroaryl groups are each substituted by 0, 1, 2, 3, or 4 R x replace; Preferably, R 4 H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, C substituted by halogen 1-6 Alkyl, or a group selected from the following:

7. A compound according to any one of claims 1 to 6, wherein R x Selected from the following groups: a) halogen, -CN, -NO2, -OH and -SH; b) -O- optionally substituted C 1-6 aliphatic and -S- optionally substituted C 1-6 aliphatic; c)-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-NR 3a R 3b 、-CONR 3a R 3b 、-CO2R 3a 、-N(R 3a )SO2R 3b and -N(R 3a )C(O)R 3b , where R 3a 、R 3b Each as defined in any one of claims 1 to 6; d) optionally substituted C 1-6 aliphatic, preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 alkyl; e) an optionally substituted 5-membered or 6-membered saturated or partially unsaturated heterocyclic group; and f) optionally substituted 8- to 10-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably optionally substituted 9-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; Preferably, R x is selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 Alkyl, -SH, -S- optionally substituted C 1-6 Alkyl, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b 、-N(R 3a )SO2R 3b 、-N(R 3a )C(O)R 3b and optionally substituted C 1-6 alkyl.

8. A compound according to any one of claims 1 to 7, wherein R 3 Selected from 9. The compound according to any one of claims 1 to 8, wherein R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a may each independently be hydrogen or optionally substituted C 1-6 alkyl, optionally substituted phenyl, or optionally substituted C 3-7 Cycloalkyl, preferably hydrogen or optionally substituted C 1-6 Alkyl, more preferably H and optionally substituted C 1-4 Alkyl, even more preferably H and CH3.

10. The compound according to any one of claims 1 to 9, wherein: R 1 Selected from -CN, -NO2, -CONR 1a R 1b 、-S(O)2NR 1a R 1b 、-CO2R 1a , phenyl and 5 or 6 membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the phenyl and heteroaryl are each separated by 0, 1, 2, 3 or 4 R x replace; R 2 is selected from hydrogen, optionally substituted C 1-6 Alkyl, -C(O)R 2a and -S(O)2R 2a ; R 3 Yes - (CH2) n Cy, and n is 0, 1 or 2, preferably 0; Cy is selected from C 3-7 Cycloalkyl, 8-10 membered saturated or partially unsaturated bicyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace; R 4 is selected from hydrogen, optionally substituted C 1-6 Alkyl, -C(O)R 4a 、-S(O)2R 4a 、C 3-7 Cycloalkyl, 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclic group having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl, heterocyclyl, aryl, and heteroaryl groups are each substituted by 0, 1, 2, 3, or 4 R x replace; and Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 Alkyl, -SH, -S- optionally substituted C 1-6 Alkyl, -NR 3a R 3b 、-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b and optionally substituted C 1-6 alkyl; R 1a 、R 1b 、R 2a 、R 3a 、R 3b and R 4a are each independently hydrogen, optionally substituted C 1-6 alkyl.

11. The compound according to any one of claims 1 to 10, wherein R 1 Selected from -CN, -NO2, -CONR 1a R 1b 、-S(O)2NR 1a R 1b and a 5- or 6-membered heteroaryl group having 1-3 (e.g., 1, 2, or 3) heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl group is surrounded by 0, 1, 2, 3, or 4 R x replace; Preferably, R 1 is selected from -CN and an unsubstituted 5-membered heteroaryl ring having 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; More preferably, R 1 Yes-CN, More preferably -CN or Even more preferred is -CN.

12. The compound according to any one of claims 1 to 11, wherein R 2 is selected from hydrogen, optionally substituted C 1-6 Alkyl, -C(O)R 2a and -S(O)2R 2a ; Preferably, R 2 is selected from hydrogen and optionally substituted C 1-4 Alkyl (preferably unsubstituted C 1-4 Alkyl, especially CH3); More preferably, R 2 It’s H.

13. A compound according to any one of claims 1 to 12, wherein R 1 is -CN, and R 2 It’s H.

14. A compound according to any one of claims 1 to 13, wherein R 3 It's Cy.

15. The compound according to any one of claims 1 to 14, wherein Cy is selected from C 3-6 cycloalkyl, 8- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, phenyl, naphthyl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the cycloalkyl, heterocyclyl, phenyl, naphthyl and heteroaryl are each replaced by 0, 1, 2, 3 or 4 R x replace; Preferably, Cy is selected from: 0, 1, 2, 3 or 4 R x substituted phenyl; 0, 1, 2, 3 or 4 R x substituted naphthyl; 0, 1, 2, 3 or 4 R x substituted 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 0, 1, 2, 3 or 4 substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably 9 or 10-membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein preferably the bicyclic heteroaryl is a fused ring system of a benzene ring and a 5- or 6-membered heteroaryl, wherein the heteroatoms are all in the 5- or 6-membered heteroaryl ring and are not common atoms; and 0, 1, 2 or 3 R x a substituted 8- to 10-membered (especially 9- or 10-membered) saturated or partially unsaturated bicyclic heterocyclyl having 1-3 (e.g. 1, 2 or 3) heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein preferably the bicyclic heterocyclyl is a fused ring system of a benzene ring and a 5- or 6-membered saturated or partially unsaturated heterocyclyl, wherein the heteroatoms are all in the 5- or 6-membered saturated or partially unsaturated heterocyclyl ring and are not common atoms; Preferably, Cy is selected from: Preferably, Cy is selected from 16. A compound according to any one of claims 1 to 15, wherein R 4 Selected from the following groups: a)H; b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 alkyl; b2) C substituted by a group selected from the following 1-6 Alkyl (preferably C 1-4 Alkyl): -OH, -SH, and 1, 2, 3 or more halogens; c)-C(O)R 4a and -S(O)2R 4a , where R 4a As defined in any one of claims 1 to 15, preferably optionally substituted C 1-6 Alkyl, more preferably optionally substituted C 1-4 Alkyl, even more preferably CH3; and d) Each is 0, 1, 2, 3 or 4 R x Substituted with the following groups: d1)C 3-7 Cycloalkyl, preferably C 4-6 Cycloalkyl; d2) a 4-, 5- or 6-membered saturated or partially unsaturated monocyclic heterocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; d3)C 6-10 aryl; and d4) a 5- or 6-membered heteroaryl group having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; Preferably, R 4 Is H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -CH2CH2CF3, -CH2CH2CH2CF3, -CH2-OH, -CH2CH2-OH, -CH2CH2CH2-OH, -C(O)CH3, -S(O)2CH3, 17. A compound according to any one of claims 1 to 16, wherein R x Selected from the following groups: a) halogen, -CN, -NO2, -OH and -SH; b) -O- optionally substituted C 1-4 Alkyl and -S- optionally substituted C 1-4 Alkyl, preferably -O-CH3 and -S-CH3; c)-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-NR 3a R 3b 、-CONR 3a R 3b and -CO2R 3a , where R 3a 、R 3b Each as defined in any one of claims 1 to 16, preferably selected from H and optionally substituted C 1-6 alkyl; d) unsubstituted or substituted by 1, 2, 3 or more halogens 1-6 alkyl; Preferably, R x Selected from F, Cl, -CN, CF3, -O-CH3, -SO2CH3 or -CO2CH3.

18. A compound according to any one of claims 1 to 17, wherein R 3 Selected from:

19. The compound according to any one of claims 1 to 18, wherein: R 1 is -CN; R 2 is hydrogen; R 3 It's Cy; Cy is as defined in any one of claims 1 to 10, in particular claims 10 to 18, and is preferably selected from an 8- to 10-membered saturated or partially unsaturated bicyclic heterocyclic group having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, C 6-10 aryl, 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the heterocyclyl, aryl and heteroaryl are as defined for Cy in any one of claims 1 to 10, in particular claims 10 to 18, and wherein the heterocyclyl, aryl and heteroaryl are each replaced by 0, 1, 2 or 3 R x replace; R 4 is selected from hydrogen, optionally substituted C 1-6 Alkyl and 0, 1, 2 or 3 R x Substituted C 4-6 cycloalkyl; and Each R x independently selected from halogen, -CN, -NO2, -OH, -O-, optionally substituted C 1-6 Alkyl, -SH, -S- optionally substituted C 1-6 Alkyl, -C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a 、-CONR 3a R 3b and optionally substituted C 1-6 alkyl; R 3a and R 3b are each independently hydrogen or optionally substituted C 1-6 alkyl.

20. The compound according to any one of claims 1 to 19, wherein Cy is selected from: 0, 1, 2 or 3 R x substituted phenyl; By 1 R x substituted naphthyl; By 1 or 2 R x a substituted 5- or 6-membered heteroaryl group having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably a 5-membered heteroaryl group having 1 nitrogen heteroatom and 0 or 1 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a 6-membered heteroaryl group having 1 or 2 nitrogen heteroatoms; It is 1, 2 or 3 R x Substituted 9- or 10-membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the bicyclic heteroaryl is a fused ring system of a benzene ring and a 5- or 6-membered heteroaryl, wherein the heteroatoms are all in the 5- or 6-membered heteroaryl ring and are not common atoms; preferably a 9- or 10-membered bicyclic heteroaryl having 1-2 nitrogen heteroatoms; and 0, 1, 2 or 3 R x substituted 9- or 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1, 2 or 3, preferably 1 or 2, heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the bicyclic heterocyclyl is a fused ring system of a benzene ring and a 5- or 6-membered saturated or partially unsaturated heterocyclyl, wherein all heteroatoms are in the 5- or 6-membered saturated or partially unsaturated heterocyclyl ring and are not common atoms; preferably a 9- or 10- (especially 9-) membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 (especially 1) heteroatoms independently selected from oxygen and sulfur, or a 9- or 10- (especially 9-) membered saturated or partially unsaturated bicyclic heterocyclyl having 1 or 2 (especially 1) nitrogen heteroatoms and 0 or 1 (especially 0) oxygen or sulfur heteroatoms; Preferably, Cy is selected from:

21. A compound according to any one of claims 1 to 20, wherein R 4 Selected from the following groups: a)H; b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 alkyl; b2) C substituted by a group selected from the following 1-4 Alkyl: -OH and 1, 2, 3 or more halogens; and d1) Unsubstituted C 4-6 Cycloalkyl; Preferably, R 4 is H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -CH2CH2CF3, -CH2CH2CH2CF3, -CH2-OH, -CH2CH2-OH, -CH2CH2CH2-OH, 22. A compound according to any one of claims 1 to 21, wherein R x Selected from the following groups: a) halogen, -CN; b) -O- optionally substituted C 1-4 Alkyl and -S- optionally substituted C 1-4 Alkyl, preferably -O-CH3 and -S-CH3; c)-C(O)R 3a 、-SO2R 3a 、-SO2NR 3a R 3b 、-CO2R 3a and-CONR 3a R 3b , where R 3a 、R 3b are each independently H or optionally substituted C 1-6 Alkyl, preferably H or optionally substituted C 1-4 Alkyl, more preferably H or CH3; and d) C substituted by 1, 2, 3 or more halogens 1-6 alkyl; Preferably, R x Selected from F, Cl, -CN, CF3, -O-CH3, -SO2CH3 or -CO2CH3.

23. A compound according to any one of claims 1 to 22, wherein R 3 Selected from:

24. The compound according to any one of claims 1 to 23, which has a structure shown in one of Formulas Ia, Iai, Ia-ii, or Ia-iii to Ia-xiv: where R 2 、R 3 and R 4 Each as defined in any one of claims 1 to 23; where R 3 and R 4 Each as defined in any one of claims 1 to 23 above; Among them, Cy and R 4 Each as defined in any one of claims 1 to 23; where R 4 and R x Each of which is defined in any one of claims 1-23.

25. The compound according to any one of claims 1 to 24, which has a structure shown in Formula Ia-xv: where R 4 is selected from hydrogen and optionally substituted C 1-6 alkyl; and Each R x independently selected from halogen, -CN and optionally substituted C 1-6 alkyl.

26. The compound according to any one of claims 1-25, wherein Cy is:

27. A compound according to any one of claims 1 to 26, wherein R 4 Selected from the following groups: a)H; b1) Unsubstituted C 1-6 Alkyl, more preferably C 1-3 Alkyl; and b2) C substituted by 1, 2, 3 or more halogens 1-4 alkyl; Preferably, R 4 It is H, -CH3, -CF3, -CH2CF3, -CH2CH2CF3.

28. A compound according to any one of claims 1 to 27, wherein R x Selected from: halogen; -CN; C substituted by 1, 2, 3 or more halogens 1-6 alkyl; Preferably, R x Selected from F, Cl, -CN and CF3.

29. A compound according to any one of claims 1 to 28, wherein R 3 Selected from:

30. The compound according to claim 1, which is selected from the group consisting of:

31. A pharmaceutical composition comprising a compound according to any one of claims 1 to 30, or its or its enantiomer, diastereomer, racemate, stereoisomer, tautomer, geometric isomer, N-oxide, metabolite, prodrug or pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound or prodrug.

32. A method comprising the steps of: The compound according to any one of claims 1 to 30 or the pharmaceutical composition according to claim 31 is administered to an individual (i) suffering from a condition characterized by axonal degeneration or (ii) at risk of developing a condition characterized by axonal degeneration.

33. A method of treating or preventing axonal degeneration, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 30 or a pharmaceutical composition according to claim 31.

34. A method of treating or preventing a neurodegenerative disease, disorder or condition characterized by axonal degeneration, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 30 or a pharmaceutical composition according to claim 31.

35. Use of a compound according to any one of claims 1 to 30 or a pharmaceutical composition according to claim 31 in the preparation of a medicament for treating or preventing axonal degeneration; or in the preparation of a medicament for treating or preventing a neurodegenerative disease, disorder or condition characterized by axonal degeneration.

36. A compound according to any one of claims 1 to 30 or a pharmaceutical composition according to claim 31 for use in treating or preventing axonal degeneration, or in treating or preventing a neurodegenerative disease, disorder or condition characterised by axonal degeneration.

37. A method of inhibiting SARM1 comprising contacting a biological sample with a compound according to any one of claims 1 to 30 or a pharmaceutical composition according to claim 31.

38. The method of claim 37, wherein SARM1 is inhibited by covalently modifying a cysteine ​​residue of SARM1.

39. The method of claim 38, wherein the cysteine ​​residue of SARM1 is Cys635, Cys629 or Cys649.